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RESUMEN EN CASTELLANO 
 
INTRODUCCIÓN 
 
Las reacciones adversas a medicamentos (RAM) es 
un importante y persistente problema de Salud Pú-
blica en términos de morbi-mortalidad y de costes. 
En un estudio realizado en los Estados Unidos 
(EE.UU.) se estimó que más de 100.000 personas 
mueren cada año a consecuencia de las RAM, y que 
más de 2 millones sufren importantes efectos se-
cundarios, situándose entre la cuarta y la sexta cau-
sa de muerte en los EE.UU. En un estudio realizado 
en el Reino Unido mostró que uno de cada 16 admi-
siones hospitalarias son causadas por RAM. El coste 
exacto atribuible a las reacciones adversas no esta 
bien determinado, es sabido que aumentan de for-
ma importante el tiempo de estancia y los costes 
sanitarios. 
La información sobre la seguridad de un medica-
mento cuando sale al mercado es limitada. Algunas 
reacciones adversas de baja incidencia o que ocu-
rren a largo plazo son difíciles de detectar en las 
fases de investigación clínica precomercialización, 
debido a que a menudo los ensayos precomerciali-
zación tienen bajo poder estadístico para detectar 
RAM y tiene cortos periodos de seguimiento. En los 
últimos años se han producido un número significa-
tivo de retiradas del mercado de nuevas moléculas 
después de ser aprobadas por las autoridades sani-
tarias. Estas retiradas se han producido después de 
haber provocado importantes problemas de salud 
pública. Por ejemplo, se ha estimado que el rofecoxib 
ha provocado 100.000 ataques cardiacos e infartos 
en EE.UU. antes de su retirada, la tercera parte de 
ellos fatales. Varios autores relacionan estos casos 
con el papel que las compañías farmacéuticas tienen 
en la farmacovigilancia de sus propios productos 
(en EE.UU. entorno al 90% de las notificaciones de 
RAM provienen de las compañías farmacéuticas). Se 
ha demostrado que la información de farmacovigi-
lancia proporcionada por los laboratorios a las auto-
ridades sanitarias puede ser enviada tarde o no ser 
notificada total o parcialmente.  
Los sistemas de notificación espontánea permiten a 
los profesionales de salud notificar directamente a 
las autoridades sanitarias, y son componentes básicos 
de la vigilancia post-comercialización de los riesgo 
inducidos por los medicamentos. Los sistemas de noti-
ficación espontánea de RAM por los profesionales 
sanitarios es la fuente más efectiva para la detección de 
RAM, y fueron diseñadas para la rápida detección de 
RAM raras o inesperadas, para a partir de ellas gene-
rar hipótesis a poner a prueba en siguientes estudios. 
Sin embargo, la baja tasa de notificación −se estima 
que solo se notifica un 10% de las RAM que se produ-
cen− limita en gran medida las ventajas de este méto-
do de farmacovigilancia. 
En Portugal la notificación espontánea de RAM a tra-
vés de la “tarjeta amarilla” inicialmente dirigida a mé-
dicos se inició en 1992. Los farmacéuticos fueron in-
corporados al sistema en 1995, notificando en colabo-
ración con los médicos hasta 1997, como en otros paí-
ses. Desde entonces pueden enviar directamente sus 
notificaciones. La tasa de notificación en Portugal en 
2001 fue de 134 notificaciones/millón de habitantes. 
De las 1342 notificaciones recibidas en el Instituto Na-
cional da Farmacia y do Medicamento, 837 fueron no-
tificaciones directas de los profesionales sanitarios. El 
número de notificaciones disminuyo en 2002 (126 noti-
ficaciones /millón habitantes) y en 2003 (110 notifica-
ciones /millón habitantes). Comparando Portugal con 
otros países, las notificaciones por millón de habitantes 
provenientes de médicos son de 71,51 frente a 138,7 de 
España, 290,9 de Francia, 288,1 del Reino Unido o 
374,0 de Suecia que tienen una tasa de notificación más 
elevada; pero por otro lado, países como EE.UU. 
(69.65), Canadá (53,7), Alemania (36,9), Italia (16,1) y 
Grecia (28,0) tienen tasas de notificación inferiores a 
las de Portugal en 2001. Para farmacéuticos es difícil 
realizar comparaciones porque las notificaciones pro-
venientes de los farmacéuticos aun no son contabiliza-
das en algunos países, aunque hay importantes refe-
rencias al importante papel que desempeñan en la 
monitorización de RAM por su buena relación con el 
paciente antes y durante el curso del tratamiento. 
También pueden jugar un importante papel en la mo-
nitorización de RAM en hospitales y son los únicos 
profesionales en contacto con los medicamentos OTC y 
medicamentos de herbolario. 
A pesar de que la infranotificación es la principal limi-
tación de los sistemas de notificación de RAM en todos 
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los países, las razones para ello aun no están claras. 
Factores como la dificultad de percibir la importan-
cia de la contribución individual al conjunto del 
conocimiento de la seguridad del medicamento, la 
falta de certeza en el diagnóstico de una RAM, falta 
de tiempo, falta de interés, falta de tarjetas amari-
llas, y miedo a consecuencias legales han sido des-
critos como potenciales causas de la infranotifica-
ción. Inman propuso en 1976 algunas actitudes co-
mo potenciales causas de la infranotificación en 
médicos, y aunque varios estudios buscaron la rela-
ción con estas actitudes, la mayoría de los estudios 
no encontraron asociación y si lo hicieron fue solo 
en una, dos o tres actitudes. En contraste con la aten-
ción dada a los médicos sobre las rezones de no 
notificar, ente los farmacéuticos no han sido estu-
diados. Que nosotros conozcamos, no hay estudios 
que valoren la influencia ejercida por varios de estos 
factores (conocimientos, actitudes, profesionales y 
características personales) en la notificación de los 
farmacéuticos. Nosotros solo hemos localizado tres 
estudios que describen las opiniones y actitudes de 
los farmacéuticos hacia la notificación de RAM, sin 
embargo no las relacionaba con su mayor o menor 
probabilidad de notificar.  
Cuando revisamos la literatura sobre posibles inter-
venciones para mejorar la notificación entre los pro-
fesionales sanitarios, nosotros solo encontramos 
cuatro artículos que desarrollen una intervención 
educativa con el propósito de mejorar la notificación 
de RAM en médicos, y ninguno de ellos es un ensa-
yo controlado aleatorio. Para los farmacéuticos no-
sotros solo encontramos dos artículos relacionados 
con este asunto. Todo esto subraya la falta de evi-
dencia de calidad en la efectividad de intervencio-
nes en esta área. 
Para evaluar si una intervención educativa podía 
disminuir la infranotificación se puso en marcha en 
Portugal un estudio en dos fases. En la fase I se 
identificaron los conocimientos y actitudes de los 
médicos y de los farmacéuticos asociados a la infra-
notificación. En la fase II se diseñó una intervención 
educativa diseñada específicamente a partir de estos 
conocimientos y actitudes, y fue evaluada su efecti-
vidad mediante un ensayo controlado aleatorio por 
clusters. 
 
OBJETIVOS 
 
1. Identificar los factores sociodemográficos y 
personales relacionados con la infranotificación 
de RAM en los profesionales de salud (los médi-
cos y los farmacéuticos). 
2. Identificar los conocimientos y las actitudes de los 
profesionales de salud (los médicos y los farma-
céuticos) relacionados con la notificación de RAM.  
3. Valorar si una intervención educativa diseñada 
para modificar los conocimientos y actitudes 
−identificadas como asociadas a la infranotifica-
ción en el segundo objetivo− aumenta la cantidad 
y la calidad (relevancia) de la notificación espon-
tánea de RAM en los profesionales de salud (los 
médicos y los farmacéuticos).  
4. Valorar la duración del efecto de la intervención 
educativa en calidad y cantidad, en médicos y 
farmacéuticos. 
5. Valorar si administrar una tarjeta amari-
lla/morada durante la intervención aumenta la 
probabilidad de notificación espontánea de RAM. 
 
MÉTODOS 
 
El estudio se llevo a cabo en la región Norte de Portu-
gal tiene una extensión aproximada de 20.000 Km2, y 
3.7 millones de habitantes (aproximadamente el 50% 
en la zona metropolitana de Oporto), con el 14% de 
ellos de más de 65 años. En la región norte hay 25 hos-
pitales y 104 centros de salud. De los 25 hospitales, 15 
de ellos son hospitales de referencia (hospitales que 
cubren un área geográfica determinada), 5 son especí-
ficos (p. ej. oncológico, materno-infantiles que abarcan 
la población de varios hospitales de referencia), y 5 son 
de pequeño tamaño. 
 
Estudios de casos y controles 
Se realizaron dos estudios de casos y controles, uno 
para médicos y otro para farmacéuticos. Para los mé-
dicos, la población estaba definida por los profesiona-
les que trabajaban en el Sistema Nacional de Salud. 
Los casos eran los 88 profesionales que notificaron al 
menos una RAM al centro regional de Farmacovigi-
lancia desde enero de 2001 hasta el inicio del estudio a 
finales de 2002. Los 771 controles eran una muestra de 
los médicos que nunca habían notificado ninguna tar-
jeta amarilla.  
Entre los farmacéuticos, los casos eran los 34 profesio-
nales que habían notificado alguna tarjeta morada al 
centro de farmacovigilancia y los controles eran una 
muestra de 280 profesionales que no habían notificado 
ninguna tarjeta morada. 
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La recogida de datos se basó usando un cuestionario 
autoadministrado. Los conocimientos y actitudes 
acerca de la notificación espontánea de RAM esta-
ban basados en “los siete pecados capitales” de In-
man. El grado de acuerdo con cada una de las cues-
tiones incluidas en el cuestionario fue medida me-
diante una escala analógica visual horizontal conti-
nua y no numerada de aproximadamente 8 cm. Las 
respuestas se cuantificaron de cero a 10 con una 
precisión de 0.5.  
Se utilizó regresión logística para determinar el 
Odds Ratio ajustado asociado al cambio en la expo-
sición correspondiente al rango intercuartílico de 
cada actitud (IqOR).  
 
Ensayo controlado aleatorio por clusters 
La población de nuestro estudio esta compuesta por 
todos los médicos y farmacéuticos menores de 71 
anos que trabajaban en el Sistema Nacional de Salud 
de la región Norte de Portugal. Se excluyeron del 
estudio los médicos sin actividad clínica (labores 
administrativas, genética, histocompatibilidad), los 
que trabajaban en centros de toxicodependencias, 
los que trabajaban en el centro regional de farmaco-
vigilancia o en aquellos servicios que tenían un pro-
grama específico de notificación voluntaria de 
RAM. También fueron excluidos del estudio los 
médicos que desarrollaban sus actividades en hospi-
tales específicos. 
 
Diseño del estudio 
Se ha llevado a cabo un ensayo controlado aleatorio 
con dos años y medio de seguimiento. Con el fin de 
eliminar la cross-contaminación entre los dos gru-
pos de estudio (intervención y control), las unidades 
de asignación no fueron médicos o farmacéuticos, 
sino spatial-clusters. Cada spatial-cluster estaba cons-
tituido por todos los médicos y farmacéuticos que 
trabajaban en los hospitales, en los centros de salud 
y en las farmacias comunitarias de la zona geográfi-
ca. Los clusters tenían el tamaño mínimo que permi-
tía minimizar la contaminación entre atención hos-
pitalaria, primaria y farmacias. Así, cada spatial-
cluster estaba formado por un hospital de referencia 
junto con los centros de salud, otros posibles hospi-
tales de su zona de influencia, y las farmacias co-
munitarias. Se formaron 15 spatial-clusters, de los 
que fueron excluidos los hospitales específicos ya 
que, al tener como zona de influencia a toda la re-
gión, aumentaban el riesgo de contaminación. 
La mayoría de los ensayos aleatorios por clusters dis-
tribuyen aproximadamente el mismo número de clus-
ter al grupo de intervención y al de control. Este es el 
distribución mas eficiente desde el punto de vista es-
tadístico, pero puede no ser la mas eficiente económi-
camente. Cuando la intervención bajo evaluación tiene 
una diferencia importante de coste respecto a la del 
grupo control puede ser más económicamente eficien-
te distribuir aleatoriamente menos clusters al grupo de 
intervención que al de control. Nosotros distribuimos 
los 15 clusters mediante unequal randomization con una 
proporción aproximada de 1:4 para los grupos de in-
tervención: control. La distribución se realizó median-
te un procedimiento informático, quedando 4 clusters 
asignados al grupo de intervención y 11 al de control.  
 
Clusters del grupo de intervención 
Según la clasificación de Grimshaw et al, se realizó 
una intervención múltiple compuesta por visitas ex-
ternas, mas recordatorio, mas una tarjeta amarilla 
/morada. El diseño de la intervención educativa se 
realizó a partir de los resultados de los estudios de 
casos y controles en los que se encontró que en los 
médicos la notificación estaba fuertemente asociada a 
varias actitudes (complacency, insecurity, diffidence, indif-
ference, y ignorance) propuestas por Inman como de-
terminantes de la notificación. En los farmacéuticos se 
encontró que estaban asociadas a tres (complacency, 
diffidence, y ignorance). 
Se diseñó un material didáctico interactivo que incidía, 
en primer lugar, sobre la importancia de las RAM en 
términos de morbilidad, mortalidad y de costes. Luego 
se justificaban las limitaciones de los ensayos clínicos 
para la detección de RAM, y se explicaban las ventajas 
del sistema de notificación voluntaria y que la infrano-
tificación era su principal limitación. En tercer lugar se 
incidían en mensajes para modificar las actitudes de 
complacenc, insecurity, diffidence, indifference, ignorance. 
En cuarto lugar se incidía en que solo necesita de cinco 
minutos para rellenar la tarjeta amarilla/morada. Fi-
nalmente se explicaban los mecanismos para notificar 
en Portugal (teléfono, fax, web, o tarjeta amarilla 
/morada). También se elaboró un díptico de color 
amarillo o morado con los principales mensajes de la 
presentación. 
Antes de las visitas se enviaba una carta a los directo-
res de cada uno de los centro de salud, directores téc-
nicos de farmacia y a los directores clínicos de los hos-
pitales seleccionados explicando los objetivos del es-
tudio y pedirle su consentimiento para participar en el 
ensayo. La intervención fue aprobada por la comisión 
de docencia de cada hospital y fue incluida como edu-
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cación médica continuada de cada centro. La inter-
vención fue realizada por uno de los investigadores 
(MTH) que participó en el diseño y preparación de 
la intervención. La intervención se realizó entre 
marzo y julio de 2004 y duraba entorno a una hora, 
con aproximadamente 30 minutos de presentación y 
otros 30 minutos de coloquio. Los grupos estaban 
formados entre 10 y 20 médicos, mientras que para 
los farmacéuticos los grupos estaban constituidos 
generalmente por entre 1 y 5 profesionales. Al final 
de la presentación se daba un díptico a cada médico 
o farmacéutico. Con el fin de evaluar la influencia 
de proporcionar la tarjeta amarilla/morada sobre la 
notificación, a un grupo de médicos y farmacéuticos 
(seleccionados de forma no aleatoria) no se facilitó 
la tarjeta amarilla/morada a cinco centros de salud, 
diez farmacias comunitarias, un servicio de farma-
cia hospitalaria y a tres servicios hospitalarios del 
grupo de intervención (aproximadamente 10% del 
grupo de intervención). La tarjeta amarilla/morada 
no fue facilitada a ningún medico o farmacéutico 
que no asistió a la intervención. 
 
Clusters del grupo de control 
Los médicos y farmacéuticos de los clusters del 
grupo control no recibieron la intervención pero, al 
igual que los del grupo de intervención, si recibie-
ron la información y la formación usual proporcio-
nada por el centro regional de farmacovigilancia de 
la región norte de Portugal. 
 
Seguimiento y fuentes de datos. 
Se realizó un seguimiento de 30 meses entre enero 
de 2003 y junio de 2005 ambos inclusive. Durante 
este seguimiento para cada médico o farmacéutico y 
en cada mes de seguimiento se generaron las si-
guientes variables dependientes: (1) número de no-
tificaciones de RAM totales; (2) graves; (3) imputa-
ción de causalidad, definitiva o probable; (4) inespe-
radas; y (5) de medicamentos con menos de cinco 
años en el mercado. Todos estos datos y la clasifica-
ción de las RAM provenían del centro Regional de 
Farmacovigilancia del Norte de Portugal. Las varia-
bles independientes características de los médicos 
estudiados (edad, sexo, especialidad y lugar de tra-
bajo) fueron obtenidos a partir de los registros de 
personal del SNS portugués. Para los farmacéuticos 
(edad, sexo y lugar de trabajo) fueron obtenidos a 
partir de los registros de la asociación de farmacéu-
ticos hospitalarios y de la asociación nacional de 
farmacias. 
Análisis estadístico 
Todo el análisis estadístico se realizó por intención de 
tratar; por se motivo los sujetos que, aunque fuesen 
asignados al grupo de intervención no la recibieron 
fueron incluidos también en el análisis como pertene-
cientes al grupo de intervención. La inclusión de todos 
los sujetos en el análisis estadístico elimina cualquier 
sesgo de selección por la no asistencia de los médicos a 
la intervención. 
Para el análisis estadístico se utilizaron modelos linea-
les mixtos con penalized quasi-likelihood. Para elaborar 
los modelos, nosotros tomamos como variable depen-
diente el número de notificaciones (totales, graves, 
definidas o probables, inesperadas, y medicamentos 
nuevos) de cada mes, el término independiente como 
efecto aleatorio, y la distribución aleatoria de los spa-
tial-cluster como efecto cluster. Los modelos se ajusta-
ron por aquellas variables sociodemográficas y perso-
nales por las que en las que los grupos pudiesen que-
dar desequilibradas después de la distribución al azar.  
Para medir el efecto de la intervención, se creo una 
variable indicadora dicotómica. Esta variable −llamada 
periodo− toma valores 0 para el periodo basal y 1 para 
los meses entre la intervención y el final del segui-
miento. El efecto de la intervención fue evaluado a 
través de la interacción entre la variable grupo (1 para 
grupo de intervención, y 0 para el grupo control) y la 
variable periodo. Para el análisis de la duración del 
efecto, se construyó otra variable indicadora con cinco 
categorías (valor 0 para el periodo basal, 1 para el pri-
mer cuatrimestre después de la intervención, y 2, 3, 4 
para los siguientes). El efecto de la intervención en 
cada cuatrimestre se evaluó a través de de la interac-
ción entre esta variable indicadora y la variable grupo. 
Todos los análisis se realizaron utilizando software S-
Plus. Los resultados se expresan en RR y sus intervalos 
de confianza al 95%, que nos indican las veces que 
aumenta la exposición la probabilidad de notificar. 
 
RESULTADOS 
 
Estudios de casos y controles 
Un total de 397 cuestionarios fueron recibidos de 731 
médicos elegibles (54.3%). Los médicos que trabajaban 
en atención primaria tienen una mayor probabilidad 
de notificar que los que trabajan en medio hospitala-
rio, y los médicos generales o los de especialidades 
médicas tienen mayor probabilidad de notificar que 
los de especialidades quirúrgicas o médico-
quirúrgicas. Las actitudes respecto a las RAM están 
fuertemente asociadas a la probabilidad de notificar. 
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Así, una disminución de una magnitud de un inter-
cuartil de las siguientes actitudes aumenta la proba-
bilidad de notificar en un: (a) 87% (p<0.05) para la 
complacency (creer que las reacciones adversas real-
mente serias ya están bien documentadas cuando el 
medicamento sale al mercado), (b) 109% (p<0.01) 
para la insecurity (creer que prácticamente imposible 
determinar cuando un medicamento es responsable 
de una reacción adversa en particular), (c) 143% 
(p<0.001) para diffidence (creer que solo se debería 
notificar una reacción adversa si se esta seguro de 
que esta relacionada con el consumo de un determi-
nado medicamento), (d) 220% (p<0.001) para indiffe-
rence (considerar que un caso de un médico indivi-
dual no puede aportar mucho conocimiento al co-
nocimiento médico), y (e) 71% (p<0.05) para igno-
rance (cree que solo es necesario notificar RAM se-
rias o inesperadas). 
Para farmacéuticos la tasa de respuesta fue del 
86.8%. La probabilidad de notificar fue mayor en los 
farmacéuticos hospitalarios que en los comunitarios 
(OR=20.0; 95CI: 3.3-125.0, p<0.001). Las actitudes 
hacia las RAM están fuertemente asociadas con la 
probabilidad de notificar. Así, una disminución 
equivalente al rango intercuartílico disminuye en 
cada una de las siguientes actitudes en: (a) 223% 
(IC95%: 51% a 595%, p<0.05) para la complacency 
(creer que las reacciones adversas realmente serias 
ya están bien documentadas cuando el medicamen-
to sale al mercado); (b) 240% (IC95%: 89% a 508%) 
para diffidence (creer que solo se debería notificar 
una reacción adversa si se esta seguro de que esta 
relacionada con el consumo de un determinado me-
dicamento), (c) 316% (IC95%: 44% a 1104%, p=0.010) 
para ignorance (cree que solo es necesario notificar 
RAM serias o inesperadas). 
 
Estudio controlado aleatorio por clusters 
Del total de 6950 médicos iniciales, fueron excluidos 
del ensayo 40 médicos por desarrollar tareas admi-
nistrativas y en centros de genética y histocompati-
bilidad, 24 por trabajar en centros de toxicodepen-
dencias, 3 por estar en centro de farmacovigilancia e 
protocolo y 432 por trabajar en hospitales específi-
cos. Finalmente fueron influidos en el análisis 6451 
médicos, de los cuales 1388 pertenecían al grupo de 
intervención y 5063 pertenecían al grupo de control. 
De los sujetos del grupo de intervención asistieron a 
la intervenciones 655 (47.2%). La tarjeta amarilla no 
fue facilitada a 184 médicos (13.3%) del grupo de 
intervención. La mediana del periodo se seguimien-
to fue de 13 meses para el periodo post-
intervención. Del total de 1451 farmacéuticos  se 
excluyeron 2 por ser miembros del centro regional de 
farmacovigilancia. Además, 16 farmacéuticos trabaja-
ban en hospitales específicos también fueron exclui-
dos. Finalmente, 1433 farmacéuticos fueron incluidos, 
342 en el grupo de  intervención, y 1091 al grupo con-
trol. La tarjeta morada no fue administrada a 46 far-
macéuticos. El número de farmacéuticos del grupo de 
intervención que realmente recibieron la intervención 
fueron 276 (80.7%).  
Respeto a las características básales del grupo de in-
tervención  y de control para los médicos, se observa 
que la distribución por sexos y por edad es similar, 
pero hay una menor proporción de médicos generales 
y de médicos que trabajan en atención primaria en los 
clusters el grupo de intervención. Cuando compara-
mos los valores básales de las notificaciones los médi-
cos del grupo intervención tenían un promedio de 
notificación global, de RAM graves, con causalidad 
definitiva o probable inferior a la del grupo control, 
mientras que tienen unos valores similares en medi-
camentos nuevos. Los farmacéuticos, el grupo de in-
tervención tiene un promedio de RAM graves, con 
causalidad definitiva o probable inferior a la del grupo 
control, mientras que tienen unos valores ligeramente 
superior para la notificación global y para las inespe-
radas. Todas estas posibles diferencias en los valores 
básales entre grupos no sesgan los resultados porque 
Poisson-GLMM ajusta por estas diferencias básales. 
Las tasas de notificación de los médicos por el total de 
RAM y por tipos de RAM, en cada uno de los periodos 
de estudio, ajustada por los valores básales y por espe-
cialidad y lugar de trabajo, se observa que la interven-
ción incrementa la tasa de notificaciones total en 10 
veces (RR=9.65; p<0.001) a lo largo del periodo post-
intervención. El efecto de la intervención en la tasa de 
notificación ajustados por los valores básales y por el 
lugar de trabajo de los farmacéuticos incrementa la 
tasa de notificación en 5-veces (RR=5.87; p=0.001) du-
rante el periodo pos-intervención. 
Al analizar la  evolución mensual de la tasa de notifi-
cación por 1000 médicos-mes en el grupo de interven-
ción y en el de control, se muestra  que la tasa de noti-
ficación en el grupo de intervención se incrementa 
bruscamente cuando se inicia la intervención (en el 
primer cuatrimestre la notificación se aumenta en mas 
20 veces (RR=23.3; p<0.001), y posteriormente decrece, 
pero se mantiene una tasa de notificación entre 4.7 y 
6.6 veces superior −y estadísticamente significativas− a 
la del control en el segundo, tercer y cuarto cuatrimes-
tre. Al estudiar la evolución mensual de la tasa de no-
tificación por 1000 farmacéuticos-mes en el grupo de 
intervención y en el de control, se observa que cuando 
empieza la intervención, en los primeros cuatro meses 
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la tasa de notificación se incrementa en mas de 20 
veces (RR=20.2; p<0.0001) y luego disminuye, pero 
se mantienen entorno a 3 veces mas que el grupo 
control en el segundo y tercer cuatrimestre. En el 
cuarto cuatrimestre la intervención incrementa en 
casi tres veces la notificación pero no es estadística-
mente significativa (RR=2.77; p= 0.354). 
El efecto de la intervención sobre la notificación de 
reacciones adversa graves, inesperadas, con causa-
lidad definida o probable, y sobre los medicamentos 
nuevos en médicos, se observa que la intervención 
multiplica por seis veces (RR=6.1, p=0.001) la tasa 
de notificación de RAM graves, por 8 veces (RR=8.5, 
p<0.001) la tasa de notificación de RAM con causa-
lidad definida o probable, en 32 veces (RR=32.6, 
p<0.001) la tasa de notificación de RAM inespera-
das, y en 8 veces la tasa (RR=8.2, p=0.002) de notifi-
cación de RAM de medicamentos nuevos. En far-
macéuticos se muestra que la intervención multipli-
ca por 10 veces (RR=9.8; p=0.002) la tasa de notifica-
ción de RAM graves, por 8 veces (RR=8.7; p=0.002) 
la tasa de notificación  de RAM con causalidad defi-
nida  o probable, en 4 veces (RR=4.4; p=0.04) la tasa 
de notificación de RAM inesperadas, y en 9 veces 
(RR=9.3; p<0.001) la tasa de notificación de RAM de 
medicamentos nuevos. 
 
DISCUSIÓN 
 
Discusión del método 
La principal limitación de los estudios de casos y 
controles tanto de médicos y farmacéuticos es la 
diferente porcentaje de respuesta entre los casos y 
los controles. Sin embargo, es razonable pensar que 
los controles que participaron son probablemente 
los más motivados. Si aun así, nosotros observamos 
diferencias entre las actitudes/conocimientos los 
casos y los controles, es razonable suponer que estas 
diferencias serían aun mayores si los casos se com-
parasen con todos los controles, incluidos los no 
respondedores. La tasa de respuesta global en far-
macéuticos se puede considerar como muy buena 
(86,8%) mientras que en médicos (54.3%), no es muy 
alta, pero es razonablemente buena especialmente si 
lo comparamos con otros estudios realizados en la 
Unión Europea por European Pharmacovigilance Re-
search Group, en el que la tasa de respuesta obtenida 
en Portugal fue del 37.0%.  
El ensayo controlado aleatorio por cluster presenta 
varias fortalezas y limitaciones. Utilizar un grupo 
control permite eliminar otros potenciales fuentes 
de sesgos como variaciones estaciónales o “brotes” de 
notificaciones. Nuestro ensayo al ser aleatorio, evita 
potenciales sesgos de selección y al realizar la distribu-
ción por cluster disminuye el riesgo de contaminación 
entre grupos, pero aumenta el riesgo de que los gru-
pos queden desequilibrados por valores básales, sobre 
todo cuado el número de clusters es pequeño como es 
el caso de nuestro ensayo. Nosotros eliminamos este 
efecto ajustando en el análisis estadístico por las varia-
bles que han quedado desequilibradas tras la rando-
mización y por los valores básales de las variables de-
pendientes y comparando los cambios antes y después 
dentro del grupo de intervención con la del control. 
Otra posible limitación es el bajo porcentaje de partici-
pación en el grupo de intervención (aunque es cifra 
parecida a la de otros estudios con sesiones en grupo). 
Para evitar que el porcentaje de participación produz-
ca un sesgo de selección (posiblemente los médicos 
que asistieron son los más motivados), se realizó el 
análisis estadístico por “intención de tratar” Este enfo-
que infraestima la eficacia de la intervención, pero 
proporciona una medida mas cercana a su efectividad.  
 
Discusión de resultados 
 
Estudios de casos y controles 
Nosotros resultados indican que las actitudes e cono-
cimientos dos médicos e farmacéuticos son un factor 
determinante en infranotificación de RAM. Desde 
1976, cuando Inman propuso los “siete pecado capita-
les” como a principal razón de la infranotificación, 
varios estudios intentaron valorar estas relaciones. 
Este es el primer estudio que encuentra una fuerte 
asociación entre las actitudes y conocimientos relacio-
nados con los “siete pecados capitas” y la subnotifica-
ción para los médicos e farmacéuticos. Además, nues-
tros resultados sugieren que el tipo de especialidad 
médica y el local de trabajo (hospital versus centros de 
salud) ejercen influencia en la notificación de los mé-
dicos. La probabilidad de notificar es mas baja en las 
especialidades quirúrgicas y médico-quirúrgicas. Por 
otro lado, los médicos que trabajan en el hospital noti-
fican siete veces menos que los médicos que trabajan 
en centros de salud. Estos resultados son similares a 
otros realizados en España, Alemania, EE.UU. y Reino 
Unido. Para los farmacéuticos la situación es diame-
tralmente opuesta a la de los médicos: los farmacéuti-
cos hospitalarios tienen una probabilidad de notificar 
mas elevada que la de los farmacéuticos comunitarios. 
Nosotros encontramos que los farmacéuticos y médi-
cos portugueses no sienten la necesidad de una re-
compensa económica por algo que sienten que tienen 
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la responsabilidad profesional de realizar, y que no 
compromete su responsabilidad legal. Estos resul-
tados están en línea de otros estudios realizados en 
Europa pero son diferentes a otros realizados en 
EE.UU. Otro factor propuesto fue la ambición de 
publicar, pero no parece un motivo importante en-
tre los médicos e farmacéuticos portugueses, ya que 
una búsqueda en el Medline, apenas hay estudios 
sobre la notificación. 
Para médicos, nuestro estudio es el primero en en-
contrar una asociación entre la probabilidad de noti-
ficar y todas las 5 razones propuestas por Inman 
(complacency, insecurity, diffidence, indifference y igno-
rance) en contraste con otros estudios que encontra-
ron apenas una, dos, tres o cuatro de estas razones 
relacionadas con a notificación. Este es el primer 
estudio que analiza a relación entre as actitudes e 
conocimientos de los farmacéuticos y la notificación 
(complacency, diffidence y ignorance). Los otros estu-
dios realizados sobre el mismo tema apenas descri-
ben las opiniones de los farmacéuticos acerca das 
RAM. Consideramos que las discrepancias entre 
nuestro estudio y otros publicados se deben a la 
utilización de una escala analógica visual. Esta esca-
la es capaz de detectar pequeñas, pero relevantes, 
diferencias en las actitudes y conocimientos de los 
médicos e farmacéuticos que no es posible captarlas 
cuando se usa una escala tipo categórica con 3 ó 4 
categorías. Así, gracias a esta escala, detectamos una 
fuerte asociación entre las actitudes y la notificación. 
De acuerdo con nuestros datos, para los médicos, 
potenciales cambios equivalentes al intervalo inter-
quartílico puede llevar asociado un aumento da 
probabilidad de notificar de un 100% para actitudes 
como insecurity, diffidence y indifference y un 50% 
para complacency, y ignorance. Para los farmacéuticos 
estas alteraciones del grado de acuerdo aumentaría 
la probabilidad de notificar RAM en 240 % para a, 
diffidence, un 223% para la complacency, y un 316% 
para a ignorance. 
 
Estudio controlado aleatorio por clusters 
En este gran ensayo controlado por clusters los mé-
dicos multiplican por más de 9 veces la tasa de noti-
ficaciones durante el año siguiente a haber recibido 
una intervención educativa de una hora de dura-
ción. Este efecto es máximo −20 veces− en los cuatro 
primeros meses, y se mantiene en 5 veces incluso 
trascurrido mas de un año desde la intervención. En 
farmacéuticos el incremento ha sido menor, pero 
muy importante: más de 5 veces. El efecto también 
es máximo en los cuatro meses con magnitudes muy 
parecidas a la de los médicos, y también se mantiene 
en el tiempo (a excepción de que a partir de un año de 
seguimiento existe un efecto −casi tres veces− pero no 
estadísticamente significativo). La intervención produ-
ce una mejora en la relevancia de las notificaciones 
incrementando la notificación de reacciones graves, 
inesperadas, de medicamentos nuevos y de imputa-
ción de causalidad elevada, tanto para médicos como 
para farmacéuticos. Los resultados de este ensayo 
pueden tener una gran importancia tanto desde el 
punto de vista educacional, como desde el punto de 
vista de la salud pública, ya que indican que estrate-
gias educativas pueden contribuir a mejorar de una 
forma muy importante la vigilancia de las RAMs. 
La magnitud del efecto encontrada en nuestro ensayo 
pocas veces se ha observado en la alteración de rendi-
miento de los profesionales sanitarios. Las revisiones 
sobre la eficacia de intervenciones para mejorar el ren-
dimiento profesional ya consideran como “modera-
damente importantes” mejoras del 20%, mientas que 
en nuestro ensayo las mejoras están en el orden del 
900%, para los médicos y de 500% para los farmacéuti-
cos y esta mejora no es solo a corto plazo, sino que se 
mantiene durante más de un año. Los factores que 
pueden explicar el efecto de una intervención en los 
cambios de los profesionales son múltiples: el objetivo 
de la intervención, el tipo de intervención (p. ej. mate-
rial impreso o formación 'face to face'), numero de in-
tervención, el organismo patrocinador de la interven-
ción, la ausencia de barreras o la existencia de incenti-
vos, el grado de interactividad de las intervenciones, o 
su diseño a partir de las lagunas o fallos detectadas en 
los profesionales sanitarios.  
Posiblemente uno de los factores que pueda explicar 
una magnitud de efecto tan importante se debe el obje-
tivo de nuestra intervención. Las intervenciones edu-
cativas dirigidas a mejorar el rendimiento de los profe-
sionales sanitarios como mejorar la prescripción, a 
optimizar la utilización de test diagnósticos, chocan 
con múltiples barreras como la presión o motivación 
de los pacientes, la influencia de la industria farmacéu-
tica, o trabas administrativas como la falta de tiempo. 
Por el contrario, el objetivo de nuestra intervención 
apenas tiene barreras: las posibles (falta tiempo y de 
tarjeta) fueron específicamente tratadas durante la 
intervención. La ausencia de barreras en este objetivo 
podría explicar también las elevadas magnitudes de 
efecto que encontraron otros autores sobre el mismo 
tema. En nuestro ensayo las únicas co-intervenciones 
eran un díptico informativo y una tarjeta. Nosotros 
creemos que la tarjeta se puede entenderse como una 
co-intervención que puede actuar como factor facilta-
dor o como de recuerdo y que, por su bajo coste, debe-
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ría acompañar a cualquier intervención educativa 
para mejorar la notificación.  
Otro factor que puede influir en la efectividad de la 
intervención es la el diseño de la intervención. Las 
revisiones sobre el tema indican que cuanto más 
interactivos sean los materiales y las presentaciones 
más efectivas son. Nuestra intervención fueron di-
señada para ser lo más interactiva posible tanto la 
exposición, discusión y el díptico. Otro punto que 
puede explicar la efectividad de nuestra interven-
ción es que fue diseñada expresamente a partir de 
las lagunas de formación detectadas en la fase I de 
nuestro ensayo. Ello permite elaborar mensajes es-
pecíficos y concretos, y por tanto más efectivos. 
Además estos mensajes eran dados por un organis-
mo patrocinador académico e independiente (“aca-
demia detail”), lo que se ha asociado a una mayor 
efectividad de la intervención.  
Se podría argumentar que la magnitud del efecto 
encontrado se debe a la baja tasa de notificación de 
partida en Portugal, lo que haría que estos resulta-
dos no fuesen aplicables a otros entornos. Si consi-
deramos la tasa de notificación total, las cifras de 
notificación en Portugal son unas de las más bajas. 
Sin embargo, cuando comparamos solo las notifica-
ciones directas de médicos observamos que la tasa 
de notificación en Portugal es superior a la de países 
como Alemania, Italia, Grecia, EE.UU. o Canadá, lo 
que indicaría que, en lo que a tasa de notificaciones 
se refiere, numerosos los entornos se podrían bene-
ficiar de una intervención como la de nuestro ensa-
yo.  
Una de las posibles limitaciones de las intervencio-
nes educativas es que su efecto puede ser limitado 
en el tiempo. Sobre esto hay muy pocos estudios 
sobre la duración de los efectos de la educación mé-
dica continuada en la práctica. Los estudios existen-
tes indican que el efecto de la educación médica 
continuada disminuye con el tiempo, pero que se 
puede mantener entre nueve meses y dos años. 
Nuestros datos indican que existe un efecto máximo 
a corto plazo, y que existe efecto menor −pero muy 
importante− mantenido en el tiempo hasta más allá 
de un año. 
No tenemos datos a largo plazo, pero creemos que 
para mantener el interés de los médicos y farmacéuti-
cos por el sistema, podría ser de interés realizar inter-
venciones repetidas y regulares. Nuestros datos mues-
tran que podría ser suficiente realizar estas interven-
ciones anuales.  
 
Los resultados de nuestro estudio indican que la infra-
notificación de RAM puede reducirse cambiando cier-
tas actitudes de los profesionales sanitarios, mediante 
estrategias educativas elaboradas a partir de las nece-
sidades de formación de los profesionales. Así, inter-
venciones educativas de menos de una hora de dura-
ción ha llevado a importantes incrementos en la notifi-
cación resultados indican que los médicos y farmacéu-
ticos responden bien y de forma prolongada a visitas 
formativas para mejorar la notificación de RAM.  
 
En el momento en que las recientes casos de retiradas 
de medicamentos ha conducido a una importante cri-
sis en la monitorización de la seguridad de los medi-
camentos, nuestros resultados pueden ser de gran re-
levancia: una de las medidas puede ser potenciar los 
métodos en de farmacovigilancia independientes de 
los laboratorios como la notificación directa de los 
médicos, que se ha mostrado muy exitoso en la identi-
ficación de nuevas RAM a pesar de la gran infranotifi-
cación existente. Nuestros resultados indican que los 
médicos responden bien y de forma prolongada a bre-
ves visitas formativas para aumentar la notificación. Si 
estos resultados pueden ser replicados a lo largo del 
tiempo  en otros entornos, podría indicar que los nu-
merosos países podrían mejorar sustancialmente en 
cantidad y relevancia la notificación de RAMs median-
te estrategias educativas diseñadas a partir de las ne-
cesidades de formación de los médicos. Ello permitiría 
aumentar el protagonismo a los profesionales sanita-
rios en la farmacovigilancia y detectar de forma mas 
tempana y fiable las RAMs, lo que supondría una im-
portante mejora de la monitorización de la seguridad 
de medicamentos. 
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1 INTRODUCTION 
Adverse Drug Reaction (ADR) is a persistent and important public health problem in terms 
of morbidity, mortality, and cost. 1-6 In a study performed in the United States (US) it was es-
timated that more than 100 000 people die every year as a consequence of ADR and more 
than 2 million suffer serious after-effects, and some researcher’s place fatal ADR between the 
fourth and sixth leading causes of death in the US. 7,8 A study carried out in the United King-
dom (UK) demonstrated that one in 16 admissions to a hospital is caused by ADR.9 The exact 
costs attributable to adverse drug reactions are not well known, it has been suggested how-
ever, that ADR can prolong hospital stays and add to healthcare expenditure.10 
Drug safety information at the time when a drug is licensed is limited.11,12 Some adverse 
events of low incidence or those occurring a long time after administration are difficult to 
detect during the clinical research phases prior to commercialization, due to the fact that pre-
marketing trials are often underpowered to detect ADR and have limited follow-up.12-14 An 
significant number of withdrawals of new molecules introduced to the market after being 
approved by competent health authorities has been observed in the last few years. This with-
drawal has been carried out after public health problems were observed. For example, it has 
been estimated that the Vioxx® (rofecoxib) molecule has provoked 100 000 heart attacks and 
strokes in US, a third of them fatal, before the market withdrawal.15 Several authors16,17 relate 
these cases to the role that pharmaceutical companies have in the pharmacovigilance of their 
own products (in US about 90% of ADR report provided by pharmaceutical companies).18 It 
has been demonstrated that pharmacovigilance information provided by companies to 
health authorities might be sent late or non-reporting of case reports or failure to report any 
ADR at all may occur.12,17 
Spontaneous ADR reporting systems empower health professionals to report directly to Na-
tional Health Authorities and are the basic components for comprehensive post-marketing 
surveillance of drug-induced risks. The spontaneous ADR systems by health professionals is 
the most effective source for ADR detection and are primarily designed for rapid detection of 
uncommon or unexpected ADR, thereby creating hypotheses to be tested in subsequent 
studies.19-21 Nevertheless, low spontaneous reporting rates greatly limit the advantages of-
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fered by this surveillance method.22-24 Indeed, it is estimated between 10 and 50% of serious 
adverse reactions are reported. 25-29 
In Portugal, the spontaneous report of ADR, through the “Yellow Form” initially use by 
physicians, started in 1992. Pharmacists were incorporated into the system in 1995, and pro-
ceeded to report in collaboration with physicians until 1997, as in other countries,30 after that 
they submitted their reports directly. Thus, the report ratio is rather low in Portugal and in 
2001 was 134 reports/million habitants.31 Of the 1342 reports received in National Institute of 
Pharmacy and Medicine, just 837 were directly from health professionals.30 The number of 
reports decreased in 2002 (126 reports/million habitants) and in 2003 (110 reports/million 
habitants), in Portugal. 
Comparing physician reports/million habitants in Portugal (71.51) with other countries, it 
were observed that Spain (138.70), France (290.94), UK (288.09) and Sweden (373.97) had re-
port ratios higher than Portugal but on the other hand, countries as US (69.65), Canada 
(53.75), Germany (36.87), Italy (16.13) and Greece (27.96) had report ratios lower than that in 
Portugal, these data are all from 2001.30 Concerning reporting by pharmacists, it is difficult to 
compare because the reports from pharmacists are not considered in some countries yet, al-
though is important referring that pharmacists are a vital link with the patient before and 
during a course of drug therapy, they could play an important role in monitoring adverse 
events in hospitals and are the only professionals in contact with over-the-counter32-34 and 
herbal medicines.35 
Despite the fact that under-reporting is the principal limitation of ADR reporting systems in 
all countries, the reasons for that are not clear. Factors such as failing to perceive the impor-
tance of the individual contribution to the overall knowledge of drug treatment safety, lack 
of certainty about the diagnosis of a particular ADR, lack of time, lack of interest, lack of re-
port forms, and fear of involvement in litigation have been described as potential causes of 
under-reporting behaviour.36-40 Inman37 first proposed some attitudes in 1976 as potential 
causes of ADR under-reporting in physicians and, even though various other studies have 
looked at these relationships,41-45 the majority of studies have either failed to find an associa-
tion or found only one, two or three  attitudes associated.43-45 In contrast to the attention 
given to medical practitioners the reasons for under-reporting among pharmacists have not 
been studied. To our knowledge, there are no studies that have assessed the influence ex-
erted by the various factors (knowledge-attitudes, professional and personal characteristics) 
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on pharmacists reporting. We have only managed to locate three studies46-48 that describe 
opinions and attitudes held by pharmacists vis-à-vis ADR reporting, yet no link was made 
between such opinions, attitudes and higher or lower likelihood of reporting. 
With under-reporting being the major drawback of the spontaneous report of ADR, it is of 
extreme importance to identify the factors that cause it, in order to improve the system. 
When reviewing the literature, numerous articles concerning the study of the factors that 
condition the reporting of ADR could be found concerning physicians but not for pharma-
cists. Nevertheless, only four articles21,39,49,50 were found about the assessment of educative 
intervention with the purpose of developing knowledge and attitudes relating to ADR, with 
the aim of increasing ADR reports by physicians, however, none of them were controlled 
randomized trials, for pharmacists we only establish two articles related with this subject,49,50 
but not a controlled randomized trials. All this highlighted the lack of good quality evidence 
on the effectiveness of intervention in this an area. 
To valuate if an educative intervention could decrease ADR under-reporting a two-phase 
study was carried out in Portugal. In phase I the knowledge and attitudes related to under-
reporting of physicians and pharmacists were identified through a case control study.51 
Phase II was then designed to modify specifically these knowledge and attitudes and was 
evaluated by a randomized controlled trial cluster. 
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2 LITERATURE REVIEW 
The 20th century bore witness to an unprecedented happening in medical history: a pharma-
cologic boom where numerous drugs have been discovered and, simultaneously, innovative 
technical and management systems were developed to allow large scale production and 
marketing of these drugs. 
In the late 1960s world public opinion began to be directed towards ADRs with the “tha-
lidomide disaster” that consisted in thousands of cases of phocomelia in children exposed to 
that drug during gestation. Since at that time there were no organised systems of drug secu-
rity monitoring after marketing, it took 4 years (from 1957 to 1961) to identify the terato-
genicity of thalidomide when the cases of phocomelia were already several hundreds. 
Following the thalidomide occurrences, the 16th World Meeting of the World Health Organi-
zation (WHO) met in Geneva in 1963 decided upon the creation of a world monitoring ADR 
program whose objective was the creation and implementation of detection, registry and 
evaluation systems of hypothetical ADR. Consequently, ADR effects could be minimised and 
their occurrence limited. Subsequent to these decisions some European countries created Na-
tional Pharmacovigilance Centres, the first of all in Netherlands in that same year. Simulta-
neously, in the US, the Food and Drug Administration (FDA) started to assume a more active 
role in the security monitoring of drugs. The pharmaceutical industry also started to develop 
they own pharmacovigilance departments. 
Currently, the majority of developed countries have systems for monitoring during the entire 
life cycle of a drug. It is well know by all that ADR are a serious health public problem with 
important implications for health care and the economy charges.20 Although many of the im-
plicated drugs have proved benefits, measures need to be put into place to reduce the bur-
den of ADR and thereby further improve the benefit: risk ratio of the drugs. 
A revision of literature shows that ADR are an important cause of hospital admissions, with 
estimates varying between 5-15%.52-55 In a largest prospective analysis performed in UK9 
about this subject, the results showed that up to 6.5% of all hospital admissions are related to 
ADR, the overall fatality was 0.15%. A study performed in Canada56 with the aims of review-
ing and summarizing studies concerning reporting rates of drug-related hospital admissions, 
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found that ADR accounted for approximately 5% of all admissions. Another study in 
Europe,52 performed in internal medicine departments of a university hospitals, found a fac-
tor of 8.4% for drug-related hospital admissions. In elderly patients, the hospital admissions 
are higher (about 19.0%)8 nevertheless for children the rate of drug-related hospital admis-
sions is lower (between 1.8 and 3.2%) except for cancer patients. 56  
Thus, prevention of unnecessary hospitalisations by ADR might be an important goal in 
health policy decision-making. Patients who developed adverse effects were hospitalized an 
average of 0.72 to 5.5 days57,58 and the excess costs associated with ADR ranged from $US 677 
to $US 4685.6,59-61 The estimates are conservative because they do not include the costs of in-
juries to patients or malpractice costs. This is important considering the fact that the majority 
of drugs (nearly 90%) are prescribed outside of hospitals, in the general community, where a 
large number of ADR can occur with the number of reports representing only a tiny fraction 
of the supposed total ADR.54 
According to 1990 study by the US General Accounting Office, 51% of approved drugs have 
serious adverse effects undetected before approval. Examples of ADR detected after market-
ing approval was what happened with drugs as cerivastatin, and rofecoxib. This situation 
created some doubts about the security of drugs and the responsibility of authorities and 
pharmaceutical companies in this process.12,29 An article published in 2003 stated that FDA 
receives approximately 280 000 such reports annually, consolidating them into a large data-
base. Healthcare practitioners and consumers submit few reports (<10%) directly to FDA. 
Rather, manufacturers receive more than 90% of reports and must report them to the FDA.18 
However, late or non-reporting of cases by drug companies, or failure to report any adverse 
event at all, are major problems, and there is indeed a conflict of interest in asking industry 
to monitor its own drugs.12 The spontaneous reporting system remains the primary and the 
best method for identifying ADR to newly marketed drugs, and physicians are in the front-
line of the FDA post-marketing surveillance program, and their reports make a significant 
difference.17 Inadequate reporting of adverse events by health professionals may delay detec-
tion of post-marketing adverse drug events.11 
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2.1 Pharmacovigilance 
No drug is completely free from adverse effects it is the evaluation of the benefit/risk of each 
drug that will determine its Marketing Authorisation Holder and its maintenance in the 
market. The development of a new drug follows a series of tests of efficiency and safety in 
animal models that are designed to evaluate their properties. This first phase of pre-
marketing studies is called pre-clinic tests, after what the clinic tests begin. During phase I of 
clinic tests, the main objective is the assessment of the molecule security in humans and a 
limited number of healthy volunteers. Phase II consists of the first tests carried out in pa-
tients so that minimum and maximum dosages can be determined. Finally, in phase III, more 
patients are observed and tests have a longer duration. In this phase it is intended to evalu-
ate the efficiency and safety in patients.62  
Clinical tests carried out during drug pre-marketing had numerous methodological limita-
tions, mainly the reduced number of individuals exposed to the drug, test duration, exclu-
sion of associated pathologies, and the exclusion of special population groups such as old 
people, children and pregnant women.13,63 Therefore, a detailed security assessment of the 
drug could not be assessed before its commercialisation. In fact, the experimental environ-
ment is significantly different from that where the drug will be used after marketing.62  
Pos-marketing studies, also known as phase IV studies, are intended to solve some of the 
lack that were left by pre-marketing studies, namely: compared efficiency; effectiveness; 
other therapeutically uses; small incidence ADR; long treatment consequences and other 
situations. Pharmacovigilance is the study of drug safety during the pos-marketing phase.20,63 
According to the WHO definition ADR is any noxious, unintended and undesired effect of a 
drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy. This 
definition excludes therapeutic failures, intentional and accidental poisoning (ex: overdose), 
and drug abuse. Also, this does not include adverse events due to errors in drug administra-
tion or non-compliance (taking more or less of a drug than the prescribed amount).7 A seri-
ous ADR is defined as any untoward medical occurrence that at any dose: results in death; 
life-threatening; requires hospital admission or prolongation of stay in hospital; results in 
persistent or great disability, incapacity, or both; congenital anomaly, birth defect.28 Several 
types of ADR can be defined: type A: dose-related (augmented) are those that can be ex-
plained by the action mechanism of the drug; type B: non-dose-related (bizarre) are those 
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that can not be explained by the action mechanism of the drug and that can be explained by 
hypersensitivity or immunological mechanisms; type C: dose-related and time-related 
(chronic) are associated with long treatments; type D: time-related (delayed) are associated 
with carcinogenicity and teratogenicity that occur delayed; type E: withdrawal (end of use) 
are those that take place after the end of use of the drug such as benzodiazepines; and finally 
type F: unexpected failure of therapy (failure) inadequate dosage of an oral contraceptive.64 
2.1.1 Pharmacovigilance in Portugal 
In Portugal, the National System of Pharmacovigilance was created in 1992 as a consequence 
of the adhesion of Portugal to European Union, former European Economic Union. The De-
cree Law 72/91 that transpose for Portuguese law the European Guidelines in the drug area 
states in Artº 94 that “Holders of Marketing Authorisation, physicians, technical directors of 
pharmacies and other health technicians should inform National Institute of Pharmacy and 
Medicine (INFARMED) the ADR that occur as a consequence of a drug use”. The Decree 
Law 107/92 from 27th of June initially defined the organization of the system. The National 
System of Pharmacovigilance is integrated net of agents that promote together for the same 
objective, to ensure a safe use of available marketed drugs. 
 
 
Figure 1. Graphic representation of National System of Pharmacovigilance and the rela-
tionship with European System of Evaluation and Supervision of Drugs as well 
as with other international organisations. 
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In Figure 1, a schematic representation of different components of the system and its relation 
with the European System of Evaluation and Supervision of Drugs as well as with other in-
ternational organisations can be seen. 
Pharmacovigilance Department of INFARMED that together with Regional Units of Pharma-
covigilance, created in 1999 through Law 605/99 that defines the standards and regulations 
coordinate the system. With the creation of Regional Units of Pharmacovigilance, the Na-
tional System of Pharmacovigilance is no longer a centralised system, similarly with what 
happens in countries such as Spain or France.  
National System of Pharmacovigilance is articulated with the European system of security 
and drugs control. The Committee for Proprietary Medicinal Products (CPMP) of European 
Agency for Evaluation of Medicinal Products (EMEA) and the respective Pharmacovigilance 
group (Pharmacovigilance working party – PhVWP) are the pieces of the system. Portugal 
contributed with drug information for WHO ADR database. National System of Pharma-
covigilance collaborated with restricted e-mail distribution list of set up to stimulate discus-
sion and facilitate rapid exchange of information between representatives of National Cen-
tres participating in WHO International Drug Monitoring Program (VIGIMED). 
The National System of Pharmacovigilance is essentially based on spontaneous reports of 
ADR by health professionals. This means that health professionals are the foundation of all 
the system. The first report form of ADR was created in 1992, inspired by the “yellow card” 
used by the English system, and was designed for use  by physicians. Later, a new form was 
designed for use by pharmacists. It is important to note that Portugal was one of first Euro-
pean countries that actively engage pharmacists in detection and report of ADR. The phar-
maceutical industry is an important piece in the system that has specific obligations defined 
by legislation, among them the responsibility for constant monitoring of drugs with Market-
ing Authorisation Holder. 
2.2 Pharmacovigilance Methodologies 
Pharmacovigilance is an observation and selection process of information about the effect of 
drugs under the usual practical clinical conditions, searching data regarding drug safety and 
risk. Two types of report systems could be identified under this assumption: the spontaneous 
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reporting system and the epidemiologic studies. The spontaneous reporting systems may be 
systematic and organized systems (for example the Yellow Card or the Prescription Event 
Monitoring Program) or anecdotic (report in medical journals). Epidemiologic studies re-
quire large enough populations or groups that allow data extrapolation such as: (1) intensive 
monitoring; (2) record-linkage systems; (3) the use of morbidity and mortality databases; and 
(4) the cohort and case-control studies that allow the certification of the alerts and hypothe-
ses originated by spontaneous report.  
Spontaneous reporting of ADR is denominated in many countries according with colour of 
formulary used to collect data, normally “Yellow Card”. This system collects information 
about general population, all medicines and all types of ADR. Prescription Event Monitoring 
is a program dedicated essentially to monitoring medicines security, in first years of com-
mercialization. This program is used for a reduced number of medicines and specific pa-
tients. The anecdotic report is an anarchic method with many limitations, the main one being 
the publication of cases where causality between the medicine and the reaction is finding. 
This situation is difficult to happen in clinical practice and could delay the alert.62 
Intensive monitoring programs were created to collect intensive and complete data about 
diagnostic and treatment of hospitalized patients, with this data is possible to build data-
bases and perform incidence and prevalence studies. Record-linkage systems are available 
only in a reduced number of countries because of the costs and of the organization. This sys-
tem has some limitations such as the included population, type of data and quality of data. 
The study of morbidity and mortality databases with information about medicines consump-
tion could be important to establish relation with a particular ADR, normally serious, and 
the use of medicines. Following the alerts generated about suspicions in security of a medi-
cine it is necessary to test the hypotheses and quantify risk. The cohort and case-control stud-
ies are normally used in this situation. These specific studies are based in groups of patients 
exposed to a specific medicine or patients that have a characteristic ADR, studding the medi-
cines used by the patient.62 
2.2.1 Spontaneous Report of Adverse Drug Reactions 
The main objective of spontaneous report of ADR is to promote the rational use of drugs 
based on security and efficiency criteria. The base parameters it are: (1) collect, evaluate and 
divulge information about ADR; (2) identify ADR; (3) analyse and examine a possible exis-
tence of a causality drug-ADR; (4) create methodologies for data acquisition; (5) evaluate the 
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safety profile of marketed drugs; (6) produce technical standards for using drugs; (7) elabo-
rate activities to reduce drug risks; and (8) collect data about drug consumption. 
The methodology used in Portugal to evaluate causality is the global introspection. This 
means that temporal relation, pharmacologic plausibility, base diseases, concomitant situa-
tions, concomitant medication, evolution after suspension, effect after re-exposition and 
quality of information are analysed altogether. Thus, the ADR profile could be defined re-
garding clinical and laboratorial evidences, severity, intensity and frequency for drugs of the 
same group, eventual action mechanism, causality nexus, predisposal factors, reversibility, 
and sequels. This evaluation allows the estimation the degree of probability that might be: 
definitive, probable, possible, improbable, conditional, and non-classifiable, according to 
WHO definitions. 
Epidemiological vigilance of drugs is based on spontaneous reports of ADR by health pro-
fessionals, through report forms. This form can be completed in an easy and fast way, and 
collects the necessary information to evaluate the ADR suspicion. The information collected 
is that considered as indispensable to obtain causality. All information collected through re-
port forms is confidential. 
In Portugal there are report forms specific (Appendix A) for each professional group: yellow 
for physicians, purple for pharmacists and white for nurses. Essentially, these forms collect 
all the same type of data but their differentiation is justified by different clinical practices.  
The spontaneous report of ADR have numerous advantages such as: (1) simple method that 
can be implemented in a short period of time; (2) is cost effective; (3) includes all the popula-
tion and all possible reporters; (4) includes all the drugs in the market during their entire life 
cycle; (5) doesn’t interfere with prescription practice; and (6) might be used as a basis for the 
design of specific epidemiologic studies. Nevertheless, this advantages come with several 
disadvantages: (1) low level of participation of health professionals, the under-reporting; (2) 
it is not possible to calculate the incidences of ADR, because it is not possible to know the 
number of patients exposed to the suspicious drug neither the exact number of induced reac-
tions; (3) it is quite difficult to detect reactions that has a large latent period as might be the 
case of carcinogenic and teratogenic reactions, (4) spontaneous report do not reliably  detect 
ADR that represent an increased risk of an adverse event that occurs commonly in popula-
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tion not exposed to the drug, and (5) identification of ADR associated with long-term ad-
ministration of drugs for chronic diseases also remains problematic.13 
2.2.2 Under-reporting 
The spontaneous reporting of ADR is fundamental to the safety surveillance of market medi-
cines. A number of studies have suggested that fewer than 10% of ADR are reported.21,54 
Even in countries with high reports ratios the usual report ratio is about 10 to 50% of serious 
ADR.25 Others studies had been suggested that at most only 14% of all suspected ADR are 
reported in general practice65 and reporting from hospitals appears to be worse, even though 
they presumably see more serious reactions.66,67 A study carried out in UK hospital shown 
that only 6.3% of the potential reports cards hospital had been sent to the Authorities.54 
The European Pharmacovigilance Research Group conducted a series of surveys in European 
Union countries to assess the attitudes of physicians towards ADR reporting between 1993 
and 1994 shown a wide variation in the percentage of physician respondents in each country, 
who stated that they had “ever” reported an ADR, ranging from 19.4 % in Italy to 74.4 % in 
France. The national reporting rate (between 1989 and 1993) for each country varied between 
44.3 reports/million habitants/year in Italy to 389.7 in France. Portugal participated in this 
study with a report of 8.6 reports/million habitants/year but the Portuguese system started 
only in 1992.68 A study30 performed with data from 2001, provided from national pharma-
covigilance centres permitted observed that some countries as Spain, France, UK and Swe-
den had spontaneous report ADR ratios from physicians higher than Portugal (71.5 physi-
cians’ report/million habitants), nevertheless countries as Italy and Greece had report ratios 
lower than Portugal. In relation to pharmacists the data were different because we did not 
had data from Sweden, UK and Greece, nevertheless, Spain and France had values higher 
than Portugal (19 pharmacists’ report/million habitants) but in Italy the report ratio are 
lower than Portugal, in both situations we talk about directly reports from health profession-
als. 
Pharmacovigilance aims at the detection, assessment and prevention of adverse effects or of 
any other possible drug-related problems.20 However, pharmacovigilance has historically 
been underused by physicians.39 Physicians are on the frontline of reports programs, and 
their reports could make the difference, the spontaneous reporting is the most effective and 
rapidly method for detection new ADR.17 Under-reporting may delay the detection of impor-
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tant ADR. Several studies performed in different environments (US,36,39,47 Portugal,51 Spain,41 
Italy,19 UK,21,44-46,48 Netherlands,42 Sweden,43 European Union,68) are stable that the knowl-
edge-attitudes of physicians and pharmacists in respect to the spontaneous ADR report sys-
tem are inadequate and associated with under-reporting.  
It is very important for pharmacovigilance centres understand the reasons of under-
reporting and take appropriate measures to increase the spontaneous report.42 Portugal is 
one of the countries where under-reporting is the major disadvantage of the system and this 
is the reason why this study intends to know the reasons that cause it, and act above them to 
increase report from our health professionals.  
2.3 Factors related with ADR report 
To simplify the bibliographic revision about factors related with ADR report a theoretical 
model for the system of spontaneous reporting of ADR was developed and was used as a 
reference to accomplish a bibliographical revision36,39,43-45,69,70 of the factors that condition the 
reporting. The bibliographic revision was done in Comprehensive Source of Life Sciences 
and Biomedical Bibliographic Information (MEDLINE). We searched these indices from 
January 1985 to January 2005 and the following search strategies were: (1) report* AND (ad-
verse-drug-reaction* OR adverse-drug-event*) AND  (attitud* OR knowled*) AND (pharma-
cis* OR physician* OR doctor), (2) drug* AND adverse* AND education* AND (medical* OR 
pharmacist*) AND continuing*. Abstracts and titles were read and the articles selected. Ad-
ditionally an ascending search based on selected articles. 
The proposed theoretical model (Fig.2) distinguishes two major condition types: (1) intrinsic 
condition, related with the health professional’s education, and (2) extrinsic condition that 
included all those factors associated to the professionals’ interaction with their work atmos-
phere. According to this model71,72 the theory of habits acquisition in health sciences knowl-
edge-attitudes-practices would explain the influence of the health professionals’ education and 
the theory of the satisfaction of needs73,74 would explain the influence of the factors on the work 
atmosphere. This theoretical model was applied to the prescription of drugs75 and too the 
spontaneous reporting of ADR76.  
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In this model, the intrinsic conditions such as the medical and pharmacist education and the 
amount and quality of the sources of information, at the professionals’ disposal in their activ-
ity, condition their knowledge in what respects the surveillance of medicines and that 
knowledge generates attitudes on the reporting system, which comes to be reflected in their 
reporting practices. However, the knowledge-attitudes-practices relationship is not univocal 
(the same knowledge does not lead to the same customs) and therefore it is modified by ex-
trinsic factors77, whose influence on the reporting can be explained by the theory of the satis-
faction of needs.78 Thus, in the process of reception of information professionals can develop 
mechanisms of selective perception capable of isolating them from information that they re-
ceived a priori. Therefore, when it is possible to generate in the professional certain attitudes 
about spontaneous reporting, these can be in contradiction with his practices, as a result of 
extrinsic factors such as his daily relationship with patient, administration and pharmaceuti-
cal companies. According to the model of satisfaction of needs, professionals will feel the need 
to keep a harmonious relationship with their work environment, thus adapting, consciously 
or unconsciously, their practices of drug surveillance to the demands, in many cases opposed 
to these three elements. 
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Figure 2. Mixed theoretical model of the factors that condition the health professionals’ 
attitudes in the reporting of ADR to medicines. 
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2.3.1 Intrinsic condition 
According to the knowledge-attitudes-practices model, the medical and pharmacist background 
together with the sources of information at the disposal of the health professionals in their 
activity, generate knowledge and attitudes on the system of spontaneous reporting of ad-
verse reactions to medicines, which condition the reporting practices. 
The knowledge acquired during university studies gives the future professional important 
information. However, this varies in a significant way among the various countries, and in 
the same country among different universities.79,83 Studies carried out in the US84 and UK85,86 
seem to demonstrate some dissatisfaction on the part of medical students with the time 
available for the teaching of pharmacology and therapeutics and they propose important 
changes in the undergraduate teaching curriculum, such as prescribing for the elderly, man-
agement of overdose, and adverse drug events. Other studies performed with pharmacy 
students demonstrated that educational activities like identification of potential ADR, 
changes in drug therapy regimens, have a positive influence on patient care.87-89 According to 
some studies90,91 the knowledge, attitude and practices of both undergraduates and pre-
scribes were comparable but they need further improvement, thus suggesting the need for 
suitable changes in the undergraduate teaching curriculum; furthermore, prescribes also 
need periodic reinforcement regarding ADR monitoring. 
The topic of continuing education is considered by some authors39,92-96 to be extremely impor-
tant in providing up-to-date information and knowledge to physicians and pharmacists. Ac-
cording to them there exists a direct relationship between the intensity of the educational in-
tervention and the number of processes that present positive results. There are many differ-
ent types of intervention that can be used to promote behavioural change among healthcare 
professionals and the implementation of research findings.97,98 Disentangling the effects of 
intervention from the influence of contextual factors is difficult when interpreting the results 
of individual studies of behavioural change. Nevertheless, systematic reviews of rigorous 
studies99-102 provide the best evidence of the effectiveness of different strategies for promot-
ing behavioural change: (1) passive dissemination of information that is generally ineffective; 
(2) didactic sessions as conferences that has little direct impact on improving professional 
practice; and (3) methods such as systematic practice-based interventions and outreach visits 
used by continuing medical education providers that are more effective. Interactive continu-
ing medical education sessions that enhance participant activity and provide the opportunity 
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to practice skills can effect change in professional practice and, on occasion health care out-
comes. A study performed in Spain103 demonstrate that a larger personalization of the ses-
sion make them more efficient, although an study realized in Indonesia104 to evaluate the ef-
ficacy of different methods of interventions to improve the appropriate use of drugs for acute 
diarrhoea, showed that the small group face-to-face intervention did not appear to offer 
greater impacts over large seminars in improving the appropriate use of drugs.  
According to the knowledge-attitudes-practices model, the university education and specializa-
tion are probably the main conditions of the health professionals’ reporting, as well as the 
sources of information at the professional’s disposal in daily work. During their professional 
life they come across numerous medicines, new therapeutic indications, and at the same time 
new adverse reactions are being discovered, all of which forces them to keep up-to-
date.90,92,93,105-107  
Based on the origin of the sources information that a physicians and pharmacists use we can 
distinguish: (1) independent sources, mainly scientific journals and books; (2) institutional 
sources, pharmacological guides, surveillance bulletins, report procedures; and (3) commer-
cial sources, mainly medical and pharmaceutical information people and publicity from the 
pharmaceutical companies. In a study108 performed in Drug Information Centres in Italy, 
was verified that 90% of these Centres produce newsletters and/or bulletins and are in-
volved in research projects, regarding the question-answer service, requests are mainly con-
cerned with clinical comparative efficacy, therapeutic use, adverse effects, and the most fre-
quent users are physicians followed by pharmacists. The most frequently used information 
sources are: books (Martindale), journals (ADR bulletin) and databases (MEDLINE). Drug 
information services in hospitals are very important for health professionals. A study de-
scribes a higher use of hospital-pharmacy-based online by physicians and pharmacists, when 
information about drugs is available on time and in comprehensive way.109 
Scientific journals are probably, the independent sources of information more objective at the 
disposal of the health professionals between their influenced does not seem to be in keeping 
with quality. For many years physicians have had to cope with the accusation that only 10-
20% of the treatments they provide have any scientific foundation. Their interventions, in 
other words, are seldom “evidence based”.110 Incorporation of evidence based medicine 
meetings into hospital routine practice has resulted in treatment guidelines being more 
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closely based on published evidence and improvements to care of patients. Written summa-
ries of the meetings are important to facilitate change.111 
The small impact that scientific journals seem to have is probably due to the great amount of 
existent literature that makes it difficult to read all the relevant material. In this sense, sur-
veillance bulletins can constitute an intermediate step between the large amount of scientific 
literature and the information on surveillance of medicines that the health professionals 
needs. The best ways of publishing suspected ADR are spontaneous reporting to drug moni-
toring centres, pharmaceutical companies and publication of case reports in medical journals. 
Spontaneous reporting is probably the quickest and most effective way of alerting physicians 
and pharmacists.112 Despite limitations of the available data, the asymmetry between the in-
formation available to the company and the information available to the patients and physi-
cians seems striking. A subjective element is present in the effort to infer whether or not the 
occurrence of untoward outcomes in users of a particular drug was actually the consequence 
of the use of that drug, and, under the current system, a pharmaceutical company’s appraisal 
of spontaneous adverse drug reaction may be influenced by economic considerations. Such 
an appraisal would best be made by an independent group.12 
In relation to the commercial sources of information, according to some authors, the pharma-
ceutical industry covers the formative deficit the health systems suffers from, which is larger 
in less developed countries, where the influence of industry is greater.113,114  
Publicity of medicines is another important method of communication between pharmaceu-
tical companies and prescribes. Prescription drugs comprise approximately 9% of the total 
cost of health care in the US.115 The manner in which physicians obtain information about 
new and changing pharmaceuticals obviously has the potential to have a profound impact 
on health care costs, pharmaceuticals companies’ profits, and the quality of health care. The 
industry feels that publicity is a good method to keep physicians up-to-date, which seems to 
contradict the large amounts of money that laboratories design to promotion. The target of 
publicity should be to inform according to scientific criteria and that is why, although it can 
be easily noticed on many occasions, the language and the scientific images used mainly ap-
peal to the physicians’ fantasy. In other situations the publicity of medicines comes in the 
form of reports resembling magazine editorial material, which can induce confusion. Adver-
tisements are a major source of income for medical journal. Most adverts in medical journals 
are about drugs and medical devices. Articles are mean to inform, instruct, comment and, 
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possibly entertain, whereas adverts are meant to persuade. A study116 carried out in US 
medical journals editors, showed that a large percentage of editors favoured more stringent 
review of drug advertisements and the reviewers felt that the advertisement would lead to 
improper prescribing if a physician had no other information about the drug, this publicity 
has little or no educational value, according to the reviewers that participated in this study. 
Nevertheless, in a study117 investigates the influences of pharmaceutical companies’ advertis-
ing programs on physicians, 67.7% of them thought that information delivered by industry it 
was not reliable and 62.8% reported that it had no effect on their prescription writing. 
Readers should not request claims in journal adverts, with or without credible-appearing 
references, on face value.118 In a study performed in Spain119, the investigators report the ex-
tent to which claims made in adverts for anti-hypertensive and lipid-lowering drugs in Span-
ish medical journals are supported by the citations attached to those claims. The citations 
were typically from strong studies in prestigious journals, suggesting that advertisers value 
the best available evidence or want to associate their demands to a respectful source, how-
ever; nearly half of the promotional statements were not supported by the associated refer-
ences. 
Numerous studies36,39,41-48,51,120 have been carried out with purpose of studying health profes-
sionals’ opinions and attitudes to the spontaneous report of ADR. Post-marketed surveil-
lance is essential to evaluate the safety of medicines and spontaneous reporting by physi-
cians and pharmacists are necessary to detect ADR, especially the rare ones and in the new 
drugs. The total rate of reporting was substantially smaller than expected based on studies 
about morbidity incidence and mortality induced by drugs. Even in countries with high re-
port rates, only between 10 and 50%of serious ADR are reported.121,122 
The reasons for the under-reporting are numerous and complex, physicians and pharmacists 
failing to report for several reasons, such as compliance, the ambition of collecting and pub-
lishing serious cases personally, ignorance of reporting rules, distrust about reporting merely 
suspicious, indifference about the physician’s individual role as a scientific investigator, lack 
of confidence in the diagnosis of a particular ADR, lack of time, lack of interest, lack of yel-
low cards.36-40,48 
Although, existing factors important in the decision to report such as: seriousness and un-
usual reaction, new product, need to build drug safety profile, the degree of confidence in 
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ADR diagnosis and awareness of similar reports (some previous publicity to a specific ADR) 
21,70,123,124 are important in health professionals’ decision of reporting however, in some stud-
ies it was observed that physician125,126 and pharmacists105 were unaware of the criteria of the 
National Drug Regulatory Agency indicating the need for additional education and informa-
tion on this point. It is know that ADR constitute a serious problem in our society and in 
therapeutics, both as a health care problem and as a problem with high financial costs.4-6  
2.3.2 Extrinsic condition 
According to the mixed theoretical model, the knowledge of surveillance is not expressed 
directly in report habits, because different extrinsic factors can significantly condition deter-
minism in the knowledge-attitudes-practices relationship. In the circumstances under which 
health professionals develop their activity, they are in interaction with industry, health ad-
ministration and patients, which will also be important in conditioning their reporting. 
Probably, it is not possible to explain the influence of industry on ADR reporting only 
through the information that it facilitates, therefore it is necessary to incorporate the model 
of satisfaction of needs, which considers a health professional’s need to be in harmony with 
them work environment. In same countries as US and Germany, physicians68,114 and pharma-
cists47 report more often to the pharmaceutical industry than to the National Drug Regula-
tory Agency. Some authors113,117,127-129 feel that the pharmaceutical companies take advantage 
of a physician’s position in the health system to create personal links with them, reinforcing 
the incentives, which can be reflected in the nature of the prescription. Physicians have a ma-
jor role in the prevention of ADR and should resist marketing pressures to prescribe new 
and potentially more toxic drugs and preferably to prescribe well-established and safer 
drugs. The majority of the adverse reports that the FDA receives come from drug manufac-
turers. Therefore, most of these reports are available to the manufacturer before the authori-
ties. Drug manufacturers have a responsibility to analyse these reports thoughtfully and to 
act on their conclusions and not just to focus on delivering their reports to the authorities in a 
timely approach. Despite limitations of available data, the asymmetry between the informa-
tion available to the company and the information available to patients and physicians seems 
striking, and under the current system, a pharmaceutical company’s appraisal of suspected 
ADR may be influenced by economic considerations.12 For example, it is surprising that ter-
fenadine was removed from the market, not when the adverse effects were identified, but af-
ter the manufacturer had developed a new product to substitute for it.130 Drug safety will 
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only improve when it is viewed as a cooperative venture between authorities, industry, and 
health professionals. 
Unlike industry, which traditionally maintains a good relationship with health professionals, 
the administration is usually seen as the control element, indifferent to the health techni-
cians’ daily problems. The polities that integrate health professionals into the system to that 
they also may feel responsible for its defects and advantages brought about widespread im-
provements in the relationship between professionals and the administration, thereby result-
ing in improvements in the health technicians’ activity. The administration should strike a 
balance between the necessary measures of control on the professional and the more impor-
tant political incentives for the professional. In some studies131,132 carried out in UK and US 
about physicians-administrators relationships, were observed that is very important to im-
plement several strategies to improve these relationships, including greater organizational 
transparency in decision-making, more frequent communication, and more physician in-
volvement in decision making, and in organizational governance. Despite the tensions cre-
ated by competition and rapid change, transformation from a blaming to a learning envi-
ronment may be a key strategic advantage in today’s health care marketplace. In relation to 
pharmacists133-135 studies suggested that expertise in drug use can benefit patients, physi-
cians, and the hospital administrators who are confronted with ever increasing costs. Cost 
reductions due to the pharmacists’ clinical interventions, such as monitoring overuse of 
drugs, unnecessarily prolonged hospitalization, correction of medication errors, and reas-
sessment of prescriptions. Hospital administrators had a positive perception of the abilities 
of pharmacy responsible but believed that there is still room for improvement. In a study 
carried out in China, the knowledge about ADR by hospital administrators was consider as a 
important factor for the increased of ADR report by health professionals,125 other study48 re-
fer a written hospital policy for ADR reporting as an encourage measure to professionals re-
ports, the unavailability of reports cards is refer from health professionals as an deterrents to 
report, in this issue the policy of hospitals could be very important too.21 Providing financial 
incentives for the time spent by a health professional’ in filling the yellow card is an often-
used approach, and according to Inman126 this is a potential factor of under-reporting, seen 
that for example pharmaceutical industry, pays to the physicians for the patient’s inclusion 
in the clinical trials. However, in most of the studies reviewed it does not seem to be a poten-
tial cause of under-reporting because pharmacists46 and physicians36,41,44,51 believe that they 
must not to be paid for something they consider a professional obligation, a fee was not con-
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sidered to be an incentive to report, but in literature appear two articles that appoint for the 
stimulation of ADR reporting with financial recompense.136,137 Fear of legal responsibility38,138 
appears to be an important factor in under-reporting. The physicians responsibility is based 
on negligence contributes to a patient’s damages. It is part of the patient-physician relation-
ship that physicians are allowed to treat their patients with the most appropriate treatment 
except in case of medicines in the investigation phase that it is necessary the patient authori-
zation previous. In studies41,51 carried out in Europe it was found that physicians believed it 
was their duty to report ADR and they did not consider that it increased their professional 
responsibility. This discrepancy between the studies carried out in US138,139 and Europe41,51 
may signify a greater concern about potential legal consequences ADR reporting on the part 
of US physicians. Physicians fail to report ADR for several reasons and neither financial in-
centives nor compulsory legislation seems to be the solution. 
Another important condition of spontaneous reporting of ADR is the interaction with pa-
tients. The surveillance system is spontaneous and therefore it is only their professional re-
sponsibility that compels physicians to report an adverse experience with a medicine involv-
ing their patients.36,66 In some studies physicians and pharmacists have pointed out that the 
cause for under-reporting is the confidentiality of the physician36,41 and pharmacist-patient 
relationship48 and the sense of guilt for having prescribed or recommend a treatment that 
provoked damages to their patient. Pharmacists are excellently placed to provide valuable 
post-marketing information on drug products owing to the fact that, they are a vital link 
with the patient before and during a course of drug therapy.30,46 Pharmacists are the only 
professionals in contact with herbal35 and over-the-counter medicines.32-34 Studies140-142about 
geriatric and asthmatic patients referred the importance of pharmacy practice in these 
groups of patients because the long-term care, over prescription, drug interactions, ADR re-
ports, and communication with the elderly, the quality of this relationship between patients 
and pharmacists seems to be important medication management. An study143 appoint patient 
as another potential source for case reports of suspected ADR, the reports were less sensitive 
than physician’s report, large scale reporting of events from patients might be valuable for 
earlier detection of symptomatic reactions to new drugs. Direct patients yielded a signifi-
cantly higher rate of ADR detection in an ambulatory care stetting than did passive ADR re-
porting system.   
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There are other factors that are pointed by health professionals as reporting barriers. The 
barriers such as lack of availability of report forms and shortage of time were appointed in 
several studies38,40,42,43,45 as an important reason for non-reporting. Health professionals re-
ferred in bibliography that: (1) reporting of ADR takes too much time; they have insufficient 
time, give priority to other matters and they lack time to fill out the reporting form; and (2) 
there are lack of report forms, there are no reporting forms available in workplace.  
The results of this bibliographic review indicate that there are several factors that might in-
terfere in the ADR report. Moreover, the combination of knowledge-attitudes-practices and the 
theory of the satisfaction of needs seemed very adequate for ADR systematization. To improve 
the participation of health professionals in surveillance systems through spontaneous report-
ing it may be necessary to designed combined strategies that modify both intrinsic (knowl-
edge, attitudes) and extrinsic (relationship between health professionals and their patients, 
the national health system and pharmaceutical companies) factors.  
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3 HYPOTHESES AND OBJECTIVES 
3.1 Hypotheses 
1. There are socio-demographic and personal factors related with under-reporting. 
2. The knowledge and attitudes of health professionals related to ADR are not ade-
quate. 
3. The knowledge and attitudes of health professionals related to ADR influence the 
under-reporting  
4. An educative intervention designed base on knowledge and attitudes marked as 
inadequate and associated to under-reporting improve the number and quality 
(relevance) of ADR reporting. 
5. Provide a report card during the intervention improves spontaneous reporting of 
ADR. 
3.2 Objectives 
3.2.1 General objective 
Increase quality (relevance) and quantity of spontaneous ADR reporting by health profes-
sionals (physicians and pharmacists). 
3.2.2 Specific objectives 
1. Identify socio-demographic and personal factors related with under-reporting by health 
professionals (physicians and pharmacists). 
2. Identify the knowledge and attitudes of health professionals (physicians and pharma-
cists) related to under-reporting of ADR. 
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3. Analyse if an educative intervention −designed for change knowledge and attitudes re-
lated with under-reporting of ADR found in the second specific objective− increases the 
quantity and quality (relevance) of spontaneous report of ADR by health professionals 
(physicians and pharmacists). 
4. Evaluate the duration of the effect of the educative intervention both in quality (rele-
vance) and quantity by physicians and pharmacists.  
5. Evaluate if providing a report card during the intervention increases the probability of 
spontaneous reporting of ADR.  
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4 METHODS  
To achieve the objectives of this work, two different studies have been carried out. A case-
control study to identify the knowledge and attitudes of health professionals (physicians and 
pharmacists) related to ADR reporting and a cluster-randomized trial study where an inter-
vention have been carried out to change this knowledge and attitudes related to under-
reporting to increase ADR reporting. 
4.1 Case-control studies  
4.1.1 Design 
Two case-control studies were performed; one for physicians and other for pharmacist. The 
cases are subject (physicians or pharmacists) with a determinate characteristic. In this case 
the characteristic is report at less one time for the Northern Pharmacovigilance Unit on north 
region of Portugal, since the begin of function the Northern Pharmacovigilance Unit until the 
date the study begin. The controls are a sample of the non-reporters. The criterion for selec-
tion the study population was the presence or absence at least the one report.  
4.1.2 Subjects 
The target population in this study is composed of physicians (working for the National 
Health System) and pharmacists (working in community and hospital pharmacies) who 
work in geographic area corresponding to the Regional Health Administration of the North. 
The database for physicians was provided by the Regional Health Administration of the 
North at the beginning of the study (year 2002) and for pharmacists by the National Associa-
tion of Pharmacies and by the Portuguese Association of Hospital Pharmacists also at the 
beginning of the study (year 2003). 
To ensure reliable results, it is necessary to define a representative sample of the population. 
In this study, 2 sub-samples (cases-controls) for each study (physicians/pharmacists) were 
created. 
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4.1.3 Sample settings 
Sample is a set of really studied subjects. The number of subjects necessary for the study is 
lower than the study population. Therefore this study works with a sample of all the 
population; in particular two sub-samples were defined.  
4.1.3.1 Sub-sample of Cases  
The case group is composed by 2 sub-samples: (1) all the physicians registering in Regional 
Health Administration of the North and (2) all pharmacists that work in community and 
hospital pharmacies registered in respective associations. In each case they must fulfil the 
following inclusion criterion: work in geographic area corresponding to the Regional Health 
Administration of the North in the beginning of the study and report at least one ADR, for 
Northern Pharmacovigilance Unit between the beginning of this operation and the beginning 
of the study. The exclusion criterions are: (1) work only in the private hospitals sector (small 
sector in Portugal) for physicians and pharmacists and (2) work as teachers, administration 
areas or pharmaceutical and distributors companies for both pharmacists and physicians. 
4.1.3.2 Sub-sample of controls  
The control group is composed by 2 sub-samples: (1) physicians registered in Regional 
Health Administration of the North and (2) pharmacists that work in community and hospi-
tal pharmacies registered in respective associations. For physicians and pharmacists, the ap-
proximate ratio with respect to the cases is 1:8. They must fulfil the following inclusion crite-
rion: work in geographic area corresponding to the Regional Health Administration of the 
North in the beginning of the study and never reported an ADR for Northern Pharmacovigi-
lance Unit between the beginning of this operation and the beginning of the study. The ex-
clusion criterions are the same used for cases. 
4.1.3.3 Determination of sample size  
The determination of the size of the samples took into consideration that if a sample were 
excessively small it would be impossible make reliable extrapolations from the resulting data 
to the population. Oppositely, if an excessive large sample is used it will be a waste of re-
courses. In this study, all the cases were included and a proportion of about 8 controls for 
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each case (in physician’s sub-sample this proportion is about 10% and in pharmacists is 
about 20% of the population in each stratus) were used. Nevertheless, a proportion of 1:4 
was considered theoretically more efficient.144 In this study, we take account that the number 
of cases is very small and that normally in this type of studies, the number of non answers by 
control group is higher (about 50%).36,41,68 
4.1.3.4 Type of sample 
The type of sample used was the stratified sample with proportional selection. This method 
consists firstly in distributing the population in subgroups or stratus, accordingly to one or 
more characteristics and secondly for creating a random sample independent in each stratus. 
This sampling method ensures that for each stratus the number of subjects is proportional to 
the number of the population subjects within that stratus. The sub-sample for the control 
group was determined by stratification of each health sub-region, proportional to the num-
ber of subjects belonging to each sub-region (Table 1). 
Table 1. Stratified sample by sub-region of health (physicians) 
Sub-region Nº of physicians Nº of reporters (cases) 
Sample of non report-
ers (controls) 
Porto 5224 67 522 
Braga 1338 16 134 
Viana do Castelo 538 1 54 
Bragança 232 2 23 
Vila Real 384 2 38 
TOTAL 7716 88 771 
 
For physicians, the method was as follows. For each stratus, a random selection of the sam-
ple was realized by attributing a random number between 0 and 1 to each subject in his sub-
region. This procedure used the random function of Microsoft Excel for the generation of 
random numbers. After that, subjects were sorted in an ascendant order of the random num-
bers. The selected subjects for each sub-sample were the first in the ordered list. The five sub-
samples were assembled to constitute a unique database with all sample components, about 
770 subjects. 
For pharmacists the process is the same used for physicians with the exception that the num-
ber of subjects was about 280 (Table 2). In sub-region of Vila Real, we did not have any re-
porter and consequently it was assumed the existence of one for computational reasons. 
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Table 2. Stratified sample by sub-region of health (pharmacists) 
Sub-region Nº of pharmacists Nº of reporters (cases) 
Sample of non report-
ers (controls) 
Porto 850 24 192 
Braga 264 6 48 
Viana do Castelo 98 1 8 
Bragança 51 3 24 
Vila Real 90 0 8 
TOTAL 1353 34 280 
 
4.1.4 Data collection 
The two methods for collecting data that could be better adjusted to the study objectives 
were the postal questionnaire and the personal interview. Nevertheless, considering the 
population characteristics (higher dispersion) and subjects (licentiate) it was decided that the 
auto-fulfilling postal questionnaire was the most indicated for the study. The main limitation 
of the postal questionnaire method is the small index of participation.144 Therefore, it is very 
important that materials are carefully elaborated. The materials sent were a letter of intro-
duction, presenting the study, and a questionnaire. In a study with these characteristics the 
questionnaire is very important. In fact the questionnaire is the measure instrument and also 
the element of motivation or dissuasion of the subject participation in the study. The ques-
tionnaire was building with the intention to be comprehensible, succinct and attractive. The 
objective was to produce in subjects a favourable attitude to fulfil the questionnaire. 
4.1.5 Questionnaire elaboration 
The questionnaire was built based in an intensely bibliographic review. The questions were 
elaborated accordingly to previous studies,36,38,39,43-45 the main reference being a study per-
formed in Spain.41 The questions were based in the “seven deadly sins” of Inman37 and the 
scale used for measuring the answers is that reported in Spanish study.41  
The questionnaire contains 25 variables in two pages (one sheet). The brevity of the ques-
tionnaire was felt to be of great importance, since according to some authors145-149 this feature 
is essential for motivating answers. In the upper part of the page, the logotype of the respon-
sible institutions (Northern Pharmacovigilance Unit and INFARMED) for the study was 
placed.145 
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The questionnaire was divided into 4 parts (Appendix B). The first part, include the fulfilling 
instructions, with intention to facilitate a fast lecture and comprehension of the fill of ques-
tions. Accordingly with the instructions, the 15 questions of the second part was the ques-
tions about knowledge and attitudes related with ADR reporting by health professionals and 
were measure using a visual analogical scale, horizontal continuous of 8 cm and not numer-
ate. The answer is marketed in a segment, with left and right extremes representing, respec-
tively, total disagreement and total agreement with the question. The subject must do a cross in 
the area of the segment that represent its opinion, as much to the right all that his agreement 
with the question and as much to the left all that his disagreement with the question. An 
equal scale drawn in a transparency and divided into 20 parts is placed over the question-
naire to make the reading of the answers easier. The visual analogical scale was divided into 
20 parts, from 0 to 20, to transform it in numerical values.  The value 0 means total disagree-
ment and 20 means total agreement. For statistically analysis, this scale was later transformed 
in a 0 to 10 scale, with 0.5 precision.150 
This type of shape had as objectives: easy fulfillment and reduction of the necessary time to 
do it and realize a statistic measurement consider the variable as quantitative. In the third 
part of the questionnaire 3 questions about the spontaneous report system of ADR and avail-
ability of cards are made. For this answers verification windows were used. The last part of 
the questionnaire included affiliation questions (age, gender), education data (specialty and 
type of activity) and questions about the environment where the health professional works 
(number of patients, level of prescription, and level of drugs dispensation). 
4.1.5.1 Validity 
In this study the validity consensus was evaluated, that consists in the evaluation of one 
characteristic by several experts. The questionnaire was submitted to the experts of the Na-
tional Pharmacovigilance Department of National Institute of Pharmacy and Medicine, 
Northern Pharmacovigilance Unit, National Association of Pharmacies, (Pharmacoepidemi-
ology studies centre), Pharmacology Department of the Pharmacy Faculty of the University 
of Coimbra, Porto and Institute Superior of Health Sciences North (Appendix C). 
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4.1.6 Material 
The motivator material was composed by the letter of introduction and the envelopes. Addi-
tionally, the questionnaire was re-sent 4 times.  
4.1.6.1 Letter of introduction 
Letter of introduction is the first contact between the subjects and the study it gives the in-
troduction and motivation to participate. Consequently, reference to the responsible institu-
tions for the study was clearly stated because according with some authors145 this could in-
crease the answer ratio. The letter was signed by the responsible for the study, and wording 
was done with objective to be personal and convincing151. The four letters sent during the 
study were always different. Each letter had more acute contents trying to motivate the sub-
jects about the importance of answering the questionnaire (Appendix D). Each letter is per-
sonalized to the subject in terms of gender. The letters of physicians and pharmacists, had 
the same contents, but additionally, some differences related with some professional differ-
ences. 
The questionnaire and letter of introduction were evaluated in terms of linguistic content by 
Communication Department of University of Aveiro and in terms of interpretation by Psy-
chology Clinic Department of Institute Superior of Health Sciences North. After this evalua-
tion, small linguistic adjustments were done in the questionnaire and in the letter. 
4.1.6.2 Envelopes 
To avoid a possible confusion with the postal publicity, the envelope sent bears the institu-
tion logotype. With the intention of facilitate the devolution of complete questionnaire inside 
of the sent envelope was a pre-paid envelope with the address filled and the questionnaires 
were duly folds. 
4.1.7 Pilot test 
The questionnaire is an instrument that used the language as a strong support, but there is 
no guarantee that the language of the investigator and the subjects are in agreement145. Be-
cause of that, it was considered important to submit the letter of introduction and the ques-
tionnaire to a sample where the subjects belong to the Regional Health Administration of the 
Centre, before the data collect. With this data it was possible to have a notion of the aptness 
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of the collection method. The questionnaire was tested relating to its reproducibility in a 
sample of 30 physicians; ten general practitioners (Health Centre of Aveiro) and twenty hos-
pital physicians (Aveiro hospital), from which ten surgeons and ten general medicine spe-
cialists and twenty pharmacists; fifteen communitarian pharmacies (Aveiro region) and five 
hospital pharmacists (Aveiro hospital). The letter of introduction was built with the same 
format as the letter used in the study, with the difference that refers the pilot test as a neces-
sity to validate the questionnaire, and ask the subjects for their comments and difficulties in 
the completion of the questionnaire.  
The same questionnaire was mailed twice for the same sample, during the pilot test, with an 
intervening period of four weeks. The first mailing was at the beginning of May in 2002 and 
the second in June. The questionnaire fulfil did not have any difficulty comments in respect 
to the use of visual analogical scale, for the 15 questions. Nevertheless, some subjects (hospi-
tals pharmacists) reported some difficulties in completing the questionnaires (in particular 
the question relating to the dispensing of drugs).  
At the end of the study, a letter of thanks was sent to the health centre, to each hospital ser-
vice director and to the community pharmacists. 
4.1.8 Questionnaire sent 
After the pilot test, the questionnaire underwent some minor changes and was sent to the 
cases and controls subjects. Exactly the same material was sent (questionnaire, letter and 
envelopes) to the case and to the controls. The questionnaire was re-sent to those that had 
not answered the previous questionnaires a maximum of 4 times. The mailings were carried 
out between December 2002 and June 2003 (physician sub-samples) and between June 2003 
and December 2003 (pharmacist sub-sample) for a period of six months with an interval of 8 
weeks. In review literature, the time period between each mailing varies between 2 to 8 
weeks.41-43  
4.1.9 Statistical Analysis 
4.1.9.1 Pilot test 
The questionnaire’s reproducibility was evaluated in the test pilot using the intraclass corre-
lation coefficient, based on the results obtained for the first and second answers, for each 
physician and pharmacist. 
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The statistical analysis was carried out using a logistic regression that allows the representa-
tion of a dichotomy dependent variable as a function of several other variables, either quali-
tative or quantitative. A transformation of the dependent variable must be made in order to 
make the relation linear and the techniques of classical regression can be used. In logistic re-
gression analysis the technique for calculation of the regression coefficients uses an iterative 
procedure using the maximum likelihood of the coefficients and their standard deviations. 
This minimizes the weighted sum of squares of the deviations. 
The advantage of logistic regression is that, although the coefficients and their standard de-
viations obtained directly from the calculations are difficult to interpret epidemiologically, 
with a simple transformation is possible to transform them in odds ratios (OR) and the values 
of the standard deviations of these in confidence intervals (CI) of OR. 
When logistic regression is applied to case-control studies, as is the case of this study, the 
dependent variable will be the case (report) or the control (non-report) and the calculated OR 
are a good estimation of prevalence ratio, since the prevalence of report in the population is 
rather low. When using this technique the following points must be taken into consideration: 
a) the dependent variable is dichotomy, being the reference category the value zero (in this 
case non-report = 0 and report = 1); b) all the possible control and exposition variables must 
be initially incorporated in the model so that can be later removed those that do not cause a 
confusion effect or a changing of the effect and that, from a theoretical perspective, lack im-
portance; c) when an independent variable is dichotomy (for instance gender) the reference 
category should have the lower value (male = 1; female = 2); d) if an independent variable 
has more than 2 categories (for example, speciality: K = 4 categories), it shouldn’t be used as 
a single variable since in this way a linear relation is assumed for the variable, and in reality, 
the codes used for each category are arbitrary; therefore the variable must be transformed, 
using a category as reference and creating new variables (K-1 dummy variables) relating 
each value of the variable with the reference value; e) when an independent variable is con-
tinuous (for example age) it should be categorised, at once is include as continue in the 
model and guess again an effect of linearity over the dependent variable.  
In the present study three categories were created for each continuous variable. The catego-
ries were created using the percentiles 33 and 66 for all the subjects. This new variable is cre-
ated using the dummy variable generation process. 
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Logistic regression analysis was used to model the associations between independent vari-
ables and the outcome of having reported an ADR. Two sets of statistical models were cre-
ated: (i) in the first, we evaluated all the personal and professional variables using crude and 
adjusted analyses; (ii) in the second, we evaluated the influence of attitudes related to ADR 
reporting, such as those quantified in the questionnaire, adjusting for personal and profes-
sional variables that proved significant in the first model. Results were expressed as OR with 
their 95% CI, which indicated the increase/decrease in the probability of being a responder 
for an increase of one unit on the continuous visual analogy scale (score range 0=total dis-
agreement to 10=total agreement). To take into account the independent variable’s distribu-
tion among the study subjects, we calculated the interquartile OR (IqOR), which is based on 
an incremental exposure corresponding to the interquartile range of these attitude measures. 
Since most OR assume values lower than unity, we calculated the inverse of the IqOR 
(1/IqOR), which can be interpreted as the increase in the probability of being a responder 
when exposure decreases from the 75th to the 25th percentile of the distribution. 
4.2 Cluster randomized trial 
4.2.1 Design 
A controlled randomized trial was carried out in two groups: intervention and control 
group, in Regional Health Administration of the North. To eliminate the cross-contamination 
between groups and units, spatial-clusters have been created. All the physicians and phar-
macists that work in hospitals, health centres and community pharmacies of the selected 
geographic area make each spatial-cluster. The clusters are formed with minimum size to 
minimize the contamination between communitarian pharmacies, primary care and hospi-
tals. Thus, each spatial-cluster was formed by one reference hospital together with health 
centre and communitarian pharmacies and other eventual hospitals of its influence zone. The 
15 geographical zones were created based on reference central and district hospitals (for 
small hospitals located in the same area). 
4.2.2 Subjects 
The population object of the study is composed by all physicians (that work for National 
Health System) and all pharmacists (that work in community and hospital pharmacies) who 
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work in geographic area corresponding to the Regional Health Administration of the North; 
the database was provided by Regional Health Administration of the North for the physi-
cians and by National Association of Pharmacies and Portuguese Association of Hospital 
Pharmacists for pharmacists. 
The exclusion criterions for pharmacists and physicians are: (1) work only in the private hos-
pitals sector (small sector in Portugal) and (2) work as teachers, administration areas or 
pharmaceutical and distributor’s companies (3) work in Northern Pharmacovigilance Unit 
and (4) work directly with Northern Pharmacovigilance Unit protocols for ARD reporting. 
The pharmacists and physicians who work in specific hospitals or services are too excluded 
because it is not possible to limit them to a specific area, such as specific hospitals, histocom-
patibility and genetic centres. Were exclude too the physicians who work in centres of toxi-
codependence. 
4.2.3 Randomization 
Most cluster-randomized trials allocate approximate equal numbers of clusters to experimen-
tal and control groups. This is the most efficient randomization ratio, but this may not be the 
most economically. When the intervention under evaluation have an important cost differ-
ence respect a control group, may be more economically efficient to randomize fewer clusters 
to the intervention group than the control group.152 Therefore, the 15 spatial clusters were 
distributed using an unequal randomization.153,154 Four spatial clusters to the intervention 
group and 11 to the control group, approximately 1:4 for intervention:control group. The 
randomization distribution was performed with computer-generated procedure and was 
made assigning a random number to each cluster and choosing the 4 clusters with higher 
number for the intervention group and the other 11 were left to the control group. 
4.2.3.1 Intervention group  
The 4 randomly select clusters make the intervention group. All the physicians that work in 
hospitals and health centres and all the pharmacists that work in community pharmacies and 
hospitals of the same area of the selected geographic area at the beginning of the study (year 
2004) are included in the cluster.  
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4.2.3.2 Control group  
The control group is made up of the other 11 clusters. The conditions for physicians and 
pharmacist are the same that were used for intervention groups. 
4.2.3.3 Sampling criteria  
The sampling process was carried out as follows: the geographical area, corresponding to 
Regional Health Administration of the North, was divided in 15 zones relatively similar; 
each zone has one or more hospital, health centre and communitarian pharmacies of the in-
fluence area of the hospital/s. 
The educational intervention was carried out in every hospitals, health centres and commu-
nity pharmacies belonging to the geographical area of intervention. 
Table 3. Distribution of physicians in each 15 zone, in relation to study group (control or 
intervention), per each sub region. Number of hospitals/health centers (nº of 
physicians in each one). 
PHYSICIANS 
TYPE SUB-REGION ZONE 
Hospitals Health Centre Specific Hospitals 
Porto 2 1(741) 6(138) 
12 1 + 1a (61) 7(62) 
Bragança 
13 1(54) 5(54) 
In
te
rv
en
tio
n 
Vila Real 14 1 + 1 b (173) 11 (105) 
1 1 (964) 3 (114) 
3 1 + 1 b (455) 6(164) 
4 1 (235) 8 (178) 
5 1 (382) 8 (173) 
6 1+1 b +1 a +1 a (187) 10 (246) 
Porto 
7 1 (77) 3(74) 
8 1 + 1 a (263)) 9 (121) 
9 1 (106)) 2 (107) Braga 
10 1 + 1 a (390) 8 (248) 
Viana do Castelo 11 1 b (238) 13 (219) 
Co
nt
ro
l 
Vila Real 15 1 (67) 5(55) 
5 (432) 
a Small hospital that was grouped to the reference hospital or several small hospitals in same geographical area; b 
Hospital centre constituted by 2 hospitals. 
From the existent 25 hospitals, 5 are specific hospital (ex: cancer, maternity, etc.) and were 
excluded from the study because treatment very specific pathologies of all north region and 
could be a mistake factor, possible cross-contamination between the clusters.  
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Remaining 20 hospitals, 5 of them are very close or very small and because this were in-
cluded in the same zone. 
The health centres were grouped by the influence areas of hospitals, accordingly to informa-
tion provided by Regional Health Administration of the North. Community pharmacies 
were grouped based on information provided by National Association of Pharmacies. 
Table 3 and Table 4 present for each of the 15 zones the number of hospitals, health centres 
and community pharmacies as well as the number of physicians and pharmacists (between 
brackets). Figure 3 shows a map of Portugal, with five sub-regions of Regional Health Ad-
ministration of the North and the geographical representation of 15 zones used in the study. 
Table 4. Distribution of pharmacists in each 15 zone, in relation to study group (control or 
intervention), per each sub region. Number of hospitals/communitarian phar-
macies (nº of pharmacists in each one). 
PHARMACISTS 
TYPE SUB-REGION ZONE 
Hospitals Communitarian pharma-cies 
Specific 
Hospitals
Porto 2 1(16) 79 (195) 
12 1 + 1a (2) 20 (28) Bragança 13 1(3) 19 (33) 
In
te
rv
en
tio
n 
Vila Real 14 1 + 1 b (4) 42 (61) 
1 1 (22) 46 (91) 
3 1 + 1 b (5) 58 (120) 
4 1 (6) 57 (90) 
5 1 (6) 56 (122) 
6 1+1 b +1 a +1 a (6) 37 (75) + 23 (41) + 32 (56) 
Porto 
7 1 (4) 27 (36) 
8 1 + 1 a (6) 37 (63) +28 (30) 
9 1 (3) 27 (45) Braga 
10 1 + 1 a (5) 61 (87) + 27 (40)  
Viana do Cas-
telo 
11 1 b (9) 62 (91) 
Co
nt
ro
l 
Vila Real 15 1 (3) 23 (29) 
5 (16) 
a Small hospital that was grouped to the reference hospital or several small hospitals in same geographical area; b 
Hospital centre constituted by 2 hospitals. 
4.2.3.4 Type of sample  
There are a number of quantitative designs that could be used to evaluate quality improve-
ment interventions: (1) randomised designs, like individual patients randomised controlled 
trials and cluster randomised trials; (2) non-randomised designs, like uncontrolled before 
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and after studies, controlled before and after studies and time series designs.155 Cluster ran-
domised trials are becoming increasingly important in health technology assessment.  
 
 
Figure 3. Portugal map and 5 sub-regions of Regional Health Administration of the 
North. Region numbers circled are those where the intervention has been car-
ried out. 
Cluster randomised trials designs are used not only to evaluate group interventions but also 
individual interventions where group level effects are relevant. In cluster randomised trials 
clusters of people, or intact social units, rather than individuals are randomised to interven-
tion and control groups and outcomes are measured on individuals within those clusters. 
Cluster randomised trials are also known as group randomised trials or community random-
ised trials.  
There are several reasons to consider cluster randomisation: one of them is avoid the possi-
bility of cross-contamination between intervention and control groups. When designing the 
educative intervention, the intervention group was randomly selected. In the selection of 
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geographical areas, the cross-contamination has been considered. Cross-contamination can 
occur when health professionals, physicians, pharmacists or others, work nearby, thus trans-
ferring between them the information received during interventions. This situation can be 
minimised when clusters are used (for example, health centre/hospital/pharmacy at the 
same geographical area).103 
The physicians and pharmacists that belong to spatial-clusters of group control did not re-
ceive the intervention but as the intervention group arriving the information usual give by 
Northern Pharmacovigilance Unit and National Institute of Pharmacy and Medicine.  
From September 2004 and March 2005, Northern Pharmacovigilance Unit give post-graduate 
education only for physicians who work in health centres belong to group control for sub 
region of Braga and Viana do Castelo (in a total of 18 health centres). For pharmacists this 
situation is different and Northern Pharmacovigilance Unit in collaboration with National 
Association of Pharmacies and other institutions, give education in the five sub regions, be-
tween March 2004 and March 2005, for pharmacists who belong to group control or interven-
tion. It is necessary to say that the Northern Pharmacovigilance Unit has an annual compro-
mise of education with Health Authorities. 
4.2.4 Data collection 
The purpose of this study is the comparison of reports arrived at the Northern Pharma-
covigilance Unit before, during and after the educational intervention. The studied period 
ranges from January of 2003 to June 2005. Additionally, the following parameters have also 
been studied: (1) severity; (2) causality; (3) type (expected/unexpected); and (4) date of Mar-
keting Authorisation Holder (new medicines). 
4.2.5 Educative intervention 
Factors that affect effectiveness of an educative intervention are rather complex. Among 
these the design and the production need special attention and are detailed next. 
4.2.5.1 Design of intervention 
The type of intervention used, results from the combination of an active intervention (group 
sessions) with a passive intervention (distribution of press material). The passive interven-
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tion acts as a support for the active intervention. This strategy is referenced in several stud-
ies.93,97,101 Another study103 indicated that personalisation of these sessions, as is commonly 
used by the pharmaceutical industry is more effective, however, this is rather costly. Accord-
ingly to some authors94,97 the intervention projects seem to have a positive impact on report-
ing, but should be carried out continuously. 
4.2.5.2 Elaboration of educative intervention 
The educative intervention was elaborated taking into account the knowledge and attitudes 
of the health professionals that lead to the under-reporting, as detected in the case-control 
study. Technical-scientific material was prepared (presentation in PowerPoint) with the ob-
ject of helping the health professionals to reduce the under-reporting and if possible to create 
a "culture of reporting". 
The educative intervention had as its main didactic material a presentation in PowerPoint, 
which is included in Appendix E. A sample slide from this presentation can be seen in 
Figure 4. The presentation was created taking into consideration some presuppositions such 
as being of short duration and objective. 
 
Figure 4. Sample slide from presentation. 
At the beginning the presentation contains the pharmacovigilance and ADR definition (2 
slides), followed by a presentation of some international studies on the effect of ADR, in 
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studies of mortality and morbidity, hospital admissions and costs for the health systems. One 
slide is dedicated to each of these subjects (4 slides). Next, the methods used in pharma-
covigilance and the spontaneous reporting of ADR (and in particular of under–reporting) are 
presented (3 slides). 
Eighteen slides were created, animated with some pictures that represent the respective 
medical and pharmaceutical health professionals, talking amongst themselves about the pos-
sible factors effecting under-reporting. The factors that appear in the presentation are those 
found in the case-control study as being the causes of under-reporting: (1) "belief that really 
serious adverse drug reactions is well documented by the time a drug is marketed", for this 
possible factor several slides had been created, explaining the limitations of the clinical tests, 
giving examples descriptions of low incidence of ADR in the literature and well-known by 
the professionals (these slides also described the types of ADR); (2) "belief that it is nearly 
impossible to determine whether a drug is responsible for a particular adverse reaction" and 
(3) “belief that I would only report an adverse drug reaction if I was sure that it was related 
to the use of a particular drug” several slides were created in order to make it clear that 
suspicions of ADR must be reported, even if it is not absolute certain and that there exists a 
commission of experts that evaluates all the reports; (4) "belief that the one case an individual 
physician might see, could not contribute you medical knowledge”, was given much impor-
tance to this factor of possible under-reporting, several slides had been elaborated to become 
evident that the participation of each one of us is essential for the system, and the system de-
pend from our individual participation and finally (5) “belief that it is only necessary report 
serious or unexpected ADR”, about of this possible factor of under-reporting, it has been 
passed the message that is important to report all the serious ADR wherever they are ex-
pected (described in the summary of product characteristics) or unexpected (not described in 
the summary of products characteristics), all the unexpected ADR; additionally, special care 
should be taken to new drugs in market (that are in the market for less than five years) and 
to all the ADR that although described in the summary of products characteristics, are con-
sidered as being rare. 
After talking on the "seven deadly sins" from Inman, one slide is presented that shows that is 
with the participation of all by sending of the respective report forms that is possible to the 
Health Authorities to evaluate each one of the report and to make decisions (this image 
meets in the pamphlet to give of some form continuity to the presentation). Slides also de-
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scribed the process of evaluation of ADR and the process of decision making, because it was 
observed in the case-control study that is important for professionals to know how the sys-
tem works, what it is made with the information that they send to the system (they do not 
know the information reported in the report card is used). Finally the question of how much 
time is need to fill the report card is also focused (and an example of filling the form is car-
ried out in real time, with a clock counting the time) because they gave very importance to 
the question "do not have time to complete the report card". The minimum parameters 
needed to fill the form is also presented (this information is also included in pamphlets). 
In the end of the presentation all the possible ways to contact the Northern Pharmacovigi-
lance Unit are presented (this information is also included in all the other supplied material 
in this intervention). 
The contents of the slides were evaluated in terms of linguistic content by the Department of 
Communication and Art of the University of Aveiro and in terms of technical-scientific con-
tent by the Northern Pharmacovigilance Unit. 
The period of intervention elapsed between March and July of 2004. In the sub-regions of 
Bragança and Vila Real, the educative intervention became fulfilled during the months of 
March and April and in the sub-region the Porto between May (communitarian pharmacies) 
and July (health centres and hospitals). None of the 4 zones enclosed for the sub-regions of 
Viana do Castelo (1 zone) and Braga (3 zones) had been selected. In the sub-region of Bra-
gança the intervention was carried through in the 3 hospitals, 12 health centres and 39 phar-
macies. In the sub-region of Vila Real the intervention was carried through in the Hospital 
Centre of Vila Real/Peso da Régua (Hospital D. Luíz I – Peso da Régua, Hospital of S. Pedro 
– Vila Real), in 11 health centres and in 42 communitarian pharmacies; finally, in the sub-
region of the Porto, the intervention occurred in one of the Central Hospitals, Hospital Geral 
de Santo António, SA; in the 6 health centres, considered of reference and the intervention 
still enclosed 79 pharmacies. 
The used didactic material was the same for all the sessions. The speaker of the interventions 
was always the same in order to prevent errors of methodology and evaluation of each inter-
vention. Intervention took 1 hour, 30 minutes for the presentation and other 30 minutes for 
conversation with participants about these issues. The groups were formed with 10 to 20 
physicians depend the size of service and with 1 to 5 pharmacists, normally. 
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4.2.6 Material 
The material for this study is constituted by: (1) letters, (1.a) letter of introduction of the edu-
cative intervention and (1.b) letter of confirmation of the day, hour and place of the same 
one; (2) the purple form or the yellow form; (3) pamphlets on the fulfilling of the report form; 
(4) a folder with article copies published in international journals, on the subjects that appear 
in the intervention; (5) participation certificate. 
In the beginning of the study a letter of introduction was sent to all the selected institutions 
(hospitals, health centres and pharmacies); the content of the letter consists on the objectives 
of the study, its purpose and importance and the marking of a meeting to appointments the 
date for the intervention (Appendix F). Additionally, a letter to the Regional Health Admini-
stration of the North (Appendix G) was sent to give knowledge of begin of the study, and of 
the educative interventions that will be made in the institutions of health of the area of this 
administration. 
After scheduling each one of the interventions, a letter was always sent (for fax or post office) 
2 or 3 days before the intervention re-confirming the date and hour of the intervention and 
requesting, when necessary, the listing of the subjects to be present (Appendix H). 
The report forms had been provided by the Northern Pharmacovigilance Unit and delivered 
to the participants in each intervention (yellow form to the physicians and purple form to the 
pharmacists). The report forms had not been distributed to five heath centres, three hospital 
services, one pharmacy hospital service and ten communitarian pharmacies (approximately 
10% of intervention group). The report form was not distributed to any pharmacist or physi-
cian that was not present into the intervention. 
The pamphlets consisted of a leaflet with the same exterior dimensions of the report form 
and of the same colour (yellow for physicians and purple for pharmacists) had been distrib-
uted by all subjects participating in the intervention. The pamphlet was elaborated to consti-
tute a remainder of the presentation, containing its main messages, as well as the key image 
of the presentation. All the available contacts of the Northern Pharmacovigilance Unit are 
also in the leaflet. The pamphlet was evaluated in terms of linguistic content by the Depart-
ment of Communication and Art of the University of Aveiro and in terms of technical-
scientific content by the Northern Pharmacovigilance Unit. The design of pamphlets was 
elaborated by a graphical designer and can be found in the Appendix (Appendix I). 
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The didactic material that was delivered consisted of articles published in international jour-
nals. The copies of articles delivered corresponded to articles shown during the presentation 
and that had been considered important to base the related data on the importance of the 
ADR in mortality terms,1,156,157 morbidity,2,3 hospital admissions59,158 and costs.4,,60                                
These articles had been delivered to the directors of the health centres, hospital services and 
communitarian pharmacy technical directors in a folder of the Northern Pharmacovigilance 
Unit (this folder contains all the contacts of the Northern Pharmacovigilance Unit). Since it is 
considered important the role of the pharmacists in herbal35 and of over-the-counter medi-
cines32,33,34, copies of articles on each one of these subjects had also been delivered.  
The certificates of participation (Appendix J) contained the same layout of the presentation 
and had been printed in colour paper of high quality. In the end of each session, the certifi-
cates had been distributed individually to each participant, as a way to control the presences 
of the subjects without questions.  
4.2.7 Statistical analysis 
Separately statistic analyses were performed for physicians and pharmacists. All statistical 
analysis was carried out by intention to treat159 and for this reason the subjects who, although 
assigned to an intervention group, were not subjected to intervention were also included in 
the analysis as belong to intervention group. Inclusion of all randomized subjects in statisti-
cal analysis avoided any bias incurred by non-assistance (equivalent to non-compliance) of 
physician to the intervention. 
Generalized Linear Mixed Models (GLMM) using Penalized Quasi-Likelihood were applied 
to statistical analysis.160,161 This statistical method allows longitudinal data analysis (repeat 
and multiples observations over the time on each of many individuals) adjusted by baseline 
values of the depending variable. This adjustment is very important when the study groups 
can become unbalanced due to a low number of random assignment units (as is the case in 
our study, with only 15 clusters). Moreover, these models offer additional advantages: first, 
they allow for the control of cluster effects derived from random assigning by subject groups 
rather than by individual subjects; and second, they allow for the introduction of random 
terms to control heterogeneity among subjects. 
For producing models, we took the number of reports from each month as a dependent vari-
able (that is a count variable, and for this we use a Poisson-GLMM), the independent term as 
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a random effect (to control initial heterogeneity among subjects), and the random distribu-
tion spatial cluster as cluster effect. The models were adjusted according to personal and 
socio-demographic variables (age, gender, specialty and primary/hospital) for avoid the 
possible not equally distribution after randomization. Since that Poisson assumption (mean 
and variance of the dependent variable are equal) was not found in our data, models were 
adjusted using the over-dispersion parameter.  
In order to measure the intervention effect, an indicator dichotomous variable was created. 
This variable -called period- takes value 0 for baseline period and value 1 for months between 
the start of the intervention to the end of the follow-up. The intervention effect was evalu-
ated through the interaction between the variable group (1 for intervention group and 0 for 
control group) and period variable. This interaction, allows quantification of the possible con-
tamination of the control group by the intervention (measure in the interaction through vari-
able period) and the baseline differences between studied groups (through variable group) 
For the effect of analysis duration, another variable was built with 5 categories (value 0 for 
baseline period, 1 for the first 4 months after intervention and 2, 3 and 4 for subsequent peri-
ods of 4 months). The intervention effect in each 4 months period was evaluated through the 
interaction between this indicator variable and the variable group. 
All the analyses were carried out using the S-Plus software. Results were expressed in rela-
tive rate (RR) with their respective 95% CI that indicate the number of times that the report-
ing probability increases. 
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5 RESULTS 
5.1 Case-control studies  
In the pilot test, all the physicians and pharmacists fill the questionnaire, in the 1st and in the 
2nd sent. The pilot test was design to investigate possible difficulties in the filling of the ques-
tionnaire by health professionals and to test the reproducibility of the questionnaire between 
two consecutive sends in the same sample. The pilot tests had the following results in physi-
cians, the correlation coefficients yielded by assessment of the questionnaire’s reproducibility 
exceeded 0.75 for all fifteen attitudes and opinions, save the attitudes, “It is only necessary to 
report serious or unexpected ADR” and “When I read medical literature I am interested in 
articles about adverse drug reactions”, in which the coefficients were 0.65 and 0.70, respec-
tively (p<0.005). For pharmacists, the pilot tests had the following results; correlation coeffi-
cients yielded by assessment of the questionnaire’s reproducibility exceeded 0.75 for all fif-
teen attitudes and opinions, except for the attitudes, “I should be financially reimbursed for 
providing the ADR service” and “I do not have time to think about the involvement of the 
drug or others causes in ADR”, in which the coefficients were 0.71 and 0.74 respectively 
(p<0.005). 
 
After pilot test, postal questionnaire was sent to all the health professionals participating in the study. 
Due to the low participation level found in similar studies36, 68 where the answer level varies 
from 30 to 38%, a series of consecutive sends was decided. On the other side, from a total of 
859 questionnaires mailed for physicians, 110 were returned by the postal service due to er-
ror in the postal addresses (100 from controls and 10 from cases), and 18 from controls were 
excluded because the physicians concerned were engaged in specializations such as anatomy 
pathology, in which they neither prescribed nor administered drugs. A total of 397 question-
naires were completed by 731 eligible practitioners (54.3 %), 66 by cases (84.6 %) and 331 by 
controls (50.7 %). From the 331 questionnaires received by the control group, 127 (38.4%) 
were received during the 1st sent, 80 (24.2%) and 63 (19%) respectively after the 2nd and 3rd 
sent and, finally, 61 (18.4%) in the last re-sent. In the case group, during the 1st sent 33 
(50.0%) questionnaires were received, in 2nd, 3rd and 4th re-sent the received questionnaires 
were 16 (24.2%), 10 (15.2%) e 7 (10.6%) as can be seen in Table 5. 
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Table 5. Distribution of physicians questionnaire sent and arrival  
RECEIVED BY SENT  SENT 
1º 2º 3º 4º 
TOTAL 
RECEIVED *RETURNED 
**NON 
PROCESSED
Non-Reporters 771 127 80 63 61 331 100 18 
Reporters 88 33 16 10 7 66 10 0 
Total 859 160 96 73 68 397 110 18 
*return by post, **specialities of anatomy and pathology 
In the next graph (Figure 5), the cumulative percentage of received questionnaires in each 
send is shown. 
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Figure 5. Level of accumulated answers for the total population of physicians. 
In Figure 6, the answer level is presented for cases and controls separately. The differences 
between the two groups are clear: in the first sent 42.3% of cases answered to the question-
naire while in the control group only 20% answer it. This tendency is observed during all the 
re-sends being in the final of 4th re-sent of 85% for cases and 50% for controls. 
Of a total of 314 questionnaires mailed for pharmacists, 19 (16 from controls and 3 from case) 
were returned by the postal service. In all, 256 questionnaires were returned by 295 eligible 
pharmacists (86.8%); of these, 31 were returned by cases (100%) and 225 by controls (85.2%). 
From the 225 questionnaires filled by the control group, 90 (40%) were filled after 1st sent, 65 
(28.9%) after 2nd sent, 42 (18.7%) after 3rd sent and, finally, 28 (12.4%) after 4th sent. For cases, 
the answers to questionnaires were 14 (45.2%) for 1st sent, and 9 (29%), 6 (19.3%) and 2 (6.5%) 
respectively for 2nd, 3rd and 4th sends (Table 6). 
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Figure 6. Level of answers of accumulated for reporters and non-reporters. 
Table 6. Distribution of pharmacists questionnaire sent and arrival 
RECEIVED BY SENT  SENT 
1º 2º 3º 4º 
TOTAL 
RECEIVED 
*RETURNED
Non-Reporters 280 90 65 42 28 225 16 
Reporters 34 14 9 6 2 31 3 
Total 314 104 74 48 30 256 19 
*return by post 
In the graph of Figure 7, the cumulative percentage of received questionnaires in each send is 
shown. A tendency for the decreasing of the number of answers is clearly observed for each 
re-sent as was observed for physicians. 
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Figure 7. Level of accumulated answers for the total population of pharmacists. 
In Figure 8, the answer level is presented for cases and controls separately. There are differ-
ences between the two groups although not so evident as for physicians; in the first sent 45% 
of cases answer to the questionnaire while in the control group only 34.1% answer it. This 
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tendency is observed during all the re-sends being in the final of 4th re-sent of 100% for cases 
and 85% for controls. 
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Figure 8. Level of answers of accumulated for reporters and non-reporters. 
5.1.1 Description of the study sample  
Age and gender (physician sample) 
As can be observed in Figure 9, the population object of study distributes in a different form 
in relation to the gender and to the age. The average of the age between the men is of 46.0 
(median 47) while in the women it is of 41.5 (median 41). There are also a bigger number of 
men 52% compared to women 48%. Additionally, there is a bigger predominance of citizens 
of medium age, for the men between the 45 and 54 years and for the women between the 35 
and 44 years. 
Comparing the resultant graphs of the stratification as a function of reporters’ character 
(Figure 10) it can be observed that in the group of reporters the percentage of women is 
larger for cases than for controls (61% against 46%). It is verified that the reporters are dis-
tributed mainly in the segment between 45 and 54 years. The distribution of the reporters in 
terms of ages is similar to the one of the sample of the population. 
Age and gender (pharmacist sample) 
As can be observed in Figure 11, of the subjects that had answered to the questionnaire, the 
number of women, 199, are much more than men, 52. The average of the age between men 
39.3 (median 37.3) and women is 37.0 (median 33.0). A clear predominance of subjects of 
young age exists, between 25 and 34 years for both men and women. 
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Figure 9. Distribution of the physicians in function of gender and age. 
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Figure 10. Distribution of the subjects in function of age and gender, divided in repot and 
non reporter.   
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Figure 11. Distribution of the pharmacists in function of gender and age. 
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Comparing the graphs of Figure 12 resulting from stratification in function of character re-
porter we verify that in the group of reporters the percentage of men is lower than in the 
group of non-reporters (10% against 22%). It is verified that the reporters were distributed in 
bigger number in the segment of ages between 25 and 34 years. The distribution of the re-
porters and non-reporters in terms of ages is similar to the sample of the population studied. 
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Figure 12. Distribution of the subjects in function of age and gender, divided in report and 
non reporter. 
Number of patients seen per day 
The average number of patients who had been received by the subject object of this study 
was of 16.4 per day (Figure 13). Dividing the population study in reporters (cases) and 
non-reporters (controls), we verify that the reporters had received in average 16.5 patients 
per day, while the non-reporters had taken care of in average 15.8 patients. 
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Figure 13. Number of patients seen per day 
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Number of prescriptions written per day 
Globally an average of 22.4 prescriptions per day could be observed (Figure 14). Reporters 
exhibit an average of 25.0 prescriptions per day, while non-reporters realize an average of 
21.9 prescriptions per day. In the reporters group there is a large percentage of general 
practitioners, which means that these physicians made more prescriptions. The type of clini-
cal speciality is not uniformly distributed between the group of reporters and non-reporters. 
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Figure 14. Number of prescriptions written per day 
Physician speciality 
The questionnaire asked for physician’s specialty through an open question. The answers 
had been grouped in 4 sub-groups: general medicine (where it was included the public 
health and labour medicine), the medical specialties, the medical-surgical and surgical speci-
alities and finally others where specialties such as pathological anatomy and clinical pathol-
ogy. In Figure 15 it can be observed that in the group of non-reporters more than half 
(52.2%), exerts its functions in medicine specialist, while in the group of reporters these are 
only 45.5% of those that had answered. It is verified that in the group of non-reporters only 
21.4% belongs to the general medicine specialty while in the reporters group half of the sub-
jects that had answered belongs to this specialty. 
In the group of non-reporters it is observed that the percentage of pertaining subjects to the 
specialties, grouped in surgery and medical-surgery, is very bigger (24.8%) than in the group 
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of reporters that it is only of 3%. It is still interesting to observe that the percentage of sub-
jects with other specialties is the same in the two groups. 
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Figure 15. Type of speciality for non-reporters (left) and for reporters (right). 
Questions about specialization were not collocated in pharmacist’s questionnaire, because 
communitarian pharmacists did not have this type of education, in Portugal, at the moment.  
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Figure 16. Work place for reporter physician (left) and for non-reporters’ physician (right). 
Work place 
Questions about the place where physicians exert its professional activity were carried out to 
both physicians (hospital, primary care or both) and pharmacists (hospital, communitarian 
pharmacy or both). In relation to the physicians, the results can be seen in Figure 16 respec-
tively to the group of reporters and non-reporters that had answered to this question. In the 
group of reporters we observe that 47% (31 subjects), exclusively exert its activity in primary 
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care and only 18% (12 citizens) in hospitals, while in the group of non reporters only 18% 
work in primary care and 39% (127 subjects) worked in hospital.  
The percentage of subjects that work in both places, hospital and primary care, is superior in 
the group of non-reporters (43%) than in the group of reporters that it is 35%. 
In relation to the group of the pharmacists, all the subject of the sample answered to this 
question. In the following figure (Figure 17), it can be observed that in the group of reporters 
30% (9 pharmacists) work in hospitals, while in the group of non-reporters only 4% work in 
hospitals. It is interesting to note there isn’t any subject that works in both the places. 
9
30%
21
70%
Hospital
Communitarian pharmacy
8
4%
213
96%  
Figure 17. Work place for reporting pharmacists (left) and for non-reporting pharmacists 
(right). 
5.1.2 Personal and professional characteristics associated with ADR re-
port  
Once individually analyzed the professional and demographic characteristics of the partici-
pant subjects in the study, a logistic regression was carried out to identify those ones that are 
associated with a greater or minor reporter character, eliminating the influence of the other 
variables. 
Table 7 and Table 9 show the OR and the CI of all the professional and demographic charac-
teristics that have been enclosed in the study. These calculations were carried out using a lo-
gistic regression multivariate model, including for the sample of physicians the following 
variables: age, gender, type of medical specialisation, number of patients seen/day, number 
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of prescriptions written/day, workplace (hospital, primary care, both) and for the sample of 
pharmacists the following  variables: age, gender, job function, workplace (hospital, commu-
nity pharmacy). Each value of the OR is compared with the category of reference (OR=1.00). 
In this way, an OR small than unity indicate a smaller trend to report. On the contrary, an 
OR high than unity indicate a higher trend to report. These conclusions can be extrapolated 
to the original population, with 95% confidence, presupposing that the 95% CI of the OR 
does not include the unity. 
Table 7 shows the personal and professional characteristics of responding practitioners for 
cases as well as controls. Although the probability of reporting any ADR was higher for fe-
males than for males [OR=1.86 (95% CI: 1.06-3.11], this was no longer significant after ad-
justment for the remaining variables.  
Table 7. Personal and professional physicians characteristics associated with ADR spon-
taneous report  
Ever reported 
an ADR (n)* Crude analysis Adjusted analysis**  
Yes No OR 95% CI OR 95% CI P value
GENDER        
      Male 26 176 1.00 ------- 1.00 -------  
      Female 40 150 1.86 1.06-3.11 1.23 0.61-2.48 0.565 
AGE        
      <40 21 116 1.00 ------- 1.00 -------  
      40-48  28 112 1.38 0.74-2.57 0.81 0.35-1.86 0.619 
      >48  17 94 1.00 0.50-2.00 0.67 0.27-1.67 0.393 
TYPE OF MEDICAL SPECIALIZATION        
      Medical 30 167 1.00 ------- 1.00 -------  
      Medical-Surgical/surgical 2 80 0.14 0.03-0.60 0.10 0.02-0.46 0.003 
      General Medicine 33 69 2.68 1.52-4.78 1.05 0.30-3.69 0.942 
      Other 1 5 1.12 0.13-9.93 7.20 0.35-148.73 0.201 
NUMBER OF PATIENTS SEEN/DAY        
      <12  20 101 1.00 ------- 1.00 -------  
      12-18  20 64 1.50 0.76-2.99 1.82 0.73-4.55 0.197 
      >18 17 83 1.04 0.52-2.09 0.64 0.23-1.79 0.391 
NUMBER OF PRESCRIPTIONS WRIT-
TEN/DAY        
      <10 18 120 1.00 ------- 1.00 -------  
      10-23 13 57 1.52 0.70-3.32 0.79 0.32-1.95 0.613 
       >23 23 81 1.89 0.96-3.73 0.68 0.24-1.90 0.465 
WORKPLACE        
       Hospital 12 127 1.00 ------- 1.00 -------  
       Primary care 31 59 5,56 2.67-11.59 7.74 1.85-32.30 0.005 
       Both 23 139 1.74 0.83-3.64 2.71 0.97-7.55 0.057 
*Continuous variables categorized in tertiles for all participants. 
**Adjusted for the effects of the other variables included in the table. 
95% CI = 95% Confidential interval; OR = Odds ratio. 
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Age failed to evince any influence on ADR reporting. In terms of specializations, while the 
crude analysis showed general medicine practitioners as being two and a half times more 
likely to report ADR than other specialists [OR=2.68 (95% CI: 1.52-4.78)], this relationship 
nevertheless disappeared in the adjusted analysis. Surgical specialists registered the lowest 
probability of reporting in both the crude [OR=0.14 (95% CI: 0.03-0.60)] and adjusted analy-
ses [OR=0.10 (95% CI: 0.02-0.46)]. Physicians’ workplace appeared to exert an influence on 
reporting probability. Practitioners who worked in primary care were over seven times more 
likely to report [OR=7.74 (95% CI: 1.85-32.30)] than those who worked exclusively in hospi-
tals. 
Table 8. Personal and professional physicians (responders and non responders) character-
istics associated with ADR spontaneous report  
 Adjusted analysis** 
 OR 95% CI P value 
GENDER    
      Male 1.0 ---------  
      Female 1.7 0.99-2.86 0.06 
AGE    
      <40 1.0 ---------  
      40-48 1.0 0.52-1.83 0.93 
      >48  0.8 0.40-1.62 0.55 
TYPE OF MEDICAL SPECIALIZATION    
      Medical 1.0 ---------  
      Medical-Surgical/surgical 0.1 0.03-0.49 0.004 
      General Medicine 0.6 0.21-1.64 0.315 
      Other 0.4 0.05-3.43 0.430 
WORKPLACE    
       Hospital 1.0 --------  
       Primary care 4.0 1.28-12.20 0.02 
       Both 3.6 1.75-7.50 0.00 
*Continuous variables categorized in tertiles for all participants. 
**Adjusted for the effects of the other variables included in the table. 
95% CI = 95% Confidential interval; OR = Odds ratio. 
Since our results might have been affected by the professional and personnel characteristics 
of non-responders (answer level was about 50%), data were collected on aspects such as age, 
gender, specialty and workplace for non-responders and a new logistic regression model for 
both responders and non-responders constructed. The results (Table 8) of this model are in 
line with the results in Table 7, and indicate that, whereas age and gender are not related to 
notification, specialty and workplace do indeed influence reporting. 
Table 9 sets out responding pharmacists’ personal and professional characteristics for both 
cases and controls. Also shown in Table 9 the influence exerted by personal and profes-
sional’s characteristics on reporting. As can be seen, after adjusting for the remaining inde-
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pendent variables only workplace was associated with reporting, with hospital pharmacists 
being 20 times more likely to report than community pharmacists [1/OR=1/0.05=20, 
p=0.001]. The variables of gender, age and job function failed to display any influence on 
ADR reporting. 
Table 9. Personal and professional pharmacists characteristics associated with ADR spon-
taneous report  
*Continuous variables categorized in tertiles for all participants. 
**Adjusted for the effects of the other variables included in the table. 
95% CI = 95% Confidential interval; OR = Odds ratio. 
 
5.1.3 Knowledge and attitudes associated with physician ADR sponta-
neous report 
Spontaneous ADR reporting attitudes and opinions, and their influence on reporting are 
shown in Figure 18 and Figure 19, for each one of the 15 questions of the physician’s ques-
tionnaire. The attitudes in respect of which physicians’ recorded highest agreement were the 
following: “I would only report an adverse drug reaction if I were sure that it was related to 
the use of a particular drug”, (median 9.0) and “I have a professional obligation to report 
ADR” (median 10). The attitudes in respect of which physicians showed the least agreement 
were as follows: ”I should be financially reimbursed for providing the ADR service” (median 
0.5), “Reporting ADR puts my career at risk” (median 1.0), “It is only necessary to report se-
rious and unexpected ADR” (median 2.0) and “I do not have time to think about the in-
volvement of the drug or other causes in ADR” (median 2.5). Some of the practitioners’ atti-
 Ever reported an ADR (n)* Crude analysis Adjusted analysis
** 
 Yes No OR 95% CI OR 95% CI P value 
GENDER        
     Male 3 49 1.00 ----- 1.00 ----  
     Female 27 172 2.56 0.75-8.80 2.08 0.57-7.58 0.271 
AGE        
     <29 7 63 1.00 ----- 1.00 ----- 0.982 
     29-39 18 83 1.95 0.77-4,96 1.39 0.49-3.89 0.537 
     >39 4 73 0.49 0.14-1.76 0.36 0.09-1.50 0.163 
JOB FUNCTION        
     Registered pharmacist 10 98 1.00 ----- 1.00 -----  
     Assistant pharmacist 9 80 1.10 0.43-2.84 0.81 0.28-2.28 0.685 
     Other 11 43 2.51 0.99-6.34 0.39 0.07-2.11 0.275 
WORKPLACE        
     Hospital 8 9 1.00 ----- 1.00 -----  
     Community pharmacy 21 213 0.09 0.03-0.25 0.05 0.01-0.30 0.001 
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tudes displayed certain discrepancies, with some physicians being in total agreement and 
others in total disagreement, e.g., “Really serious adverse drug reactions are well docu-
mented by the time a drug is marketed”, “The one case an individual physician might see 
cannot contribute to medical knowledge”, and “I do not have time to think about the in-
volvement of the drug or the other causes in ADR”. 
The following attitudes and opinions registered a statistically significant inverse relationship 
with reporting probability (see Table 10), inasmuch as a lower degree of complacency (the be-
lief that really serious adverse drug reactions are well documented by the time a drug is 
marketed), insecurity (the belief that it is nearly impossible to determine whether a drug is 
responsible for a particular adverse reaction), diffidence (the belief that one would only report 
an adverse drug reaction if one were sure that it was related to the use of a particular drug), 
indifference (the belief that the one case an individual physician might see, could not contrib-
ute to medical knowledge) and ignorance (the belief that it is only necessary to report serious 
or unexpected ADR) were all associated with a higher probability of reporting. Hence, a one-
unit decrease on the visual analogy scale (score range 0=total disagreement to 10=total 
agreement) increased the probability of reporting by 12% in the case of complacency and ig-
norance (1/OR=1/0.89=1.12), rising to 20% in the case of insecurity (1/0.83=1.20), diffidence 
(1/0.84=1.19) and indifference (1/0.84=1.19).  
The OR for a change in exposure corresponding to the interquartile range of these measures 
(see Table 10), indicates that a change from the 75th to the 25th percentile in assessments of the 
following attitudes or opinions would lead to reporting probability rising by 87% for com-
placency, 109% for insecurity, 143% for diffidence, 220% for indifference, and 71% for igno-
rance. 
Other attitudes and opinions that showed an association with under-reporting were linked 
to: (1) lack of time, e.g., “I do not have time to complete the yellow card”, and “they do not 
have time to think about the involvement of the drug or other causes in ADR”; and (2) 
method of reporting, e.g., “would be more likely to report ADR if there were an easier 
method” and ”they do not know how the information reported in the yellow card is used”. 
Similarly, the variable “When I read medical literature, I am interested in articles about ad-
verse drug reactions” also appeared to be associated with probability of reporting [OR=1.13 
(95% CI: 1.00-1.27)]. 
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Figure 18. Statements of the physician’s questionnaire and their influence on reporting 
ADR. 
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Figure 19. Statements of the physician’s questionnaire and their influence on reporting 
ADR. 
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Table 10. Influence of several physicians attitudes and opinions (1) on spontaneous adverse 
drug reaction (ADR) reporting. 
Percentile Adjusted analysis (2) 
OR (3) 1/IqOR (4)  ATTITUDE OR OPINION (1) 25 50 75 
OR 95% CI 1/IqOR 95% CI P 
Really serious adverse drug reaction is well docu-
mented by the time a drug is marketed  
3.0 6.5 8.5 0.89 0.81-0.98 1.87 1.13-3.10 0.015 
It is nearly impossible to determine whether a drug is 
responsible for a particular adverse reaction 
1.5 3.0 5.5 0.83 0.74-0.94 2.09 1.27-3.41 0.004 
I would only report an adverse drug reaction if I were 
sure that it was related to the use of a particular drug
5.0 9.0 10.0 0.84 0.77-0.91 2.43 1.63-3.65 <0.001
The one case an individual physician might see could 
not contribute to medical knowledge 
1.5 4.0 8.0 0.84 0.76-0.92 3.20 1.73-5.85 <0.001
When I read medical literature I am interested in 
articles about adverse drug reactions 
5.5 8.0 9.5 1.13 1.00-1.27 0.61 0.38-0.99 0.046 
I would be more likely to report ADR if there were an 
easier method 
3.5 7.5 9.0 0.80 0.73-0.87 3.46 2.10-5.69 <0.001
I think that the most correct way to report ADR is in 
medical literature 
1.0 3.0 7.0 0.89 0.81-0.99 1.96 1.06-3.62 0.031 
I should be financially reimbursed for providing the 
ADR service 
0.5 0.5 1.5 0.99 0.88-1.12 1.01 0.89-1.13 0.937 
I have a professional obligation to report ADR 9.0 10.0 10.0 1.04 0.83-1.29 0.97 0.78-1.20 0.751 
Reporting ADR puts my career at risk 0.5 1.0 4.5 0.91 0.81-1.02 1.44 0.91-2.28 0.120 
It is only necessary to report serious or unexpected 
ADR 
0.5 2.0 5.5 0.90 0.81-0.99 1.71 1.02-2.89 0.044 
I do not have time to complete the yellow card 1.0 3.5 6.0 0.88 0.80-0.97 1.91 1.17-3.09 0.010 
I do not have time to think about the involvement of 
the drug or the other causes in ADR 
1.0 2.5 5.5 0.87 0.77-0.97 1.90 1.14-3.19 0.014 
I do not know how the information reported in the 
yellow card is used 
2.5 6.5 9.5 0.81 0.74-0.88 4.49 2.43-8.23 <0.001
I talk with pharmaceutical companies about possible 
ADR with their drugs 
6.0 8.5 9.5 0.94 0.85-1.04 1.26 0.89-1.80 0.196 
(1) Measured using a continuous, horizontal visual analog scale. Recorded answers were read in a range from o (total dis-
agreement) to 10 (total agreement), with a precision of 0.5. 
(2) OR adjusted for specialization and workplace. 
(3) OR indicates the increase/decrease in the probability of being a responder for every one-unit rise in the value of the visual 
analog scale (score range 0-10) 
(4) The 1/IqOR based on a change corresponding to the interquartile range of attitude or opinion measures. 
5.1.4 Knowledge and attitudes associated with pharmacists ADR spon-
taneous report 
Spontaneous ADR reporting attitudes and opinions, and their influence on reporting are 
shown in Figure 20 and Figure 21 for each one of the 15 questions of the pharmacist’s ques-
tionnaire. In general, pharmacists tended to agree with attitudes, such as “I would only re-
port an adverse drug reaction if I were sure that it was related to the use of a particular 
drug” (median 8.5), and “I have a professional obligation to report ADR” (median 10), and 
disagree with others, such as “I do not have time to complete the report card” (median 1.5), 
“Reporting ADR puts my career at risk” (median 1.5), and ”I should be financially reim-
bursed for providing the ADR service” (median 0.5). In the case of other attitudes, however, 
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wide discrepancies were in evidence, e.g., “Really serious adverse drug reaction is well 
documented by the time a drug is marketed” (interquartile range, 55% of the visual analogi-
cal scale), and “The one case an individual pharmacist might see cannot contribute to phar-
maceutical knowledge” (interquartile range, 90% of the visual analogical scale).  
Table 11 shows the degree of agreement between the study subjects and each of the attitudes 
studied (in terms of percentiles) and the related influence on reporting (in terms of the OR 
and IqOR) and also shown the relationship between attitudes and opinions statistically asso-
ciated with a lower likelihood of reporting ADR. A one-unit decrease on the visual analogi-
cal scale (score range 0=total disagreement to 10=total agreement) increased the probability 
of reporting by: 19% (1/OR=1/0.84=1.19, p=0.01) in the case of 1-complacency, “Really serious 
adverse drug reaction is well documented by the time a drug is marketed”; 20% (1/OR=1.20, 
p=0.01) in the case of 2-ignorance, “It is only necessary to report serious and not expected 
ADR”; and 37% (1/OR=1.37, p<0.01) in the case of 3-diffidence, “I would only report an ad-
verse drug reaction if I were sure that it was related to the use of a particular drug”. The OR 
for a change in exposure corresponding to the interquartile range of these measures, indi-
cates that a change from the 75th to the 25th percentile in assessments of the following atti-
tudes or opinions would lead to reporting probability rising by 223% for complacency, 316% 
for ignorance, and 240% for diffidence (see Table 11). 
Other attitudes and opinions that showed an association with under-reporting were linked 
to: (1) lack of time, e.g. “I do not have time to think about the involvement of the drug or 
other causes in ADR” (p=0.020); and (2) method of reporting, e.g., “I would be more likely to 
report ADR if there were an easier method” (p=0.024). 
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Figure 20. Statements of the pharmacist’s questionnaire and their influence on reporting 
ADR. 
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o) I talk with pharmaceutical companies about possible ADR 
with their drugs 
 
Figure 21. Statements of the pharmacist’s questionnaire and their influence on reporting 
ADR. 
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Table 11. Influence of several pharmacists attitudes and opinions (1) on spontaneous ad-
verse drug reaction (ADR) reporting.  
PERCENTILE ATTITUDE OR OPINION 
25 50 75 
OR  
(95% CI) 
1/IQOR 
(95%CI) 
P 
Really serious adverse drug reaction is well docu-
mented by the time a drug is marketed 3.0 6.0 8.5 0.84 (0.73-0.96) 3.23 (1.51- 6.95) 0.011 
It is nearly impossible to determine if a drug is respon-
sible for a particular adverse reaction 2.5 4.5 7.5 0.98 (0.85-1.13) 1.20 (0.59- 2.45) 0.814 
I would only report an adverse drug reaction if I were 
sure that it was related to the use of a particular drug 5.0 8.5 10.0 0.83 (0.74-0.93) 3.40 (1.89- 6.08) 0.002 
The one case an individual pharmacist might see can-
not contribute to pharmaceutical knowledge 1.0 4.0 8.0 0.93 (0.82-1.06) 1.74 (0.74- 4.08) 0.264 
When I read pharmaceutical literature I am interested 
in articles about adverse drug reactions 7.5 9.0 10.0 0.97 (0.79-1.17) 1.14 (0.72- 1.78) 0.724 
I would be more likely to report ADR if there were an 
easier method 1.5 5.0 8.0 0.86  (0.75-0.98) 4.20 (1.68- 10.45) 0.024 
I think that the most correct way to report ADR is in 
pharmaceutical literature 1.5 4.0 6.5 0.99 (0.86-1.15) 1.58 (0.77- 3.25) 0.896 
I should be financially reimbursed for providing the 
ADR service 0.5 0.5 1.5 1.01 (0.83-1.22) 1.02 (0.85- 1.24) 0.898 
I have a professional obligation to report ADR 9.0 10.0 10.0 1.45 (0.81-2.61) 0.66 (0.37- 1.18) 0.217 
Reporting ADR puts my career at risk 0.5 1.5 5.0 0.85 (0.69-1.04) 2.23 (0.90- 5.49) 0.110 
It is only necessary to report serious or unexpected 
ADR 0.5 2.0 5.5 0.73 (0.58-0.93) 4.16 (1.44- 12.04) 0.010 
I do not have time to complete the purple card 0.5 1.5 5.5 0.86 (0.72-1.01) 2.43 (1.05- 5.66) 0.072 
I do not have time to think about the involvement of 
the drug or other causes in ADR 1.0 2.5 6.0 0.81 (0.68-0.97) 2.71 (1.13- 6.49) 0.020 
I do not know how the information reported in the 
purple card is used 1.0 3.5 8.0 1.00 (0.89-1.12) 1.62 (0.71- 3.72) 0.998 
I talk to pharmaceutical companies about possible ADR 
with their drugs 3.0 5.5 8.5 0.96 (0.84-1.09) 0.92 (0.45- 1.87) 0.492 
*Measured using a continuous, horizontal visual analogy scale. Recorded answers were read in a range from 0 
(total disagreement) to 10 (total agreement), with a precision of 0.5. 
5.2 Cluster Randomized Trial 
In this study, data was acquired through the cluster-randomized trial. An educative inter-
vention was designed and performed in 4 clusters of the intervention group, with the follow-
ing results.  
For physicians we had a total of 6950 physicians of the initial database, (Figure 22) and ac-
cording with the exclusion criteria previously defined, 40 were excluded because they work 
in the administrative or analytic (histocompatibility and genetic centres) areas, 24 because 
they work in toxic-dependency centres, 2 because they are members of Northern Pharma-
covigilance Unit and finally 1 that made a specific protocol (immunoallergology service from 
a central hospital) with the Northern Pharmacovigilance Unit. 
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North region of Portugal
25 hospitals (15 reference, 5 specífic and 5 
small hospitals), 104 health centres (N=6,950 
physicians)
15 spatial-clusters 
(unit of randomización)
PHYSICIANS EXCLUDED BY 
PROTOCOL
• 5 specific hospitals(a) 
(n=432)
• Administration (n=35)
• Farmacovigilance (n=2)
• Specific reporting
protocol (n=1)
• Histocompatibility and
genetics (n=5)
• Toxicodependency centres 
(n=24)
(a) Specific hospitals (cancer, maternity, etc.) than influence area is all north Portugal region were excluded from
the study, because the possibility of cross-contamination.
(b) Each reference hospital and small or very closely hospitals were associated to the health centres of its influence
area and were incluid in the same cluster.
Aggregated hospital and respective
health centres in spatial-clusters(b)
4 Spatial-Clusters to intervention group
4 Hospitals (4+1 small aggregated)
29 Health centres
1388 physicians
11 Spatial-Clusters to control group
11 Hospitals (11+4 small
aggregated)
75 Health centres
5063 physicians
1388 physicians were followed
during 30 months
655 (47.2%) physicians present
in the intervention
733 not present
5063 physicians were
followed during 30 
months
unequal randomization
Ratio 1:4
 
Figure 22. Flow-chart of the study design for physician  
Additionally, the 432 physicians working in specific hospitals were also excluded. Finally, 
6451 physicians were included, from which 1388 belong to the intervention group and 5063 
to the control group. The reporting card was not given to 184 physicians (13.3 %) of the in-
tervention group. The number of physicians belonging to the intervention group that effec-
tively had participated was 655 (47.2%). The median of the following period was 13 months 
for the pos-intervention period. The design of the study could be observed in the flow-chart 
(Figure 22). 
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North Region of Portugal
25 hospitals (15 reference, 5 specifics and 5 
of small dimensions), 761 communitarian 
pharmacies (N= 1451 pharmacists)
15 spatial-clusters 
(unit of randomization)
Pharmacists excluded by  
PROTOCOL
• 5 Specific hospitals(a) 
(n=16)
• Pharmacovigilance (n=2)
Aggregated hospitals and 
communitarian pharmacists in 
spatial-clusters(b)
4 Clusters randomized for intervention 
group
4 Hospitals (4+1 small aggregated)
160 Communitarian Pharmacies
342 pharmacists
11 Clusters randomized for control 
group
11 Hospitals (11+4 small 
aggregated)
601 Communitarian Pharmacies
1091 pharmacists
342 pharmacists were followed 
during 30 months
276 (80.7%) pharmacists 
present in the intervention
66 (19.3%) not present
1091 pharmacists 
were followed during 
30 months
unequal randomization
(a) Specific hospitals (cancer, maternity, etc.) than influence area is all north Portugal region were excluded from
the study, because the possibility of cross-contamination.
(b) Each reference hospital and small or very closely hospitals were associated to the health centres of its influence
area and were incluid in the same cluster.
Ratio 1:4
 
Figure 23. Flow-chart of the study design for pharmacists. 
The design of the study for pharmacists could be observed in the Figure 23.  
For pharmacists and accordingly with the database we have a total of 1451, that were ex-
cluded 2 because they are members of Northern Pharmacovigilance Unit. Additionally, the 
16 pharmacists working in specific hospitals were also excluded. Finally, 1433 pharmacist 
were included, from which 342 belong to the intervention group and 1091 to the control 
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group. The reporting card was not given to 46 pharmacist of the intervention group. The 
median of the following period was 13 months for the pos-intervention period. The number 
of pharmacists belonging to the intervention group that effectively had participated was 276 
(80.7%). 
5.2.1 Personal and professional baseline characteristics of the study 
sample  
Next tables (Table 12 and Table 13) presented baseline personal and professional characteris-
tics of intervention and control groups, for physicians and pharmacists. 
In Table 12, for physicians it was observed that distribution by gender and age are similar, 
although slightly less general medicine specialists exist in the intervention group clusters, (a 
possible explication for this fact is that in Portugal the physicians who working in urgency 
service in hospitals appears in database as general medicine, in spite of had other speciali-
ties).  
 
Table 12. Personal and professional physicians characteristics in each study group*  
 Intervention group (n=1388) 
Control group 
(n=5063) 
GENDER    
    Male 681 (49.1) 2432 (48.0) 
    Female 707 (50.9) 2631 (52.0) 
AGE   
    Average (SD) 43.5 (9.2) 45.1 (8.8) 
    Median (percentile 25, 75) 43 (34, 50) 46 (38, 51) 
SPECIALITY   
    General medicine 427 (31.7) 1902 (38.3) 
    Medical 542 (40.2) 1839 (37.0) 
    Medical-surgical 195 (14.5) 646 (13.0) 
    Surgical 115 (8.5) 163 (3.3) 
    Others 69 (5.1) 136 (2.1) 
    Not appear 40 (2.9) 96 (1.9) 
WORKPLACE   
    Primary Care 358 (25.8) 1701 (33.6) 
    Hospital 1030 (74.2) 3362 (66.4) 
* Values are expressed as number (percentage) unless otherwise indicated. SD = Standard deviation. 
Table 13 presents baseline characteristics of intervention and control groups for pharmacists. 
It was observed that distribution by gender, age and workplace are similar, in both groups.  
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Table 13. Personal and professional pharmacists characteristics in each study group*  
 Intervention group (n=342) 
Control group 
(n=1091) 
GENDER   
    Male 70 (20.5) 221 (20.3) 
    Female 272 (79.5) 870 (79.7) 
AGE   
    Average (SD) 38.2 (11.7) 37.5 (11.3) 
    Median (percentile 25, 75) 35 (30, 43) 34 (29, 42.8) 
WORKPLACE   
    Pharmacy 315 (92.1) 1013 (92.9) 
    Hospital 27 (7.9) 78 (7.1) 
*Values are expressed as number (percentage) unless otherwise indicated. SD = Standard deviation.  
5.2.2 Reporting rate of ADR 
In the next tables (see Table 14 and Table 15) the baseline reporting values were compared 
(the baseline year is 2003), for physicians and pharmacists. The physicians of the intervention 
group had an average of global reporting and ADR with inferior definitive or probable cau-
sality and serious ADR than the control group, whereas they have similar values in new 
drugs (Table 14). 
Table 14. Reporting rate of ADR per 1000 physicians-month. Description by characteristics 
of ADR, and by period. 
Period 
Post-intervention 
4-month period 
Reporting Group 
Basal Overall pe-
riod 1º 2º 3º 4º 
Intervention 
with RF 0.36 (7) 7.71 (130) 17.2 (83) 3.53 (17) 4.76 (23) 2.91 (7)
Intervention 
without RF 2.26 (7) 12.8 (31) 16.3 (12) 13.6 (10) 5.4 (4) 24.0 (5)
Intervention 
Pooled 0.63 (14) 8.35 (161) 17.1 (95) 4.86 (27) 4.86 (27) 4.61 (12)
Totals 
Control 0.94 (79) 1.21 (82) 1.09 (22) 1.09 (22) 1.43 (29) 1.26 (9)
Intervention 0.36 (8) 2.91 (56) 5.40 (30) 0.90 (5) 3.06 (17) 1.54 (4)
Serious Control 0.50 (42) 0.66 (45) 0.69 (14) 0.64 (13) 0.64 (13) 0.70 (5)
Intervention 0.13 (3) 2.33 (45) 4.32 (24) 1.08 (6) 1.62 (9) 2.30 (6)Unexpected 
Control 0.29 (24) 0.15 (10) 0 (0) 0.25 (5) 0.20 (4) 0.14 (1)
Intervention 0.45 (10) 6.12 (118) 12.24 (68) 3.42 (19) 3.96 (22) 3.46 (9)High causality 
Control 0.63 (54) 1.00 (68) 0.99 (20) 0.79 (16) 1.23 (25) 0.98 (7)
Intervention 0.31 (7) 3.94 (76) 7.56 (42) 2.34 (13) 2.33 (13) 3.07 (8)New drugs 
Control 0.32 (27) 0.47 (32) 0.49 (10) 0.44 (9) 0.49 (10) 0.42 (3)
RF: Report Form. In the fourth 4-months period the following of all the subjects was not complete. 
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The pharmacists (see Table 15), of the intervention group had an average of ADR with 
slightly inferior definitive or probable causality and serious ADR than the control group, 
whereas have slightly superior values in global reporting and unexpected drugs. All of these 
possible differences in baselines values between groups do not bias the results, because the 
Poisson-GLMM adjusts for those baseline differences. 
Table 15. Reporting rate of ADR per 1000 pharmacists-month. Description by characteris-
tics of ADR, and by period. 
Period 
Post-intervention 
4-month period 
Reporting Group 
Basal Overall pe-
riod 1º 2º 3º 4º 
Intervention 
with RF 2.90 (13) 29.77 (132) 52.36 (62) 29.56 (35) 22.73 (27) 9.39 (8)
Intervention 
without RF 1.36 (1) 9.35 (6) 16.3 (3) 5.43 (1) 5.43 (1) 11.11 (1)
Intervention 
Pooled 2.69 (14) 27.19 (138) 47.5 (65) 26.3 (36) 20.41 (28) 9.55 (9)
Totals 
Control 2.43 (44) 3.97 (58) 2.06 (9) 4.81 (21) 5.50 (24) 2.59 (4)
Intervention 0.96 (5) 13.00 (66) 16.81 (23) 16.81 (23) 8.75 (12) 8.49 (8)
Serious Control 1.27 (23) 1.64 (24) 0.46 (2) 2.29 (10) 2.76 (12) 0 (0) 
Intervention 0.96 (5) 7.09 (36) 13.16 (18) 7.31 (10) 1.83 (8) 0 (0) Unexpected 
Control 0.77 (14) 1.30 (19) 0.92 (4) 1.60 (7) 4.37 (6) 2.12 (2)
Intervention 0.96 (5) 16.15 (82) 25.58 (35) 14.62 (20) 14.58 (20) 7.42 (7)High causality 
Control 1.16 (21) 2.12 (31) 1.15 (5) 1.37 (6) 3.90 (17) 1.94 (3)
Intervention 1.15 (6) 11.30 (57) 17.54 (24) 12.43 (17) 7.31 (10) 6.37 (6)New drugs 
Control 1.44 (26) 1.50 (22) 0.92 (4) 1.60 (7) 2.06 (9) 1.29 (2)
RF: Report Form. In the fourth 4-months period the following of all the subjects was not complete. 
The next 2 figures (Figure 24 and Figure 25) show the monthly evolution of the number of 
reports by 1000 physician-month and by 1000 pharmacist-month in the intervention group 
and in control group. In Figure 24, it possible see that from the beginning of the intervention, 
in first 4 months the spontaneous report increase more than 20-fold (RR=23.3; p<0.001, see 
Table 16) and after decrease, but maintain about 5-fold higher than control group, in the sec-
ond, third and fourth 4-months period, RR for second, third and fourth 4-months period is 
between 4.7 and 6.6-fold higher and statistically significance to the control group for second, 
third and fourth 4-months period (see Table 16, model 2). In Figure 25, it possible see that 
from the beginning of the intervention, in first 4 months the spontaneous report increase 
more than 20 times (RR=20.2; p<0.0001, Table 17) and after decrease, but maintain about 3.0-
fold higher than control group, in the second and third 4-months period, RR for second, third 
4-months-period is between 3.0 and 4.8-fold higher and statically significance (Table 17, 
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model 2). In four 4-months periods the intervention is not more statically significance 
(RR=2.77; p= 0.35). 
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Figure 24. Reporting rate of ADR per 1000 physician-month (between January 2003 and 
June of 2005) 
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Figure 25. Reporting rate of ADR per 1000 pharmacists-month (between January 2003 and 
June of 2005) 
The figures (Figure 26 and Figure 27) show the effect of the intervention on the reporting of 
serious, unexpected, with defined or probable causality, and on new drugs ADR for 1000 
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physician-month and 1000 pharmacist-month respectively. In Figure 26 (a, b, c, d) could be 
observed that the intervention multiplies by 6-fold (RR=6.07; p=0.001) the serious ADR report-
ing; by 8-fold (RR=8.47; p<0.001) the ratio of report ADR the defined or probable causality; in 
32-fold (RR=32.60; p<0.001) the ratio to report ADR unexpected and finally increase in 8-fold 
the ratio of reporting ADR to the new medicines (RR=8.24; p=0.002). 
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a) Reporting rate of new medication ADRs* per 1000 physician 
month 
b) Reporting rate of unexpected ADRs* per 1000 physician 
month 
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c) Reporting rate of high causality (definitive or probable)  
ADRs* per 1000 physician month 
d) Reporting rate of serious ADRs* per 1000 physician month  
 
Legend: CONTROL INTERVENTION  
 
Figure 26. Reporting rate of ADR per 1000 physician-month (serious, highly probability, 
unexpected and new medicines). 
In Figure 27 (a, b, c, d) could be observed that the intervention multiplies by 10-fold 
(RR=9.79; p=0.002) the serious ADR reporting; by 9-fold (RR=8.67; p=0.002) the ratio of re-
port ADR the defined or probable causality; in 4-fold (RR=4.41; p=0.04) the ratio to report 
ADR unexpected and finally increase in 9-fold the ratio of reporting ADR to the new medi-
cines (RR=9.33; p<0.001)). 
In Table 16 it is possible observed the effect of the intervention in the report ratios, adjusted 
by baseline values and the speciality and workplace for physicians. Intervention increase to-
tal report ratios about 10-fold (RR=9.65; p<0.0001) during the pos-intervention period (see 
Table 16, model 1).  
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c) Reporting rate of high causality (definitive or probable) ADRs 
* per 1000 pharmacists month 
d) Reporting rate of serious ADRs* per 1000 pharmacists month 
 
Legend: CONTROL INTERVENTION  
 
Figure 27. Reporting rate of ADR per 1000 pharmacist-month (serious, highly probability, 
unexpected and new medicines). 
In Table 17 it is possible observed the effect of the intervention in the report ratios, adjusted 
by baseline values and workplace for pharmacists. Intervention increase total report ratios 
about 6-fold (RR=5.87; p=0.001) during the pos-intervention period (see Table 17, model 1).  
It is observed that the yellow card administered during the intervention increases in more 
than 3-fold the effectiveness of the intervention that without yellow card (15.3 vs. 4.5), and 
this effect is maximum in first 4 months and disappear in the following months. The distri-
bution of purple card during the intervention not influenced the effectiveness of the same. 
Our results present an RR=5.9, when the purple card is distributed during the intervention 
and a RR=4.2, when the purple card is not distributed during the intervention. 
Finally, in models it is possible see that exist a very small cross-contamination effect between 
groups; for example control group only increase 29% the total reports ratio (RR=1.29; p=0.30) 
during the pos-intervention period for physicians and 63% for pharmacists (RR=1.63; 
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p=0.13). The baseline differences between groups are not relevant for all dependent variables 
(the statistic significance for group variable is always higher than 0.5), although the models 
show results adjusted by these differences. 
Table 16. Effect of intervention over ADR reporting of physicians. Evaluation of the effect 
of the report form and duration of the effect. 
Models Results 
Model description with dependent variable Independent variables  RR (IC95%) P-Value 
Model 1. Effect of intervention on total number of ADR 
reporteda 
Period 
Group 
Period x Group 
1.29 (0.80-2.08) 
0.72 (0.27-1.98) 
9.65 (3.63 -25.68) 
0.30 
0.53 
<0.0001 
Model 2. Effect of time (in 4-month periods) since interven-
tion on total number of ADR reported 
4-month period 1º  
4-month period 2º  
4-month period 3º  
4-month period 4º  
Group 
Group x 4-month period 1º 
Group x 4-month period 2º 
Group x 4-month period 3º  
Group x 4-month period 4º 
1.15 (0.55 – 2.41) 
1.15 (0.55 -2.41) 
1.52 (0.78 – 2.95) 
1.31 (0.45 – 3.83) 
0.75 (0.31 – 1.83) 
23.27 (7.42 – 72.95) 
6.61 (1.90 – 22.99) 
5.02 (1.50 – 16.73) 
4.73 (0.94 – 23.71) 
0.71 
0.71 
0.22 
0.62 
0.53 
<0.001 
0.003 
0.009 
0.06 
Model 3. Effect of intervention on serious ADR reportinga Period 
Group 
Period x Group 
1.33 (0.76 – 2.27) 
0.74 (0.28 – 1.94) 
6.07 (2.04 -18.02) 
0.30 
0.53 
0.001 
Model 4. Effect of intervention on definitive-probable ADR 
reportinga 
Period 
Group 
Period x Group 
1.55 (0.94-2.57) 
0.78 (0.30-2.05) 
8.47 (2.98-24.05) 
0.09 
0.63 
<0.001 
Model 5. Effect of intervention on unexpected ADR report-
inga 
Period 
Group 
Period x Group 
0.52 (0.19-1.41) 
0.48 (0.09-2.51) 
32.60 (4.94-215.20) 
0.20 
0.39 
<0.001 
Model 6. Effect of intervention on new drug ADR reportinga  Period 
Group 
Period x Group 
1.46 (0.70-3.02) 
1.13 (0.35-3.68) 
8.24 (2.20- 30.83) 
0.31 
0.84 
0.002 
Model 7. Effect of report form on total number of ADR 
reporteda 
Period 
Intervention without RFb 
Intervention with RFb 
Intervention without RFb x Period 
Intervention with RFb x Period 
1.28 (0.79-2.07) 
1.08 (0.30-3.88) 
0.42 (0.12-1.40) 
4.46 (1.14-17.47) 
15.29 (4.26-54.94) 
0.31 
0.91 
0.16 
0.03 
<0.001 
Model 8. Effect of time (in 4-month periods) since interven-
tion and of report form on total number of ADR reported 
4-month period 1º  
4-month period 2º  
4-month period 3º  
4-month period 4º  
Intervention without RFb 
Intervention with RFb 
Without RF x 4-month period 1º 
Without RF x 4-month period 2º 
Without RF x 4-month period 3º  
Without RF x 4-month period 4º 
With RF x 4-month period 1º 
With RF x 4-month period 2º 
With RF x 4-month period 3º  
With RF x 4-month period 4º 
1.15 (0.55-2.41) 
1.15 (0.55-2.41) 
1.52 (0.78-2.95) 
1.31 (0.45-3.83) 
1.56 (0.47-5.25) 
0.50 (0.15-1.66) 
6.27 (1.23-31.93) 
5.22 (0.98-27.89) 
1.58 (0.21-12.01) 
8.01 (1.01-65.17) 
39.86 (9.74-163.13) 
8.16 (1.72-38.70) 
8.38 (1.92-36.64) 
4.74 (0.67-33.48) 
0.71 
0.71 
0.22 
0.63 
0.47 
0.26 
0.03 
0.05 
0.66 
0.05 
<0.001 
0.008 
0.004 
0.12 
Period: Months before intervention =0, months after intervention =1. 
Group: Control group=0, intervention group=1 
4-month period: Reference category: Months before intervention 
a. During all post-intervention period (median of 13 months following) 
b. Reference category: control group 
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Table 17. Effect of intervention over ADR reporting of pharmacists. Evaluation of the effect 
of the report form and duration of the effect. 
Models Results 
Model description with dependent variable Independent variables  RR (IC95%) P-Value 
Model 1. Effect of intervention on total number of 
ADR reporteda 
Period 
Group 
Period x Group 
1.63 (0.87-3.06) 
1.52 (0.35-6.68) 
5.87 (1.98-17.39) 
0.13 
0.58 
0.001 
Model 2. Effect of time (in 4-month periods) since 
intervention on total number of ADR reported 
4-month period 1º  
4-month period 2º  
4-month period 3º  
4-month period 4º  
Group 
Group x 4-month period 1º 
Group x 4-month period 2º 
Group x 4-month period 3º  
Group x 4-month period 4º 
0.85 (0.27-2.69) 
1.98 (0.86-4.56) 
2.26 (1.02-5.03) 
1.06 (0.20-5.51) 
1.54 (0.35-6.75) 
20.21 (4.60-88.87) 
4.80 (1.31-17.57) 
3.27 (0.88-12.05) 
2.77 (0.33-23.35) 
0.78 
0.11 
0.05 
0.95 
0.58 
<0.0001 
0.02 
0.08 
0.35 
Model 3. Effect of intervention on serious ADR re-
portinga 
Period 
Group 
Period x Group 
1.30 (0.59-2.84) 
1.08 (0.18-6.37) 
9.79 (2.24-42.66) 
0.51 
0.93 
0.002 
Model 4. Effect of intervention on definitive-
probable ADR reportinga  
Period 
Group 
Period x Group 
1.82 (0.87-3.81) 
1.15 (0.20-6.47) 
8.67 (2.12-35.42) 
0.11 
0.88 
0.002 
Model 5. Effect of intervention on unexpected ADR 
reportinga 
Period 
Group 
Period x Group 
1.68 (0.74-3.80) 
1.24 (0.37-4.18) 
4.41 (1.11-17.53) 
0.22 
0.73 
0.04 
Model 6. Effect of intervention on new drug ADR 
reportinga  
Period 
Group 
Period x Group 
1.05 (0.50-2.16) 
0.80 (0.26-2.51) 
9.33 (2.53-34.40) 
0.90 
0.71 
<0.001 
Model 7. Effect of report form on total number of 
ADR reporteda 
Period 
Intervention without RFb 
Intervention with RFb 
Intervention without RFb x Period 
Intervention with RFb x Period 
1.63 (0.87-3.06) 
1.22 (0.04-36.76) 
1.53 (0.35-6.75) 
4.24 (0.13-135.24) 
5.98 (1.97-18.21) 
0.13 
0.91 
0.57 
0.41 
0.002 
Model 8. Effect of time (in 4-month periods) since 
intervention and of report form on total number of 
ADR reported 
4-month period 1º  
4-month period 2º  
4-month period 3º  
4-month period 4º  
Intervention without RFb 
Intervention with RFb 
Without RF x 4-month period 1º 
Without RF x 4-month period 2º 
Without RF x 4-month period 3º  
Without RF x 4-month period 4º 
With RF x 4-month period 1º 
With RF x 4-month period 2º 
With RF x 4-month period 3º  
With RF x 4-month period 4º 
0.85 (0.26-2.68) 
1.98 (0.86-4.56) 
2.26 (1.02-5.03) 
1.06 (0.20-5.51) 
1.30 (0.04-39.14) 
1.54 (0.35-6.86) 
14.20 (0.31-646.52) 
2.03 (0.02-189.27) 
1.78 (0.02-164.53) 
7.78 (0.07-902.59) 
20.67 (4.60-92.78) 
5.00 (1.33-18.76) 
3.38 (0.89-12.78) 
2.58 (0.29-22.80) 
0.78 
0.11 
0.05 
0.95 
0.88 
0.57 
0.17 
0.76 
0.80 
0.40 
<0.0001 
0.02 
0.07 
0.39 
Period: Months before intervention =0, months after intervention =1. 
Group: Control group=0, intervention group=1 
4-month period: Reference category: Months before intervention 
a. During all post-intervention period (median of 13 months following) 
b. Reference category: control group 
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6 DISCUSSION 
6.1 Discussion Method 
6.1.1 Case-Control study 
This is a case-control study which means that the subjects participating in the study were 
separated according to a yes/no variable that known priori (report of ADR in this study), 
needs different fraction of each sample group, for example for physician group 100% for 
cases and about 10% for controls. However, it lacks longitudinal character, since the exposi-
tions, were not measured previously to the appearance of the effect, bell that in the cases if 
carries through a time that this occurred. This would be an inconvenience for studies of eti-
ologist causing pathologies, where the risk factor could be affected by the appearance of the 
pathology. In studies where attitudes and personal characteristic of subjects were analysed 
(gender, education, etc.) it can be assumed that a transversal or posterior measure to the ef-
fect is as valid as one carried out retrospectively, since these are characteristics with high sta-
bility along time. In this study, only variable “I do not know how the information reported in the 
yellow/purple card is used”, might have been influenced by the reporter condition, since when 
an ADR is reported the Northern Pharmacovigilance Unit gets in touch with the reporter, 
thus increasing its knowledge about the system functioning. 
The spontaneous report of ADR program is focussed in several health professionals such as 
physicians, pharmacists, dentists and nurses. Nevertheless, the health professionals included 
in the studies were only physicians and pharmacists. It is important to note that Northern 
Pharmacovigilance Unit just star working in the beginning of 2001 (although a few reports 
arrived during December 2000). 
The data collection selection method was based on the following criteria: (1) need of time 
and human and material resources; (2) geographical covering of the North region of Portu-
gal; and (3) quality of answers. The auto-fulfilling questionnaires represent a limitation when 
they are sent to the population in general, in people with a lower or middle cultural level, 
and the quality of the reply in this situation can be poor. In the present study, the population 
to the questionnaire was sent is a population of university degree, which means that is 
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probably not a problem. Due to three previously characteristics it was opted by an auto-
fulfilling questionnaire, sent by mail. This possibly represents a limitation, and the answer 
ratio expected is lower than if a personal interview was adopted. 
The calculation of the sample size in epidemiologic studies is complex162 being in the reality 
the efficiency criteria that really condition it.  In this study, all the subjects that filled the con-
dition of case established in the beginning of the study had been included and were com-
pared with a number approximately eight times superior of controls (due to the very re-
duced number of cases) although a ratio of one to four is more efficient from a statistical 
point of view. The stratification by sub-regions, was carried out to get a homogenous geo-
graphically distribution of the controls sample. It was used this variable as base because it 
was the only one that in reality could be used, since the databases did not contain informa-
tion concerning other variables.  
The questionnaire is the instrument for measurement of the data; if it presents low repro-
ducibility, the results are limited. The limitations of the method of data collection, are inher-
ent to any the other type of method based on opinion studies. Thus, the possibility of col-
lected answers was not adjusted to reality for the following reasons:  
(1) Treatment of complacency on the part of those questioned, answering with what they be-
lieve is expected of them.  
(2) Similar phenomena, but at a corporate level, answering with what they believe society 
expects that a "good professional" thinks, so that the image of the groups is not affected.  
 (3) The existence of an identification number in each questionnaire (essential for re-sending 
of questionnaires to those that had not answered). Despite the letter of introduction guaran-
teeing absolute confidentiality, the possibility of the opinions of the questioned subjects to be 
not totally trusted, thus revealing opinions which have the intention to safeguard the image 
of "good professional", before possible auditing.  
The topics above limit, to a certain extent, the validity of the method of data acquisition; 
however, an anonymous questionnaire is the only possible way to collect information on the 
enclosed aspects in this study. To measure the validity of the questionnaire the only possible 
method was the opinion of experts. The pilot test demonstrates high reproducibility for all 
the 15 statements, as can be observed in the results chapter. 
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The internal validity of this study is determined by the non-agreement between the theoreti-
cal and the real sample, because the participation of the subjects is not of 100%. From the 731 
physicians who could have answered, only 397 answered it what represents 54.3% of the to-
tal. In relation to the pharmacists, the results are more interesting, because from the 295 that 
could have answered, 256 had returned the filled questionnaire, which means 86.8% of the 
total. Analyzing these data by the condition of being case or control, we verify that the per-
centage of cases that reply is higher than in controls. These differences of participation can be 
attributed to: (1) a bigger motivation of the cases in relation to the ADR, the same motivation 
that took them to fill the questionnaire; (2) the professionals who already had participated in 
the system of ADR report are familiarised to the system, having a less cautious attitude when 
filling the questionnaire. 
The reply level was significantly more raised in the pharmacists than in physicians, possibly 
because these have a more fixed workplace than physicians (when specialising, physicians 
circulate between several services) and more availability of time.  
An important aspect to have into account is that the controls that had participated in the 
study possibly are inside the group of non-reporters, the most motivated for the subject of 
the ADR.  
6.1.2 Cluster Randomized Trial 
Our study presents several strengths and limitations. The use of control group allowed the 
negation of other potential source of bias and confounding such as seasonal variation or 
"outbreak of reports" (like produced in year 2000 in UK in meningococcal by group C conju-
gate vaccines).163 This potential effect makes “before and after” comparisons difficult to in-
terpret.21,39,49,50 
 This is a randomized study and because that avoids the potential selection biased of partici-
pants based on its greater or smaller probability of potential answer to the intervention; and 
when making the distribution by cluster diminishes the risk of contamination between 
groups. However it increases the risk of which the groups are left unbalanced by baseline 
values mainly, when the number of clusters is small as it is the case of our study. We elimi-
nated this effect fitting in the statistical analysis the variables that have been unbalanced after 
the randomization and by the baseline values of the dependent variables164 and comparing 
the values before the intervention, the changes before and after the intervention and control 
group.165 
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Most cluster-randomized trials allocate approximate equal numbers of clusters to experimen-
tal and controls groups. This is the most statistically efficient randomization ratio, but this 
may not be the most economically efficient.152 When the intervention under evaluation have 
an important cost difference respect control group, may be more economically efficient to 
randomize fewer clusters to the intervention group than the control group.152 Therefore, we 
carried out an unequal randomization,153,154 that allows that with the same resources increase 
the statistically power of the study, since we could increase the size of the control group 
sample without any cost in the intervention. 
Statistically analysis of clusters randomized trial must take into account the clustering ef-
fects, otherwise values are likely to be to small and confidence intervals too narrow (the 
chances of spuriously significant findings are increased). Consequently, standard statistical 
techniques as applied to individual-level data are not appropriate.166 The analysed by means 
of multilevel/hierarchical regression modelling techniques that allow for the clustering and 
permit both individual level and group characteristics to be taken into account. A recent 
study published demonstrated in a simulation study161 that the performance of penalized 
quasi-likelihood method (the same we used in our study) is superior for analysis of clustered 
exponential family observations. An additional problem in cluster randomized trial design is 
that carrying out the cluster random distribution (not by individuals) implies that the statis-
tical analysis needs to take care of the cluster effect (the intra-cluster correlation is higher 
than the inter-cluster). 
A possible limitation is that only half of the physicians of intervention group went to the 
formation, although this number is similar to that other study103 with group sessions. To 
reach the other half of physicians it might be needed active search strategies by means of 
one-to-one interventions that present a greater percentage of participation. In order to avoid 
that the percentage of participation produces a slant equivalent to the one of selection (possi-
bly the physicians who attended are motivated in subjects of ADR), a statistical analysis by 
"intention to treat"159 was carried out: all the physicians of intervention clusters were in-
cluded in the statistical analysis although they did not go to the intervention. This approach 
infra-considers the effectiveness of the intervention, but it provides a measurement more 
close to the effectiveness of the intervention. For pharmacists the results are very different, 
80.7% of intervention group went to the formation, mainly because we went to each commu-
nitarian pharmacies the strategy was of one-to-one interventions that present a greater per-
centage of participation, nevertheless, the efficiency of pharmacists interventions to improve 
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the ADR reporting were lower compared with physicians results in our study, this effect is 
similar to other study104 that showed that the small group face-to-face intervention did not 
appear to offer bigger impacts over large seminars in improving the appropriate use of 
drugs.104 
6.2 Discussion of Results 
6.2.1 Case-Control studies 
When in 1992, the National System of Pharmacovigilance was created, and consequently the 
Program of Spontaneous Report of ADR, already its main limitation was known. Thus the 
experience accumulated in other countries and regions indicated a low level of participation 
of the professionals where the system of Pharmacovigilance is based.22,36,38,39  
In Portugal in the end of 2000, beginning of 2001, had been created the regional units of 
pharmacovigilance, among others things, with the intention to bring the system closer to 
those who contribute to it, and also to diminish the problem of under-reporting. In the be-
ginning of this study, the number of medical reporters was of 88 (final ones of 2002) and of 
pharmacists was of 34 (2003 middle). 
The number of spontaneous ADR reports in the Northern Pharmacovigilance Unit in the first 
3 years of functioning was of 445 (146 in 2001, 165 in 2002 and 134 in 2003). The number of 
national reports (including health professional and pharmaceutical industry) started with 9 
reporters in 1992 and was growing very slowly. In 2001, the national totals of reports had 
been 1342, in 2002 of 1263, in 2003 decreasing of 1100 reports.31 
The north region of Portugal, has an extension above 20.000Km2 and about 3.7 millions of 
person (50% of them live in the metropolitan zone of Porto), 14% have more than 65 years 
old. The numbers of physicians that work for the Regional Health Administration in North 
of Portugal are about approximately 7000 physicians and the number of pharmacists about 
1400 (work in hospitals and communitarian pharmacies). In 2001 the Northern Pharma-
covigilance Unit received only 114 spontaneous reports from physicians and 19 from phar-
macists. The ratios of report are very low compared to values collected in different biblio-
graphical sources.36,78,120 Pharmacist's reporters ploughs less than physicians in Portugal, the 
value is less than study performed in Netherlands.30  
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In these circumstances, it was judged important to carry through a study whose objectives 
are: (1) to analyze the factors that condition the low level of participation of the physician 
and pharmacists population of north Portugal and (2) to intervention in this group of profes-
sionals to increase its participation in the spontaneous report ADR system. 
6.2.1.1 Personal and Professional characteristics related with ADR reporting 
In relation to the personal and professional characteristics of the physicians who had an-
swered to the questionnaire, we verify that in relation to gender, the probability to notify is 
bigger in women then in men. However, this characteristic loses meant when we adjust to 
the remaining variables.36 Nevertheless, in the bibliography, some studies exhibit differences 
in the probability to notify in relation to gender.25,41 In relation to the age it is not verified in 
this study, such as in others,36,41 influence of the age in the probability of notifying. Our dates 
indicate that, acts and to gender to appear you have in influence on pharmacist's reporting. 46 
About relation to “the number of patients seen to per day”, we could think that it would 
have influence in the probability to notify, but in this study, it was observed that the average 
of patients received per day is very similar between reporters (16.5) and no reporters (15.8), 
such as in other study.41 Another study36 points out that this variable only has influence on 
the ADR report when the number of patients consulted per day is superior to 20. 
In relation to “the number of prescriptions written to per day” in our work, the reporters car-
ried out a slightly higher number of prescriptions (25.0) than non reporters (21.9), however it 
can not be determined any influence of this variable in the report. Additionally, it is impor-
tant to note that in the group of reporters there are a higher percentage of general practitio-
ners that are physicians who usually prescribe a bigger number of drugs. In other studies, 
this variable presents influence in the report, but only for average prescription values of 15 
or higher.36,41 This might be due to fact that when there are more prescriptions the probabil-
ity of ADR detection increases and, simultaneously, the probability of reporting.36 In relation 
to the pharmacists the following question was placed in the questionnaire "Approximately, 
how many drugs dispense, in average, per day", but it was eliminated from the results be-
cause in relation to the hospital pharmacists it is difficult and non-objective to answer to it. 
It is well known that ADR have a strong impact in hospital practice; indeed, some studies 
state that >6%9,52,56 of all hospital admissions are due to ADR, while others report that >30% 
of hospitalised patients suffer from ADR8,9,56 thereby leading to increased costs5,6 and excess 
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mortality.59 Nevertheless, in Portugal, physicians who work in hospitals are seven times less 
likely to report ADR than physician’s who work in primary care. These findings are similar 
to other studies conducted in Spain,41 Germany,114 the US70 and UK.45 It might be thought that 
the reason for this is that there are some hospital-based specialities that are associated with a 
low number of prescriptions, yet our study reveals that this effect remains and indeed in-
creases when adjustment is made for speciality and number of prescriptions. We observed 
that reporting probability is lower among surgical and medical-surgical specialities, a find-
ing that is in agreement with other studies42,43 and one that is perhaps due to differences in 
post-graduate education.93 
The inclusion of pharmacovigilance subjects in under and post-graduate degree syllabuses is 
vital for medical knowledge.80,91 However, this varies significantly, not only between coun-
tries but also between different universities in same country.68,79 In view of the lower prob-
ability of reporting in hospital environments, it could, therefore, be important to give priority 
to hospital interventions when these are designed.167,168 
Among Portuguese pharmacists, however, reporting is twenty times higher in a hospital 
than a community setting, a finding in line with other study.169 Setting-related differences in 
reporting, albeit of a diametrically opposed nature, have also been observed among medical 
practitioners, both in Portugal51 and elsewhere.41,42,68 Such workplace-related differences 
might be due to a several factors, namely: hospitals pharmacists are better informed as re-
gards pharmacovigilance and clinical pharmacy subjects;82 constant contact with serious 
ADR;47 and a close relationship with physicians47 who sometimes delegate ADR report to 
hospital pharmacists. The finding of a lower reporting probability among community phar-
macists could be great interest when it comes to designing educational programs, since this 
would indicate the need to assign priority to educational interventions addressing this seg-
ment.34,50,106 
6.2.1.2 Knowledge and attitudes related with ADR reporting 
The results shown that differences in terms of knowledge, attitudes or opinions are those 
conditioned the reporter character of physicians and pharmacists. In 1976, Inman proposed 
the “seven deadly sins” (initially he had proposed seven reasons,37 but later added an eight69) 
as reasons for under-reporting, though in so doing he had medical practitioners in mind. It is 
conceivable however, that many of the reasons could be common to medical practitioners 
and pharmacists alike.  These reasons could be divided into two different groups:76 (i) three 
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linked to attitudes relating to professional activity (financial incentives, legal aspects and 
ambition to publish); and (ii) five linked to ADR-related attitudes and knowledge (compla-
cency, insecurity, diffidence, indifference, and ignorance). 
Our data indicate that Portuguese physicians and pharmacists do not see any need for addi-
tional financial recompense, the following statement intent to represent this “I should be fi-
nancially reimbursed for providing the ADR service”, the payment of a fee it was describe by 
Inman in addition to not reporting, because the physicians are pay for example69 for the 
pharmaceutical companies to participate in clinical trials for example in majority of studies 
we could observed that this is not appointed as an reason to not reporting36,41,46,114 but in lit-
erature appear two articles that appoint for the stimulation of ADR reporting with financial 
recompense.136,137 The physicians and pharmacists think that reporting is their duty ”I have a 
professional obligation to report ADR”.36,41 Portuguese pharmacists and physicians that can 
in no way compromise their professional liability “Reporting ADR puts my career at risk”, 
these results are in line with studies conducted in Europe addressing the same topic44-46,68,114 
but are different from other studies involving US physicians37,39,138 perhaps because the 
health system are different. Inman37 described the fear of possible involvement in litigation or 
investigation of prescribing costs by the Health departments, as a cause to not reporting. An-
other proposed reason was the ambition to collect and publish a personal series of cases;37 that 
appear in the questionnaire as this “I think that the most correct way to report ADR is in 
medical/pharmaceutical literature”, nevertheless this does not seem to be an important fac-
tor for Portuguese physicians and pharmacists, e.g. a bibliographic review found a reference 
to few Portuguese paper on ADR reporting in MEDLINE review indices (key words: adverse 
drug reaction or events, Portugal; in June the 2005). This is in line with European study68 that 
included Portuguese physician's, we observed that none of Inman’s reasons connected with 
professional activity displayed any influence on ADR reporting and we could observed the 
same in another European study45 and in an Chinese study.125 
The first reason linked to ADR-related attitudes and knowledge, proposed by Inman37 was 
the complacency, designed for the encouraged by one-side drug promotion and the belief that 
only safe drugs are allowed on the market, in our study this statement is “Really serious ad-
verse drug reaction is well documented by the time a drug is marketed”. It might be con-
cluded that majority of Portuguese physicians and pharmacists in this study are those who 
are more in agreement with this statement, like in other studies.39,41,68 Our study51 indicated 
that this attitude is statistically associated with probability to notify an increment equivalent 
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to the interquartile range could lead to a rise in report probability of 87% for physicians and 
223% for pharmacists, which implies a huge importance of the effect. Comparison of the pre-
sent study with other studies is difficult, since only a few of these used the same type of vis-
ual analogical scale. Nevertheless, some studies carried out in Spain,41 UK44 and US36 also 
exhibit statically significant differences. 
Other reason for under-reporting is the insecurity; in our questionnaire the statement is “It is 
nearly impossible to determine whether a drug is responsible for a particular adverse reac-
tion”. The majority of pharmacists (median 4.5) and physicians (median 3.0) are disagree-
ment with this question. This question is statically significant for our physicians, increased 
the probability to notify in 20% for one-unit decrease on the visual analogical scale. It is of 
interest that the opinion of physicians in our survey was similar to those previously reported 
from physicians in the US,36 UK,44 Netherlands42 and Spain.41 This statement is not statisti-
cally significant for pharmacists; however, it is interesting to note that in a UK study46 where 
pharmacists start to notify since 1997, where one question placed in a questionnaire was 
“level of clinical knowledge makes it difficult to decide whether or not an ADR has oc-
curred” and one third of inquired agrees that this factor discourage pharmacists from report-
ing ADR. 
Inman37 recognises that the afraid of ridiculous for reporting an ADR suspicion that is diffi-
dence as one of the causes that determine the fulfilment and the sent of the report card to au-
thorities. The question placed in the questionnaire was “I that one would only report an ad-
verse drug reaction if I was sure that it was related to the use of a particular drug". The ma-
jority of pharmacists and physicians might be in agreement with this assertion because per-
haps they think that only are accepted forms that demonstrate a causal relation. These results 
are similar to a study68 carried out in several European countries where the Portuguese phy-
sicians answering to the questionnaire present a higher percentage of agreement answers 
with this statement (10.8% of the responders), in other study performed in Sweden43 physi-
cians, referee this assertion as an cause for under-reporting as in a study assemble in US39 
and in German.114 This statement in our study is statistically significant for both profes-
sional’s, for physicians21,41,125 the interquartile range of these measure indicate that a change 
from 75th to the 25th percentile would lead to reporting probability rising by 143% and for 
pharmacists the value is 240%. Other studies found significant statistically for similar state-
ment like as a study carried out in the US,47 from the 235 pharmacists that answered to the 
questionnaire 32.3% considered that this is a cause for non-reporting. A study performed in 
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UK,46 shown that pharmacists were more likely to report if there was a degree of certainty 
that the drug had caused an ADR (82.4% of 280) and a lack of confidence in the diagnosis of 
an ADR46,47,48 was important for pharmacists, they more likely report ADR when they are 
more confident about the ADR. This is a consistent finding from all surveys, and may reflect 
the anxieties of reporters “not to appear foolish”, a sentiment that needs to be dispelled 
through communications from regulatory agencies and education. 
It seems evident that the opinion of a single physician might substantially influence the 
knowledge of several other colleagues, as for instance the Mc Bride170 case, the Australian 
physician that with a single letter to the director of a medical journal, allows the finding of 
the association between thalidomide and a teratogenicity reaction. The opinion related to 
“The one case an individual physicians might see could not contribute to medical knowl-
edge”, that, according to Inman37 represents the indifference on the part an individual physi-
cian to his essential role as a clinical investigator who should be contributing to the general 
advancement of medical knowledge and is one of the seven causes for under-reporting. In 
our study pharmacists and physicians disagree mostly with this statement (median 4.0). In a 
study carried out in US36 it was verified that physicians that answered to the questionnaire 
disagree mostly with this assertion, but there were no major differences between reporters 
and non-reporters. This question has a significant statically in our study only for physicians, 
the probability of notify increase about 20%, when a one-unit decrease on the visual analogi-
cal scale, in other studies36,41,44 where this statement were present the significance statically 
were observed too. For pharmacists the statement not presented significance statistically. 
This statement could be related with other assertion present in the questionnaire “when I 
read medical/pharmaceutical literature I am interested in articles about ADR”, mostly 
pharmacists and physicians agreement with this declaration (median respective 9.0 and 8.0), 
nevertheless this statement did not have significance for pharmacist sample that answered 
the questionnaire.  
The last reason linked to ADR-related attitudes and knowledge, proposed by Inman37 was 
the ignorance of the Committee’s requirements for reporting. The spontaneous report of ADR 
program was designed to detect all types of undesirable effects that might be associated to 
each drug, thus including severe and less severe reactions. Consequently the following ques-
tion is placed in the questionnaire “It is only necessary to report serious or unexpected 
ADR”. Our study found that the mostly physicians and pharmacists disagree with is state-
ment (median 2.0). The lack of knowledge bout the functioning of system of spontaneous re-
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port of ADR by physicians and pharmacists is presented in several studies.21,42,43,46,47,114 Ac-
cording to our data, potential changes equivalent to the interquartile range could lead to a 
rise in reporting probability of 71% for physicians and 316% for pharmacists, other studies 
realized with pharmacists in UK46 and US47 and physicians21,42,44,45,125 present significance sta-
tistically for this statement. In Portugal, the program of spontaneous report of ADR is such in 
other countries, for reporting of all kinds of ADR but is especially dedicated to severe and 
unexpected ones. In some countries, as UK besides that, special attention is devoted new 
drugs in market (less than 5 years).  
After these five reasons, others statements related with reporting system: as possible com-
plexity or unknown of the use of information was answered (1) “I would be more likely to 
report ADR if there were an easier method” and (2) “I do not know how the information re-
ported in the report card is used”. In relation to these statements, the answers from pharma-
cists and physicians are quite different; for the first statement the majority of physicians 
agree (median 7.5) and pharmacists are in the middle (median 5.0). To the second question 
about this issue the position from to professional groups are very different, mostly physi-
cians agree with the affirmation (median 6.5) nevertheless, pharmacist disagree with this 
statement (median 3.5). These results could demonstrate that Portuguese pharmacists know 
better than physicians what happen with this information, and the importance of that for 
pharmacovigilance system. It is comprehensible that if potentially reporters ignore the utility 
of the information that they could introduce in the system and the cards reports contain in-
formation about the report and the patient, even guarantying confidentiality, is logical that 
those who do not know the system are more reticent to report ADR, because they does not 
like report confidential information, this problem was refereed in several studies. 41,44,45,48,120 
The both statement are significantly for physicians, the probability of notify increase about 
25%, when a one-unit decrease on the visual analogical scale, nevertheless only the first ques-
tion has significance for pharmacists, about 16%. In others studies41,42,44,114 physicians referee 
as significantly reason not to report the bureaucratic of the system.  
This questionnaire has two questions regarding the time necessary to report an ADR. Leth-
argy was classified as “don’t’ have time” and the questions that represent this concept are: (1) 
“I do not have time to complete the report card” and (2) “I do not have time to think about 
the involvement of the drug or the other causes in ADR”. Our results show that both profes-
sional’s disagree with first statement, the median for pharmacist is 1.5 and for physicians 3.5. 
In numerous studies the physicians and pharmacists appoint this as one cause to not re-
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port.21,42,46,48 Other studies found similar results for this statement like as.36,39,41 For the second 
question the median (2.5) are the same for both, the majority of physicians and pharmacists 
that answer to the questionnaire disagree with this statement, nevertheless the pharmacist’s 
agreement with this statement increase compared with first question of time, perhaps be-
cause the lack of time to actively look for ADR while in clinical practice.46 In our study the 
two statements are statistically significance for physicians, like in other studies21,41,42 however 
for pharmacists only the second question is significantly.46  
The last question placed in the questionnaire is related to the relation between health profes-
sionals and the pharmaceutical industry, and the statement was “I talk with pharmaceutical 
companies about possible ADR with their drugs”. In the current study this point is not stati-
cally significant for physicians neither for pharmacists when an ADR is reported. Neverthe-
less, the majority of physicians agree with this affirmation (median 8.5) to contrary of phar-
macists that are in the middle (median 5.5). This question is difficult to compare with other 
studies, because normally the statements in other studies is about the sent of the reports card 
to pharmaceutical company as in US,47 this situation occurred in countries did not have the 
same system as the major European countries. In the majority European countries like in Por-
tugal, to avoid economical interests, the health professionals, should report ADR directly 
through the spontaneous reporting system to regional pharmacovigilance centres (these cen-
tres belong to the Pharmacovigilance Department of Healthy Ministry) and the pharmaceuti-
cal companies must have a Pharmacovigilance Department too and should informed the 
Healthy Authorities about the security of them products, accordingly with the law. 
To the five ADR-related reasons proposed by Inman’s for physicians we are the first to find 
association with all of them, in contrast with others that have found only one, two, three or 
four of these. 41,43,44,114,121 For pharmacists we found association with the complacency,47 igno-
rance46,47 and diffidence46,48 these factors seem to be associated with the lower reporting 
probability, comparing these results to those of other studies is difficult since this is the first 
study to examine the link between pharmacists’ attitudes and reporting; indeed, relating it to 
similar studies undertaken on medical practitioners proved scarcely feasible. We believe that 
the discrepancies between our and other published results could be due to our use of a visual 
analogue scale. This scale would be able to detect small, albeit relevant, differences in medi-
cal and pharmacists’ attitudes that are not discernible when using a categorical-type scale 
with three or four categories. Moreover, thanks to this scale41,51 we have detected a strong 
association between attitudes and reporting. With respect to the results of pharmacists, it is 
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important to refer that from the methodological point of view the sample is smaller than for 
physicians and that confidence intervals are bigger although significant. For the attitudes 
complacency, diffidence and ignorance they are less accurate.  
Pharmacists can play an important role in pharmacovigilance, both in community practice 
and in a hospital setting. In both settings, co-operation among pharmacists and medical prac-
titioners is important. Pharmacists can contribute considerably to the quantity and quality of 
ADR reporting, normal their reports are well documented.171 Nevertheless is interest referee 
that pharmacist’s reports more often concern external organs systems such as disorders of 
the skin and the eyes.30 Until now, nothing has been known about which factors induced and 
which inhibited pharmacists vis-à-vis reporting. Hence, the results of our study may well 
constitute an important contribution, since they indicate which ADR attitudes are strongly 
associated with reporting. It therefore follows that modifying such attitudes could greatly 
reduce ADR under-reporting. 
This strong association between knowledge/attitudes and under-reporting may well indi-
cated that educational interventions purpose-designed to change such knowledge/attitudes 
could bring about important improvements in reporting [i.e. knowledge-attitudes-practices 
model].76 However, in order for this to occur it is also important that these educational 
strategies enhance the degree of balance between medical and pharmacists practitioners, 
their environment (patients, colleagues, health system administration and pharmaceutical 
industry: needs satisfaction theory)76 and their ADR-related motivation. Not only must such 
education be undertaken by institutions involved in this field, such as universities, pharma-
covigilance units and other health system professionals having a duty to ensure that it be-
comes an activity that forms an integral part of their daily routines. To the end, pharmacists’ 
and physicians’ ADR education80,81,87 must be improved, possibly through the implementa-
tion of educational programs focusing on altering attitudes identified by the study as being 
associated with under-reporting. We feel that this study could provide a good basis for de-
signing interventions studies aimed at decreasing under-reporting, and creating a “reporting 
culture” among health professionals. 
6.2.2 Cluster Randomized Trial  
In this large, controlled, cluster randomized trial the physicians multiply by more than 9-fold 
and the pharmacists multiply by more than 5-fold the number of report card notifications 
during the year following to the educative intervention of one hour of duration. The effect is 
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maximum, 20-folds in the first 4-month period (for physicians and pharmacists) and for phy-
sicians the effect remains about 5-fold during more than one year after the intervention. For 
pharmacists the results remained about 3.0-fold higher than control group, in the second and 
third 4-months period. Also an improvement in the quality (relevance) of the reports has 
been observed because an increase of serious, unexpected, new drugs and imputation of high 
causality ADR reporting occurs. The results of this study might be very important from both 
educational and public health point of views, since it indicates educative strategies that 
might significantly improve ADR vigilance. 
The magnitude of the effect found in our study not very often has been observed in the al-
terations of health professional’s performance.93,100,101,103 The revisions on the effectiveness of 
interventions to improve the provider behaviour already consider as "moderately important" 
improvements of 20%172 while in our case the improvements were in the order of 900% for 
physicians and 500% for pharmacists. These improvements were maintained during more 
than one year after the intervention. The factors that can explain these magnitudes of effect 
in professional behaviour change are multiple: the target of the intervention,100 the type of 
intervention (outreach visit),103 the number of interventions,100,173 the organising organism of 
the intervention,98 inexistence of barriers,100,174 the existence of incentives,136,137 degree of in-
teractivity of the interventions,174 and its design from gaps detected in the health profession-
als. 100 
The target of the intervention may also account for the high effect magnitudes reported by 
other authors who addressed this same topic; a study realized in UK (Dublin)21, over 3 
months, the greater availability of yellow cards and reminders about reporting ADRs led to 
an approximate five-fold increase in reports but reporting declined rapidly thereafter when 
verbal reminders were withdrawn, despite continued ready availability of cards suggesting 
that making cards available alone does not significantly increase reporting, another study 
performed in US (Rhode Island)39 present more than 17-fold increase in reports submitted by 
physicians, after intervention. A teaching hospital in Puerto Rico49 implemented a new policy 
for reporting ADR. After the first year, the number of ADR reported per year increased from 
an average of 32 ADR/year to 167/year, during the second year, 274 ADR were reported for 
a 750% increase. This significant improvement is the result of an effective educational cam-
paign, a simplified reporting method, and a more complete definition of an ADR. In this 
study suspected ADRs were reported to pharmacy: (1) direct observation and reporting by 
health professionals; (2) reports by quality assurance and (3) by laboratory service, the form 
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is signed by the person making the report and sent to pharmacy for evaluation by a clinical 
pharmacy. A program was created to stimulate reporting of ADRs in US (Mississippi) in-
cluded both institutional and community based health care facilities located in urban and 
rural settings. Pharmacists had the expertise and responsibility to assume a more active role 
in the reporting of ADRs. The intervention included a promotional packet outlining the pilot 
project plus ADR reporting guidelines. There had been follow-up mailings to reinforce the 
program goals in addition the publication of the Department responsible for the program 
included several articles related to ADR reporting.  Methods used in this project increased 
the monthly average of reported ADRs from 3.94 to 16.5 (318%).50  
By comparing pharmacists with physicians, it can be observed that the latter show better re-
sults. Some of the factors that might justify these differences are: (1) the educative interven-
tion was designed based on the results of study 1 that was itself designed based on knowl-
edge and attitudes derived from the Imann’s seven signs planned for physicians was also 
used for pharmacists with some adaptations; (2) in study 1 the differences for pharmacists 
are smaller than for physicians both in number of attitudes and in the magnitude of the 
found effect; (3) there are also some differences in interventions and participants; therefore, 
the background of the professional, the interaction between participants and the size of the 
target group is important.104,175 In our study the professionals’ physicians and pharmacist 
have different background, the size of the group and consequently the interaction between 
participants during the intervention are different too. The intervention in pharmacists was 
more individual in each communitarian pharmacy, this difficult the interaction between par-
ticipants.  
Possibly one of the factors that can explain this so important effect is the subject of our inter-
vention. Our results as well as those from other authors21,39 on the same subject found a very 
important answer to the intervention for improve the reporting. It has been described that 
for some objectives of intervention (like changes in the prescription, use of diagnostic tests, 
reporting ADR) not all the changes in the knowledge and attitudes of the professionals pro-
duce changes in health care outcomes due to multiple barriers100 like the expectations of the 
patient, or administrative ties like the lack of time.174 We thought that unlike others, our in-
tervention has the advantage to present few barriers, and those detected – the need of much 
time to reporting or the absence of the report card were explicitly covered during the inter-
vention. 
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It has also been described that educative interventions to improve health professional’s per-
formance are more effective when multiple interventions were carried out. The other studies 
to improve the notification use multiple interventions (mailings,39,50 newsletters,39,50 and oral 
presentations,39,50 articles in staff newsletters,39,50 advertisement,39 and cooperation with hos-
pital pharmacy39) whereas our single study consisted of only one session of one hour of du-
ration, accompanied by an informative leaflet and a report card for each professional. It has 
been described that the availability of the report card could improve the notification of ADR 
about 50%.40 In Portugal report card is distributed every year through a medicine formulary, 
in all formation about this issue and replaced if there is a reporting, and that is possible to 
report without the report card (through internet, telephone or fax). When the Northern 
Pharmacovigilance Unit was created in 2001 were sent to health centre directors and hospital 
clinical directors report cards and are still sent whenever requested. We feel that the report 
form may be construed as a cointervention which can act both as a facilitating factor and as a 
remainder40 and which, by virtue of its low cost, ought to accompany all educational inter-
ventions aimed at improving reporting.  
Another factor that can influence in the effectiveness of the intervention is its design. The re-
visions on the subject indicate that the more interactive the materials and the presentations 
the more effective they are.174 Our intervention was designed to be the most interactive pos-
sible with respect to the presentation, the discussion and the leaflet. Another point that can 
explain the effectiveness of our intervention is that it was designed specifically from gaps of 
education detected in phase I of our study. This allows the elaboration of specific and con-
crete messages, and therefore more efficient.100 In addition, these messages were given by an 
academic and independent organising organism ("detail academy"), which can increase the 
effectiveness of the intervention.176 Unlike interventions made by the national systems of 
health, that can be based on the negotiation,136,137 our intervention is based on the persuasion 
that derives from the authority and credibility of the educator, and of the evidence that can 
contribute when coming from a university organization.  
The observed efficiency of the intervention could also be attributed to the low departure 
level.30 Thus, one might think that the levels of the departure reporting of Portugal were very 
low, and that therefore the magnitude of the effect found in our study is not applicable to 
other cases in which the numbers of under-reporting are not so low. Nevertheless, when we 
consider the direct reports of physicians we observed that in Portugal the number of notifica-
tions is approximately of 70 by million inhabitants, inferior to the European average but su-
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perior to countries like Germany, Italy, Greece, US and Canada. For pharmacists, Spain and 
France had values higher than Portugal (19 pharmacists’ report/million habitants) but in It-
aly the report ratio is lower than in Portugal. In both situations we talk about directly reports 
from health professionals, and are from 2001.30  
One of the possible limitations of the educative interventions is that its effect can be limited 
in time. Nevertheless, there are only a few studies of continuing medical education methods 
that evaluate the duration of changes in clinical practices,177 the existing studies indicate that 
the effect of the continuing medical education diminishes with time, but that can be main-
tained between nine months103,178 and two years.178,179 Our data indicate that the effect is 
maxim in the first months, but it remains stable, at least one year after the intervention. We 
don’t have long-term data but we believe that in order to maintain the interest of the physi-
cians and pharmacists in the system, it could be of interest to make repeated and regular in-
terventions. Our data show that it could be sufficient to make these interventions with an 
annual interval. In addition, we think that the successive interventions should not be centred 
again in the initial message, and could be based on practical factors that have been very ef-
fective to improve the behaviour of physicians and pharmacists to fulfil the report card.  
6.3 Policy Implications 
ADR is a persistent and important public health problem in terms of morbidity, mortality, 
and cost and the under-reporting is the principal limitation of ADR reporting systems in all 
countries. We detect during this study that health professionals had inadequate knowledge 
about ADR and about the pharmacovigilance system and that these attitudes/knowledge are 
associated with ADR reporting. These results should encourage health political leaders to 
design continuing educational strategies for physicians and pharmacists in order to generate 
a reporting culture. This is especially true presently since in the last years we could observe a 
medicine safety crisis with the withdrawal of a series of drugs from the market,180-182 mainly 
in countries where the pharmacovigilance systems are based in data provided from pharma-
ceutical industry. The establishment of a reporting culture in health professionals will allow 
data acquisition with no bias that could detect earlier medicine safety problems and also in-
crease the motivation and involvement of health professionals in the pharmacovigilance 
process. 
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From gaps detected in the attitudes/knowledge study we design an educative intervention 
with approximately one hour that proved to be extremely effective in increasing the quantity 
and quality of ADR reporting. Since the results were effective during more than one year af-
ter the intervention, it indicates that health professionals respond well to this type of inter-
ventions. If these results can be replicated over time in other settings, it might well indicate 
that many countries could substantially enhance ADR reporting in terms of both volume and 
relevance by means of educational strategies purpose-designed to meet professionals’ train-
ing needs. This would enable the role of health professionals in pharmacovigilance to be en-
hanced and ADRs to be detected earlier and more reliably, thus making for substantial im-
provements in drug safety monitoring. To keep the effect it will probably be necessary re-
minding interventions that, ideally, should be oriented to more practical questions, for in-
stance workshops that will allow the continuation of the interest. Additionally other types of 
interventions are described such as mailings, phone calls, leaflets, bulletins, etc., but have 
proven to be less efficient. 
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7 CONCLUSION 
• Factors socio-demographic and personal related with under-reporting of ADR found 
in our study for physicians were: type of medical specialization and workplace; for 
pharmacists this factor was the workplace. 
• Knowledge-attitudes −based in “seven deadly sins”of Inman− related with under-
reporting of ADR were for physicians: complacency, insecurity, diffidence, indifference, 
and ignorance and for pharmacists the found related with under-reporting were: com-
placency, ignorance, and diffidence. 
• Educative intervention increases the quantity and quality (relevance) of spontaneous 
report of ADR. In terms of quantity, the spontaneous report increased about 10-fold 
for physicians and 6-fold for pharmacist during more of one year after intervention. 
In terms of relevance quality: (1) for physicians the intervention multiplies by 6-fold 
the serious ADR reporting; by 8-fold the ratio of report ADR the defined or probable 
causality; in 32-fold the ratio to report ADR unexpected and finally increase in 8-fold 
the ratio of reporting ADR to the new medicines; and (2) for pharmacists the inter-
vention multiplies by 10-fold the serious ADR reporting; by 9-fold the ratio of report 
ADR the defined or probable causality; in 4-fold the ratio to report  ADR unexpected 
and finally increase in 9-fold the ratio of reporting ADR to the new medicines. 
• For physicians the duration of effect remains about 5-fold higher than control group, 
in the second, third and fourth 4-months period. For pharmacists the duration of ef-
fect remains about 3.0-fold higher than control group, in the second and third 4-
months period, in four 4-months period the intervention is not more statically signifi-
cance. 
• It is observed that the yellow card (physicians) administered during the intervention 
increases in more than 3-fold the effectiveness of the intervention that without report 
form, and this effect is maximum in first 4 months and disappear in the following 
months. For pharmacist the distribution of purple card during the intervention not 
influenced the effectiveness of the same. 
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APPENDIX A 
Report Forms: yellow form (physicians); purple form (pharmacists) and 
white form (nurses). 
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APPENDIX B 
Questionnaires 
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Physician’s questionnaire (original) 
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Physician’s questionnaire (translation) 
 
APPENDIXES 
146 
 
  APPENDIXES 
  147 
 
Pharmacist’s questionnaire (original) 
 
 
APPENDIXES 
148 
 
 
 
 
 
 
  APPENDIXES 
  149 
Pharmacist’s questionnaire (translation) 
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APPENDIX C 
Expert’s opinion (validity) 
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1. National Pharmacovigilance Department of INFARMED 
Questionnaire is balanced (questions nº, fulfill time, etc.). Questions are very well 
elaborated in sense to identify the causes of under reporting in Portugal by health 
professionals. 
 
2. Northern Pharmacovigilance Unit 
Questionnaire is balanced (questions nº, fulfill time, etc.). Questions are very well 
elaborated in sense to identify the causes of under reporting in Portugal by health 
professionals. 
In relation to the scale it could be better if has a middle division with 50 value or 3 
divisions with values 25, 50 and 75. 
 
3. Pharmacology Department of the Pharmacy Faculty, University of Coimbra, (Professor 
Margarida Carmona) 
Questionnaire is balanced (questions nº, fulfill time, etc.). Questions are very well 
elaborated in sense to identify the causes of under reporting in Portugal by health 
professionals. 
In relation to the scale it could be difficult the answer form because pharmacists did 
not know this type of scale.  
 
4. Pharmacology Department of the Pharmacy Faculty, University of Porto (Professor Jorge 
Oliveira) 
Questionnaire is balanced (questions nº, fulfill time, etc.). Questions are very well 
elaborated in sense to identify the causes of under reporting in Portugal by health 
professionals. 
In relation to the scale could be happen some problems with fulfil of the questionnaire 
and with analyse. The scale could be better has individual values between 0 and 10. 
 
5. Institute Superior of Health Sciences of North (Professor Jorge Proença) 
Questionnaire is balanced (questions nº, fulfill time, etc.). Questions are very well 
elaborated in sense to identify the causes of under reporting in Portugal by health 
professionals. In relation to the scale it could be better if has a middle division with 50 value. 
 
6. Pharmacoepidemiology Studies Centre of National Association of Pharmacies (Prof. 
Ana Martins) 
Questionnaire is balanced (questions nº, fulfill time, etc.). Questions are very well 
elaborated in sense to identify the causes of under reporting in Portugal by health 
professionals. 
The scale could be better has individual values between 0 and 10. Communitarian 
pharmacists could have problems to know how many medicines dispense in middle per day 
it could be better establishing a range of 1 week for example. 
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APPENDIX D 
Introduction letter (Case-Control Study) 
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First physician’s letter 
 
 
 
 
 
 
        Porto, 3 de Dezembro de 2002 
 
Caro colega 
 
Após dez anos de funcionamento do Programa de Notificação Espontânea de Reacções Adversas a 
Medicamentos (RAM), através da Ficha Amarela, vamos realizar um estudo farmacoepidemiológico1 com o 
objectivo de identificar e avaliar as atitudes e opiniões dos profissionais de saúde, de forma a corrigir 
deficiências no seu funcionamento e melhorar o grau de participação dos médicos na notificação de RAM. 
 
Como sabe, a Notificação Espontânea de RAM, por parte dos profissionais de saúde, constitui o método 
farmacoepidemiológico mais usado e universalmente aceite, para a detecção de RAM de medicamentos, 
recentemente comercializados e de RAM inesperadas ou raras. Por isso, o seu valor é inestimável, no seio de um 
sistema de saúde moderno, por contribuir para uma maior segurança e eficácia no uso terapêutico dos fármacos. 
 
O universo deste estudo é formado por uma amostra representativa de 800 médicos inscritos na ARS-Norte, 
seleccionados de maneira aleatória e por um procedimento informático. 
 
Do ponto de vista metodológico, é fundamental que haja uma participação completa e com uma elevada 
qualidade das respostas. Por isso, é de importância vital que dedique cinco minutos do seu precioso tempo ao 
questionário que juntamos, desenhado a pensar num rápido e fácil preenchimento. 
 
Garantimos a confidencialidade absoluta dos dados. O código numérico do questionário utilizar-se-á mantendo o 
anonimato, para resolver o problema das “não respostas”. A informação recolhida só será apresentada de 
maneira agrupada e utilizada unicamente para fins científico-académicos. Comprometemo-nos desde já enviar os 
artigos a que der lugar este estudo. 
 
No cabeçalho do questionário, encontrará as instruções para o seu correcto preenchimento, que agradecemos leia 
atentamente. Quando terminar de preencher o questionário, coloque-o dentro do envelope franquiado e envia-o 
pelo correio. Se tiver alguma dúvida ou problema durante o preenchimento do questionário, pode telefonar para 
o número 225573990. 
 
Agradecendo antecipadamente a sua colaboração, enviamos os melhores cumprimentos. 
 
 
 
 
 
 
 
 
Prof. Doutor Jorge Polónia    Mestre Teresa Herdeiro 
Coordenador da UFN      Prof. Coord. Equip. IPSN 
 
 
Insistimos novamente na importância do preenchimento cuidadoso do questionário, pois disso dependerá a validade do estudo. 
1com a colaboração da Universidade de Santiago de Compostela. 
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Second physician’s letter 
 
 
 
 
 
 
       Porto, 5 de Fevereiro de 2003 
 
 
Caro colega 
 
 
Como se recordará, no passado mês de Dezembro, enviámos um questionário com o objectivo de identificar e 
avaliar as atitudes e opiniões dos profissionais de saúde, sobre o Programa de Notificação Espontânea de 
Reacções Adversas a Medicamentos (RAM) através da Ficha Amarela. O estudo tem como finalidade corrigir as 
eventuais deficiências do Programa de Notificação de RAM, assim como motivar e melhorar o grau de 
participação dos médicos na notificação de RAM. 
 
Como resultado do envio anterior obteve-se um elevado nível de respostas. Contudo, solicitamos de novo a sua 
colaboração, dado que o nosso interesse está em que o estudo seja um reflexo fiel da opinião de todos os médicos 
inscritos na ARS-Norte. 
 
Para efeito, remetemos um novo questionário e agradecemos desde já a sua valiosa colaboração, melhores 
cumprimentos. 
 
 
 
 
 
 
 
 
 
Prof. Doutor Jorge Polónia    Mestre Teresa Herdeiro 
Coordenador da UFN      Prof. Coord. Equip. IPSN 
 
 
 
 
 
 
 
Se não recebermos noticias suas em breve, entraremos em contacto consigo para resolver qualquer dúvida que 
possa ter. 
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Third physician’s letter 
 
 
 
 
 
 
 
        Porto, 4 de Abril de 2003 
 
Caro colega 
 
 
Como sabe, estamos a realizar um estudo com o objectivo de conhecer as atitudes e opiniões dos médicos 
inscritos na ARS-Norte, sobre distintos aspectos do Programa de Notificação Espontânea de Reacções Adversas 
a Medicamentos (RAM), depois de 10 anos de funcionamento. 
 
Até agora enviamos por duas vezes o questionário, obtendo um nível de resposta satisfatório; contudo para 
conseguir a validade metodológica adequada somos obrigados a insistir de novo na necessidade de participação. 
Para isso, enviamos de novo o questionário, que foi desenhado pensando num rápido e fácil preenchimento 
(apenas cinco minutos), por sermos conhecedores das limitações de tempo na nossa profissão. 
 
Solicitamos que o envie tão depressa quanto possível, já que cada questionário recebido contribui grandemente 
para aumentar a validade final do estudo. Por isso, a sua colaboração é muito importante. 
 
Ao mesmo tempo que insistimos na confidencialidade absoluta dos dados, aproveitamos para agradecer a 
valiosa colaboração.  
 
 
Melhores cumprimentos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prof. Doutor Jorge Polónia    Mestre Teresa Herdeiro 
Coordenador da UFN      Prof. Coord. Equip. IPSN 
 
 
 
 
 
 
 
Para qualquer esclarecimento, não hesite em contactar-nos para o telefone 225573990. 
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Fourth physician’s letter 
 
 
 
 
 
 
 
Porto, 2 de Junho de 2003 
 
Caro colega 
 
 
Como sabe, estamos a realizar um estudo com o objectivo de conhecer as atitudes e opiniões dos médicos 
inscritos na ARS-Norte, sobre distintos aspectos do Programa de Notificação Espontânea de Reacções Adversas 
a Medicamentos (RAM), depois de 10 anos de funcionamento. 
 
Até agora enviamos três questionários, alcançando um nível de participação satisfatório; contudo para conseguir 
a validade metodológica adequada somos obrigados a insistir de novo na necessidade de participação. Para isso, 
enviamos de novo o questionário, que foi desenhado pensando num rápido e fácil preenchimento (somente cinco 
minutos), por sermos conhecedores das limitações de tempo na nossa profissão. 
 
Solicitamos que o envie tão depressa quanto possível, já que cada questionário recebido contribui grandemente 
para aumentar a validade final do estudo. Por isso, a sua colaboração é muito importante. 
 
Ao mesmo tempo que insistimos na confidencialidade absoluta dos dados, aproveitamos para agradecer a 
valiosa colaboração.  
 
 
 
Melhores cumprimentos. 
 
 
 
 
 
 
 
 
 
 
Prof. Doutor Jorge Polónia    Mestre Teresa Herdeiro 
Coordenador da UFN      Prof. Coord. Equip. IPSN 
 
 
 
 
 
Junto com o questionário enviamos uma Ficha Amarela, para o caso de necessitar. 
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First pharmacist’s letter 
 
 
 
 
 
 
 
         Porto, 5 de Junho de 2003 
Cara colega 
 
Após dez anos de funcionamento do Programa de Notificação Espontânea de Reacções Adversas a 
Medicamentos (RAM), através da Ficha Roxa, vamos realizar um estudo farmacoepidemiológico1 com o 
objectivo de identificar e avaliar as atitudes e opiniões dos profissionais de saúde, de forma a corrigir 
deficiências no seu funcionamento e melhorar o grau de participação dos farmacêuticos na notificação de RAM. 
 
Como sabe, a Notificação Espontânea de RAM, por parte dos profissionais de saúde, constitui o método 
farmacoepidemiológico mais usado e universalmente aceite, para a detecção de RAM de medicamentos, 
recentemente comercializados e de RAM inesperadas ou raras. Por isso, o seu valor é inestimável, no seio de um 
sistema de saúde moderno, por contribuir para uma maior segurança e eficácia no uso terapêutico dos fármacos. 
 
O universo deste estudo é formado por uma amostra representativa de 300 farmacêuticos que exercem a sua 
profissão na área geográfica da Administração Regional de Saúde do Norte, seleccionados de maneira aleatória e 
por um procedimento informático. 
 
Do ponto de vista metodológico, é fundamental que haja uma participação completa e com uma elevada 
qualidade das respostas. Por isso, é de importância vital que dedique cinco minutos do seu precioso tempo ao 
questionário que juntamos, desenhado a pensar num rápido e fácil preenchimento. 
 
Garantimos a confidencialidade absoluta dos dados. O código numérico do questionário utilizar-se-á mantendo o 
anonimato, para resolver o problema das “não respostas”. A informação recolhida só será apresentada de 
maneira agrupada e utilizada unicamente para fins científico-académicos. Comprometemo-nos desde já enviar os 
artigos a que der lugar este estudo. 
 
No cabeçalho do questionário, encontrará as instruções para o seu correcto preenchimento, que agradecemos leia 
atentamente. Quando terminar de preencher o questionário, coloque-o dentro do envelope franquiado e envia-o 
pelo correio. Se tiver alguma dúvida ou problema durante o preenchimento do questionário, pode telefonar para 
o número 225573990. 
 
Agradecendo antecipadamente a sua colaboração, enviamos os melhores cumprimentos. 
 
 
 
 
 
Mestre Teresa Herdeiro      Prof. Doutor Jorge Polónia 
Prof. Coord. Equip. IPSN      Coordenador da UFN    
    
Junto com o questionário enviamos uma Ficha Roxa, para o caso de necessitar. 
Insistimos novamente na importância do preenchimento cuidadoso do questionário, pois disso dependerá a validade do estudo. 
1com a colaboração da Universidade de Santiago de Compostela. 
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Second pharmacist’s letter 
 
 
 
 
 
 
 
 
        Porto, 3 de Agosto de 2003 
 
 
Cara colega 
 
 
Como se recordará, no passado mês de Julho, enviámos um questionário com o objectivo de identificar e avaliar 
as atitudes e opiniões dos profissionais de saúde, sobre o Programa de Notificação Espontânea de Reacções 
Adversas a Medicamentos (RAM) através da Ficha Roxa. O estudo tem como finalidade corrigir as eventuais 
deficiências do Programa de Notificação de RAM, assim como motivar e melhorar o grau de participação dos 
farmacêuticos na notificação de RAM. 
 
Como resultado do envio anterior obteve-se um elevado nível de respostas. Contudo, solicitamos de novo a sua 
colaboração, dado que o nosso interesse está em que o estudo seja um reflexo fiel da opinião de todos os 
farmacêuticos que exercem a sua profissão na área geográfica da ARS-Norte. 
 
Para efeito, remetemos um novo questionário e agradecemos desde já a sua valiosa colaboração. 
 
Melhores cumprimentos. 
 
 
 
 
 
 
 
 
 
Mestre Teresa Herdeiro     Prof. Doutor Jorge Polónia 
Prof. Coord. Equip. IPSN      Coordenador da UFN   
 
 
 
 
Se não recebermos noticias suas em breve, entraremos em contacto consigo para resolver qualquer dúvida que 
possa ter. 
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Third physician’s letter 
 
 
 
 
 
 
 
        Porto, 4 de Outubro de 2003 
 
Cara colega 
 
 
Como sabe, estamos a realizar um estudo com o objectivo de conhecer as atitudes e opiniões dos farmacêuticos 
que exercem a sua profissão na área geográfica da ARS-Norte, sobre distintos aspectos do Programa de 
Notificação Espontânea de Reacções Adversas a Medicamentos (RAM), depois de 10 anos de funcionamento. 
 
Até agora enviamos por duas vezes o questionário, obtendo um nível de resposta satisfatório; contudo para 
conseguir a validade metodológica adequada somos obrigados a insistir de novo na necessidade de participação. 
Para isso, enviamos de novo o questionário, que foi desenhado pensando num rápido e fácil preenchimento 
(apenas cinco minutos), por sermos conhecedores das limitações de tempo na nossa profissão. 
 
Solicitamos que o envie tão depressa quanto possível, já que cada questionário recebido contribui grandemente 
para aumentar a validade final do estudo. Por isso, a sua colaboração é muito importante. 
 
Ao mesmo tempo que insistimos na confidencialidade absoluta dos dados, aproveitamos para agradecer a 
valiosa colaboração.  
 
Melhores cumprimentos. 
 
 
 
 
 
 
 
Mestre Teresa Herdeiro     Prof. Doutor Jorge Polónia 
Prof. Coord. Equip. IPSN      Coordenador da UFN   
 
 
 
 
Se não recebermos noticias suas em breve, entraremos em contacto consigo para resolver qualquer dúvida que 
possa ter. 
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Fourth physician’s letter 
 
 
 
 
 
 
 
 
Porto, 2 de Dezembro de 2003 
 
Cara colega 
 
 
Como sabe, estamos a realizar um estudo com o objectivo de conhecer as atitudes e opiniões dos farmacêuticos 
que exercem a sua profissão na área geográfica da ARS-Norte, sobre distintos aspectos do Programa de 
Notificação Espontânea de Reacções Adversas a Medicamentos (RAM), depois de 10 anos de funcionamento. 
 
Até agora enviamos três questionários, alcançando um nível de participação satisfatório; contudo para conseguir 
a validade metodológica adequada somos obrigados a insistir de novo na necessidade de participação. Para isso, 
enviamos de novo o questionário, que foi desenhado pensando num rápido e fácil preenchimento (somente cinco 
minutos), por sermos conhecedores das limitações de tempo na nossa profissão. 
 
Solicitamos que o envie tão depressa quanto possível, já que cada questionário recebido contribui grandemente 
para aumentar a validade final do estudo. Por isso, a sua colaboração é muito importante. 
 
Ao mesmo tempo que insistimos na confidencialidade absoluta dos dados, aproveitamos para agradecer a 
valiosa colaboração.  
 
 
Melhores cumprimentos. 
 
 
 
 
 
 
 
 
 
 
Mestre Teresa Herdeiro     Prof. Doutor Jorge Polónia 
Prof. Coord. Equip. IPSN      Coordenador da UFN   
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APPENDIX E 
Presentation in PowerPoint 
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Physician presentation (original and translation) 
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Pharmacist’s presentation (different slides) 
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APPENDIX F 
Letter of introduction (Cluster-Randomized Trial) 
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Hospital letter 
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Health Centre letter  
 
 
 
 
 
 
 
 
 
 
Director do Centro de Saúde de Ribeira de Pena 
Dr Paulino Rodrigues 
Lugar de Salvador 
4870-151 – Ribeira de Pena 
 
 
 
 
Data: 2004/02/28 
Assunto: Acção de formação em Farmacovigilância 
 
A Unidade de Farmacovigilância do Norte encontra-se a realizar um estudo farmacoepidemiológico desde 2002, 
com a colaboração da ARS-Norte. Este estudo teve como primeiro objectivo identificar e avaliar as atitudes e 
opiniões dos profissionais de saúde (médicos e farmacêuticos), sobre a notificação espontânea de Reacções 
Adversas a Medicamentos. Com base nos resultados obtidos no primeiro estudo, propomo-nos a realizar acções 
de formação com o objectivo de ajudar os profissionais de saúde a diminuir a sub-notificação e se possível criar 
uma “cultura de notificação”. 
 
Gostaríamos de realizar, na Vossa instituição acções de formação, sobre o assunto em epígrafe, pelo que 
sugeríamos a marcação de uma reunião com a brevidade possível, para agendarmos a formação (data/local). 
 
 
Com os melhores cumprimentos 
 
 
 
 
 
 
 
 
 
 
Prof. Doutor Jorge Polónia    Mestre Teresa Herdeiro 
Coordenador da UFN      Prof. Coord. Equip. IPSN 
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Communitarian Pharmacists  
 
 
 
 
 
 
 
 
 
Farmácia Cortes Pinto 
Dra. Alexandra Cortes Pinto 
Rua João Pedro Ribeiro, 841 
4000-308 – Porto 
 
 
 
 
Data: 2004/03/8 
Assunto: Acção de formação em Farmacovigilância 
 
A Unidade de Farmacovigilância do Norte encontra-se a realizar um estudo farmacoepidemiológico desde 2002, 
com a colaboração da ARS-Norte. Este estudo teve como primeiro objectivo identificar e avaliar as atitudes e 
opiniões dos profissionais de saúde (médicos e farmacêuticos), sobre a notificação espontânea de Reacções 
Adversas a Medicamentos. Com base nos resultados obtidos no primeiro estudo, propomo-nos a realizar acções 
de formação com o objectivo de ajudar os profissionais de saúde a diminuir a sub-notificação e se possível criar 
uma “cultura de notificação”. 
 
Gostaríamos de realizar, na sua farmácia acções de formação, sobre o assunto em epígrafe, pelo que sugeríamos 
a marcação de uma reunião com a brevidade possível, para agendarmos a formação (data/local). 
 
 
Com os melhores cumprimentos 
 
 
 
 
 
 
 
 
 
 
Mestre Teresa Herdeiro     Prof. Doutor Jorge Polónia 
Prof. Coord. Equip. IPSN     Coordenador da UFN 
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APPENDIX G 
Letter for Regional Health Administration of North (Cluster-
Randomized Trial) 
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vossa ref.: 
        data:    
 
nossa ref.: UFN/02.39 
         data: 2004/03/08      
 
Assunto: Avaliação do conhecimento e atitudes dos profissionais de saúde face à notificação 
espontânea de reacções adversas a medicamentos 
 
Na sequência da nossa carta sobre o assunto em epígrafe enviada em Janeiro de 2002, vimos 
pela presente dar-vos conhecimento da actual situação do estudo que estamos a realizar na 
Unidade de Farmacovigilância do Norte, Faculdade de Medicina da Universidade do Porto. 
A primeira fase do estudo que tinha como objectivo realizar uma revisão bibliográfica 
exaustiva, recolher e analisar através de um questionário, as opiniões e atitudes dos médicos e 
farmacêuticos da Região Norte, no que diz respeito ao programa de notificação e identificar 
por sua vez os factores que estão associados à notificação de reacções adversas a 
medicamentos (RAM), encontra-se terminada. 
Estamos neste momento a iniciar a segunda fase do estudo ou seja uma vez identificados os 
factores associados à notificação RAM, preparamos uma intervenção educativa para melhorar 
a Notificação Espontânea. Vamos assim dar início às acções de formação nos Centros de 
Saúde, Hospitais e farmácias seleccionadas, pelo que agradecemos a Vossa colaboração. 
Com os nossos melhores cumprimentos. 
 
 
 
Coordenador da Unidade de Farmacovigilância do Norte 
Administração Regional de Saúde 
Rua Santa Catarina, 1288 
4447 - Porto 
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APPENDIX H 
Confirmation letter (Cluster-Randomized Trial) 
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Confirmation letter  
 
 
 
 
 
 
 
 
 
 
 
 
Director do Centro de Saúde de Ribeira de Pena 
Dr Paulino Rodrigues 
Lugar de Salvador 
4870-151 – Ribeira de Pena 
  
 
 
 
Data: 2004/03/5 
Assunto: Acção de formação em Farmacovigilância 
 
De acordo com reunião tida esta semana, confirmamos a acção de formação acima descrita para o dia 18 de 
Março do corrente ano, às 17 horas, no centro de saúde de Ribeira de Pena. 
 
Agradecíamos o envio do nome dos médicos do centro de saúde para assim prepararmos os certificados de 
participação a entregar no dia da acção de formação. A lista poderá ser enviada para o fax 225573971. 
 
 
 
 
 
Com os melhores cumprimentos 
 
 
 
 
Prof. Doutor Jorge Polónia    Mestre Teresa Herdeiro 
Coordenador da UFN      Prof. Coord. Equip. IPSN 
 
 
 
 
APPENDIXES 
198 
  APPENDIXES 
  199 
APPENDIX I 
Pamphlets 
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Physician pamphlet (original) 
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Physician pamphlet (translation) 
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